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SUMMARY
Biodegradable polymers have important uses in drug delivery systems. Bacterially 
produced poly-D(-)-3-hydroxybutyrate (PHB) and its copolymers with poly- 
hydroxyvalerate (P(HB-HV)) have emerged as new candidates for use in drug delivery
devices.
Current literature available on the synthesis and physical properties of these 
polyesters is reviewed. Experimental studies of the physicomechanical properties of
bacterial P(HB-HV) polyesters and their potential use in drug delivery are reported.
Mechanical, thermal, ageing and crystalline properties have been investigated in detail.
These properties were generally dependent on both polymer molecular weight and copolymer 
composition. Static tensile testing of solvent cast films showed that PHB was relatively 
hard and brittle whereas copolymerization with HV produced tougher, less brittle and 
more pliable copolymers. Mechanical properties of polymer films were modified on 
incorporation of a particulate drug (Sodium Fluorescein). Differential Scanning 
calorimetry (DSC) and Thermogravimetric analysis were used to assess thermal properties. 
Melting points, glass transition temperatures, and thermal degradation temperatures were 
determined. Mechanical and thermal properties of solvent cast films changed with time 
following manufacture. The ageing effect was related to copolymer composition.
Spherulitic crystallization kinetics and morphology were assessed using polarized light 
microscopy, DSC and X -ra y  diffraction. Crystallization rate and morphology were 
Influenced by crystallization temperature, copolymer composition, presence and 
concentration of a model drug (Methyl Red) and to some extent polymer molecular weight.
Spray drying was investigated for producing injectable polymer microparticles for drug 
delivery. Successful use of the process was limited to low molecular weights of PHB.
Drug release (Methyl Red) from implantable solvent cast and melt-pressed films was also 
investigated. Release was dependent on polymer molecular weight, copolymer composition, 
drug loading and fabrication technique. Release of Methyl Red was predominantly
controlled by diffusion rather than polymer erosion.
Bulk properties of P(HB-HV) polymers and drug release kinetics from melt pressed discs 
were thought to be related to the underlying crystalline morphology within films. This 
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ORIGINS AND SCOPE
P o ly -D (- ) - 3 - hydroxybutyrate (PHB) and its copolymers with poly-D (-)-3-hydroxyvalerate  
(P(HB-HV)) are optically active, crystalline polyesters produced by a wide variety of 
bacteria and a number of other microorganisms [137]. These polymers are the most common 
in the more general class of polyhydroxyalkanoates (PHA) which are produced by 
microorganisms as energy reserve materials. As a consequence of recent advances in 
biotechnology, P(HB-HV) polymers can be produced in multikilogram batches from the 
bacterial fermentation of a glucose utilizing mutant of Alcallgenes eutrophus.
The major advantage of these ’biopolymers’ is that they can be extracted from bacteria 
in a very pure form. This is In contrast to conventional synthetic thermoplastics, such 
as polylactide/polyglycolide (P(LA-GA)) systems, which can contain inorganic catalyst 
residues even after extensive purification.
Preliminary reports suggested that P(HB-HV) polymers were both biodegradable and 
biocompatible [149]. The homopolymer, PHB, degrades to the monomer, D ( - ) - 3 -  
hydroxybutyric acid, which is a normal constituent of blood and therefore likely to be 
tolerated well in vivo. Further studies at Bath showed that these polymers degraded by 
surface hydrolysis [286 -  287]. The surface confined (heterogeneous) degradation of these 
polymers offers the potential advantage of predictable drug release kinetics. This is in 
contrast to the situation with P(LA-GA) systems (widely used for drug delivery 
purposes) which undergo homogeneous degradation (bulk hydrolysis). This degradation 
method results in unpredictable permeability changes within the bulk polymer and 
consequently leads to unpredictable drug release kinetics from P(LA-GA) systems. On the 
basis of these preliminary studies indicating potential advantages of P(HB-HV) 
biopolymers over existing biodegradable polymers, these materials were chosen as 
potential candidates for drug delivery systems.
At the onset of this research, although much information was available on the 
biosynthesis of P(HB-HV) polymers, little was known of their physicomechanical
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properties or of their potential for use in drug delivery applications.
It was the aim of this research to study the fundamental physicomechanical properties of 
P(HB-HV) polymers and to examine their possible use in delivering both macromolecular 
and low molecular weight drugs. Chapters 2, 3, 4 and 5 report on the mechanical, 
thermal, ageing and crystalline properties of P(HB-HV) polyesters. Wherever possible the 
influence of model drugs on the fundamental properties of these polymers has been
examined. In particular, the influence of a model drug, Methyl Red, on the crystalline 
morphology and subsequent drug release kinetics from these polymers has been
investigated.
In terms of drug delivery, both spray-dried microparticles and thin film matrices
(solvent cast and melt-pressed) have been examined as drug carriers. The study was
limited to the use of model drugs and did not extend to therapeutic actives. Methyl Red 
was used as a model for low molecular weight drugs and preliminary studies on
macromolecular drugs were carried out using Azocasein.
Microparticles have traditionally been prepared by batch processes involving organic 
solvent evaporation. Such processes are likely to encounter scale up problems and thus, 
may be economically unviable. It was, therefore, that in this study, spray drying was 
investigated as a continuous process for producing injectable microparticles and is 
discussed in Chapter 6. For comparative purposes, melt-pressed and solvent cast films 





1.1 Rationale for controlled drug delivery
Conventional methods (oral and parenteral) of administering low molecular weight drugs 
suffer from several disadvantages [1 -7 ]. One of the major disadvantages is that they 
involve frequent and repeated doses which not only leads to compliance problems but also 
results in peak and trough fluctuations in the plasma drug concentrations. Such 
variations in plasma drug concentrations are particularly undesirable when aiming to 
maintain plasma drug levels within a narrow therapeutic range (i.e when differences 
between therapeutic and toxic concentrations of drug in plasma are small) [7]. If 
plasma drug levels rise above the toxic limit then, as a consequence of the non- 
targetted nature of conventional drug delivery, systemic side effects will occur.
A number of approaches have been examined for targetting drugs to specific sites in 
order to avoid systemic side effects. These include the use of soluble polymers [8 -10 ], 
monoclonal antibodies [11-13] and particulates such as polymer microspheres [14-20], 
emulsions [21] and liposomes [22-30]. However, the injection of particulate systems into 
the circulation results in rapid uptake by cells of the reticuloendothelial system 
(RES) and therefore targetting using particulate systems Is largely limited to the RES 
[31-34]. Although modification of particle surfaces with certain coatings has allowed 
some control in targetting to specific sites within the RES [17-19], targetting to 
extravascular sites is problematic and for it to realize its full potential must 
overcome vascular endothelial and cellular barriers [32].
The limitations of conventional drug delivery systems are further highlighted in the
delivery of polypeptide drugs. Recent advances in bioengineering and cell biology have
led to the development of many pharmacological active peptides such as tissue
plasminogen activator (for treatment of thrombi), erythropoietin (for treating anaemia*
in renal failure), atrial natriuretic factor (treatment of hypertension) and 
interferons (indicated in certain cancers) [35-38]. The routine use of such peptides in 
medicine is unlikely to be feasible using traditional methods of drug administration. 
Macromolecular peptides are usually ineffective by the oral route as they are rapidly
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degraded and deactivated in the gastrointestinal tract by proteolytic enzymes [39].
Those which are stable under such conditions may still not pass through biological 
barriers because of their chemical polarity and large molecular weights [40]. 
Consequently, at present they are administered parenterally. However, parenteral 
administration is often complicated by their very short half-lives [41]. Frequent
injections are required to maintain effective or therapeutic plasma concentrations of
peptides but peak and trough effects remain. This problem may be overcome by using
biodegradable polymers as matrices for sustained or controlled delivery of peptides 
(and low molecular weight drugs) for implantation or parenteral administration.
Polymer matrix (monolithic) devices are essentially of two types. One in which the drug 
is physically dispersed as discrete solid particles within the polymer matrix and the 
other in which the drug is dissolved in the polymer matrix at concentrations below its 
saturation solubility [42].
The aim of such devices is to allow for the controlled release of drugs into the body 
over long periods of time (weeks or even months), thereby constantly maintaining a 
therapeutic plasma drug concentration that is above the minimum effective level but 
below the toxic level. The formulation should ideally be biodegradable for two reasons.
Firstly, so that the device can disappear from the site of administration obviating the 
need for surgical removal of the drug -  depleted device. Secondly, the degradation of the 
polymer can potentially be used to precisely control the rate of drug release from the 
matrix. Biodegradable polymers also offer opportunities for the protection of labile 
macromolecules as an additional property, coupled to the advantages of controlled 
release [43]. The breakdown products of such a formulation should be non-toxic and
biocompatible [40].
It should, however, be noted that although much work in the past has been carried out 
using polymer devices in the aim of achieving a zero-order drug release profile [4 4 - 
45], this may not always be the ideal release pattern. The optimum delivery of
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endogenous peptides may require release rates and profiles which mirror those observed 
during their normal physiological release and may be of a pulsatile nature [46]. The 
mode of delivery is clinically important since, for example in the case of luteinizing 
hormone -  releasing hormone (LHRH) analogues, opposing pharmacological effects have been 
observed depending on whether they are delivered in a pulsatile or continuous manner 
[38]. Pulsatile administration of LHRH, which mimicks the natural secretory pattern, 
causes a sustained secretion of gonadotropins [47-48]. However, administration of long 
acting synthetic analogues of LHRH as a single daily subcutaneous injection has been 
shown to desensitize (down -  regulate) the receptors in the pituitary gland and thus 
inhibit the release of gonadotropins [66-68]. in the case of LHRH, continuous release 
and subsequent down regulation of receptors in the pituitary gland is clinically more 
useful than pulsatile release. This fact is now being exploited clinically for female 
contraception [38] and Zoladex, a preparation allowing continuous release of a LHRH 
analog is currently available for the treatment of prostate carcinoma.
Recent evidence suggests that the biological response to a given drug may also vary 
according to the body’s circadian rhythms [49-50] and hence the drugs chronopharmacology 
will influence the required release profile for optimum delivery of the agent [50]. It 
should also be emphasized that for devices which do not deliver direct to the 
circulation, the rate at which drug is delivered to the implant site does not
necessarily reflect its rate of delivery to the circulation. A constant rate of release
of a drug into tissues (other than directly into blood by intravenous administration)
will not necessarily produce a constant concentration in blood plasma [51]. The latter
depends on factors such as the o il-in -w ater partition coefficients of lipid soluble 
drugs, molecular size of lipid soluble drugs and local blood flow [51].
1.2 Biodegradable matrices for drug delivery.
Biodegradable, bioerodible and bioresorbable are terms which are often used
interchangeably in the literature to refer to simple hydrolysis and/or enzymatically 
induced hydrolytic degradation of polymers. However the precise definition for each term
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has varied from author to author and has led to some confusion in their meaning. This 
problem has been highlighted in a recent review by Holland et al [52]. For example 
Williams [53] defines biodegradation as the biological breakdown of the polymeric 
material, as opposed to simple hydrolytic breakdown, whereas Gilding [54] reports that 
the phrase ’biodegradable polymer’ refers to any polymer that undergoes in vivo 
degradation. The term bioerodible has been used by Heller [53 -  57] who defined it as the 
conversion of an initially water insoluble material to a water soluble material which 
may or may not involve major chemical degradation. In this thesis, biodegradation is 
taken to refer to hydrolytic, enzymatic and microbial degradation processes occurring in 
a polymer which do not necessarily proceed to a stage where the physical form of the 
polymer is altered.
Heller [53-57] has proposed three different mechanisms for the erosion of biodegradable 
polymers, however in practise erosion usually occurs by a combination of these 
mechanisms. Type I erosion occurs when water-soluble polymers that have been
insolubilized by covalent crosslinking undergo hydrolysis at either the cross -  links 
(Type IA) or at the water-soluble backbone (Type IB). Type II erosion occurs when water- 
insoluble polymers become water-soluble as a result of either hydrolysis, ionization or 
protonation of pendent groups. Type III erosion occurs by random cleavage of an 
insoluble polymer backbone producing aqueous-soluble oligomers. In the case of 
hydrophobic biodegradable polymers, erosion can be further classified as either 
homogeneous (bulk erosion) or heterogeneous (surface erosion) [53-57]. The former 
involves water uptake into the bulk of the matrix to cause random hydrolytic breakdown 
of polymer chains and therefore, random changes in the permeabilty of the matrix. In 
contrast, surface erosion involves controlled hydrolysis at the outer surface such that 
the bulk of the matrix remains essentially unchanged. Surface eroding devices 
potentially offer more predictable release kinetics than matrices undergoing bulk 
erosion and provided surface eroding devices maintain a constant surface geometry, 
constant drug release rates can be obtained [57].
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Historically, the pioneering studies on implantable controlled drug delivery focused on 
non -  biodegradable systems [58 -  60] such as polyethylene [58], silicone [59] and more 
recently ethylene vinyl acetate copolymers [63 -  80]. The first reports of non- 
biodegradable polymers for sustained release of peptides appeared in the early 1970’s 
[61-62]. It was shown that prolonged release of immunoglobulin, luteinizing hormone, 
bovine serum albumin (BSA), insulin and prostaglandin could be achieved using cross- 
linked polyacrylamide and polyvinylpyrrolidine gels [61-62]. Subsequent studies by 
Langer and Folkman [63] using polyhydroxyethylmethacrylate and ethylene-vinyl acetate 
copolymers demonstrated that large molecules with molecular weights up to 2 X 106 Da can 
be released steadily from the implanted polymeric device over periods longer than 3 
months. However, the reproducibility of the drug release was poor in these studies and 
was later improved upon, firstly using a low temperature solvent casting method [64 -  65] 
and later by using a sintering technique [69-70] for incorporating macromolecules into 
polymer matrices.
The studies of Langer and coworkers [71 -  74] showed that the release of proteins (using 
BSA as model) from biocompatible ethylene-vinyl acetate copolymers (EVAC) was dependent 
on particle-size and drug loading. The release mechanism involved diffusion of the 
protein through interconnecting channels in the matrix which were initially formed by 
the insolubilized polypeptide particles during matrix casting. The geometry of the 
device also influenced release rate [75]. Release rate was inversely proportional to the 
polymer molecular weight [76]. Release rates approaching zero order could be achieved by 
utilizing a hemisphere device with an impermeable coat, but which contained a small hole 
at the centre of the flat face [74]. Release durations of several months were reported. 
Additional controls on release rates of BSA could be obtained using magnetism [77-78] 
and ultrasound [79]. Although Langer and coworkers [80] have demonstrated the in vivo 
efficacy of continuous insulin release from EVAC copolymers for more than 100 days in 
diabetic rats, the ultimate utility of controlled release devices for insulin therapy 
may best be achieved by regulated pulsatile release in response to blood glucose levels.
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In early studies, blodegradatlon of the polymer was not considered and was thought to 
represent a less well defined and unnecessary experimental variable [81,]. Subsequently, 
interest in biodegradable polymers developed for two reasons. Firstly, as the field 
expanded from research to application, It was recognized that surgical removal of a drug 
depleted delivery system was difficult, yet leaving non -  degradable foreign materials in 
the body for an indefinite time period constituted an undesirable toxicological hazard 
[82]. Secondly, delivery of macromolecules and drugs with poor solubility could not be 
facilitated by diffusion through the polymers [73,81] and controlled erosion of polymer 
was thought to offer greater potential for controlling release of such drugs.
It was not until the advent of resorbable surgical sutures in the early 1970’s [83] that 
research into biodegradable delivery systems gained momentum. A number of different 
classes of biodegradable polymers have been investigated for potential in controlled 
drug delivery applications. These Include polyesters [84 -  85], polyamides [86], 
polyurethanes [87], polyacrylonitriles [88-89] and polyphosphazenes [90]. Because of 
their development as surgical sutures, polyglycolide (PGA), poly-DL-lactide (PLA) and 
their copolymers (P(I_A-GA), have been the most extensively studied biodegradable systems 
for drug delivery.
1.2.1 P(LA-GA) polymers for drug delivery
A number of excellent reviews exist on the use of P(LA-GA) polymers for use in drug 
delivery and surgical applications [43,52,82,84,91-94]. These synthetic polymers are 
biocompatible [91 -96] and hydrolytically degrade to the monomeric acids L -  lactic acid,
D-lactic acid, and glycolic acids. L -  Lactic acid and glycolic acids are metabolized by 
the Krebs cycle whilst D-lactic acid is excreted intact [38]. The degradation rate is 
dependent on copolymer composition and related to the crystallinity of the polymers [91 -  
93]. Poly-DL-lactide is amorphous but Poly-L-lactide (37%) and polyglycolide (up to 50%) 
are crystalline [93,97]. Copolymers comprising of 25 -  75 mole% GA are thought to be 
amorphous [97]. Consequently these copolymers degrade more rapidly than the crystalline
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homopolymers. Careful choice of monomer composition can produce devices which can 
degrade completely over a desirable timescale of months to years [91,93].
The P(LA-GA) polymer systems have been used as matrix implants and as microparticles for 
the delivery of many therapeutic agents including local anaesthetics [98 -  99], vaccines 
[43], cytotoxic agents [100], steroids [101], narcotic antagonists [102-103], nucleic 
acids [104] and more recently, peptide drugs [40,41,105-111]. Drug release from these 
polymers usually occurs by a combination of diffusion and polymer degradation. In the 
case of P(LA-GA) microspheres containing a LHRH analog, triphasic release of the 
peptide has been reported [109-111]. In the initial phase the peptide is released from 
the surface layers and channels within the polymer matrix connected to the outside 
layers. This initial phase is followed by a "dormant' period in which the remaining 
peptide is trapped within the bulk matrix and is eventually released in the third phase 
when bulk erosion of the device occurs [109-111].
The major commercial success of P(LA-GA) systems to date results from their use as 
matrices for the continuous delivery of LHRH analogs in the treatment of prostate 
cancers. In one formulation, the peptide hormone (goserelin) is dispersed within a P(LA- 
GA) copolymer matrix (Zoladex; ICI) which degrades slowly to release the peptide over a 
28 day period when inserted parenterally as a small cylindrical implant into the 
abdominal wall [40,41,112]. In another parenteral formulation, P(LA-GA) copolymer 
microcapsules deliver another LHRH analog (Decapeptyl; Ipsen Biogen) at therapeutic 
levels for over a month [495]. Furthermore, poly-L-lactide microspheres containing 
bromocriptine (Parlodel; Sandoz) have also been marketed [495] and P(LA-GA) microspheres 
containing norethisterone have been undergoing clinical trials and are likely to be 
marketed for long term contraception [113,495].
The major disadvantage of P(LA-GA) systems is that they undergo bulk hydrolysis 
(homogeneous degradation) as opposed to surface erosion (heterogeneous degradation) 
[114]. Because changes In permeability during bulk hydrolysis of P(LA-GA) matrices 
cannot be predicted with time, the resultant drug release kinetics are also somewhat
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unpredictable. In addition, the matrix can disintegrate before drug release is complete 
[57] and the resultant burst in the rate of drug delivery could in some cases be fatal.
Such bursts have been reported [115]. In view of these drawbacks, delivery systems 
having more desirable release kinetics have been examined. Hydrophobic polymers that 
undergo surface erosion, such as polyorthoesters and polyanhydrides, have been 
investigated as alternatives.
1-2.2 Polyorthoesters
Polyorthoesters can be sub-divided into the commercially developed Chronomer (Alza) 
series [116] and those developed by Heller and colleagues [117, 119-126] at SRI 
international. It is the latter series of polyorthoesters which are discussed below.
Heller et al [119] have synthesised surface eroding polyorthoesters by the condensation 
of diols and diketene acetals. Linear and cross linked aliphatic polyorthoesters have 
been prepared which can degrade in time frames of a few hours to many months by the 
addition of various basic or acidic excipients [121]. Polyorthoesters are stable in 
basic environments, hydrolyse slowly at physiological pH and become progressively more 
labile as the pH to which they are exposed is lowered [121]. Taking advantage of the pH 
dependence of the rate of orthoester cleavage, Heller and colleagues [117-126] have been 
able to achieve preferential hydrolysis at the surface by either adding basic substances 
(e.g. Mg(OH)2) to suppress degradation in the bulk or by incorporating acidic catalysts 
(e.g. acid anhydrides) to promote degradation on the surface. Polyorthoesters are 
amorphous and by varying the ratio of the diol used, polymers with glass transitions 
between 20°C and 115°C can be prepared [119]. Drug loaded polyorthoester devices can be 
fabricated by blending both drug and excipient into the heat-softened polymer [119] or 
by physical mixing of drug and excipient into the viscous prepolymer and subsequent 
curing of the cross-linked polyorthoester at 76°C [124-126]. Although initial studies 
with methylene blue suggested that drug release could be predominantly controlled by 
polymer erosion [117-118], this has not always been the case with therapeutic drugs
[122-126]. Release of norethindrone from circular polyorthoester devices containing 
sodium carbonate as the basic excipient, in fact, was not mediated by polymer erosion 
but rather by the formation of a swollen hydrophilic layer at the surface of the 
device allowing release of the drug by diffusion through the swollen polymer [122-123]. 
Although polymer erosion was thought to control both in vitro and in vivo (rabbit) 
release of levonorgestrol from cross linked polyorthoester devices containing Mg(OH)2 
[124], incorporation of 5 -  fluorouracil and a LHRH analog into the same polymer resulted 
in predominantly diffusion controlled release [125]. However, as the release of the two 
drugs was modified on changing the diol or the amount of copolymerized 9,10- 
dihydroxystearic acid used in the synthesis, polymer erosion was thought to be 
involved, albeit to a lesser extent because changes in the drug release rates reflected 
the expected changes In polymer erosion rates [125].
As a result of the variable drug release patterns obtained with cross linked 
polyorthoesters, Heller and coworkers [126] have recently examined the cure behaviour of 
polyorthoester implants in order to Improve reaction conditions such that devices having 
reproducible erosion and drug release behaviour routinely can be prepared. Clearly, the 
non-reproducible release behaviour and the inclusion of additives (up to 10%w/w), which 
in some cases [119] can be greater than the loading of the therapeutic agent, makes 
polyorthoesters less than Ideal materials for drug delivery. Furthermore, the long-term  
biocompatibility of polyorthoesters and their hydrolysis products is yet to be reported 
even though preliminary studies indicate absence of any adverse tissue reaction during 
in vivo release experiments [117].
1.2.3 Polyanhydrides
In designing a biodegradable system that would degrade by surface erosion without the 
use of additives, Langer and coworkers [129-134] have developed polyanhydrides based on 
a variety of aliphatic and aromatic dicarboxylic acids. The aliphatic polyanhydrides 
were initially proposed by Hill and Carothers in the 1930’s [127,128] to be substitutes 
for polyesters in the textile industry. The idea was later rejected because of their
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hydrolytic instability. However by combining aliphatic segments with the more 
hydrolytically stable aromatic anhydrides, Langer and colleagues [130] have been able to 
achieve a service life in the range 2 weeks to several years for 1mm-thick 
polyanhydride devices. For example in the series poly[bis(p-carboxyphenoxy) alkane 
anhydrides] by changing the alkane from a methyl to a hexyl group, degradation rates in 
the range 10"1 to 10"4 mg/hr/cm2 were obtained [130]. Degradation of polyanhydrides was 
pH dependent, being enhanced at high pH and slower in acidic conditions [130]. However, 
polyanhydrides can undergo hydrolysis under atmospheric conditions and therefore need to 
be stored in an anhydrous environment [134]. A recent report suggested that the 
materials were stable when properly packaged into aluminium foil under anhydrous 
conditions and the shelf life can be further extended when stored at subambient (-20 °C ) 
temperatures. However, no formal stability data were presented for the polymers [134].
The polyanhydrides are thought to be crystalline [133] and have been reported to have 
good biocompatibility [131]. The In vitro growth of mammalian cells was unaffected as 
measured by cell morphology and cell growth rate [131]. No inflammatory responses were 
observed when the polymers were implanted either into the corneas of rabbits for 6 weeks 
or subcutaneously into rats for 6 months. The degradation products of the polymers were 
thought to be nonmutagenic, noncytotoxic and were reported as having low teratogenic 
potential [131]. However, biocompatibility studies were only carried out on poly[bis(p- 
carboxyphenoxy) propane anhydride] (PCPP), poly(terepthalic acid anhydride) (PTA) and 
their copolymers with sebacic acid [131] and consequently, the biocompatible nature of 
other polyanhydrides cannot be inferred.
Drug release studies from injection -  moulded devices of PCPP containing p-nitroaniline, 
as a model drug, showed that predominantly erosion controlled release could be obtained 
for up to 8 months [130]. As a result of this and a previous study with cholic acid as a 
model drug [129], Langer and coworkers have investigated release of a peptide (insulin) 
from polyanhydrides [132,133]. In the initial study, incorporation of insulin into 
polyanhydride microspheres (PCPP:sebacic acid, 21:79) was achieved by use of a "hot-
melt' technique since water could not be present during the encapsulation process due to 
the hydrolytic instability of the polymer bonds [132]. The hot-melt technique involved 
incorporation of peptide at temperatures above the melting of the polymer. Although the 
melting temperature of this polymer (76°C) was significantly lower than of the pure PCPP 
(225°C), the temperature employed (~80°C) can be expected to have deleterious effects on 
a peptide hormone. At least some of the insulin incorporated was biologically active as 
evidenced by in vivo reduction in blood glucose levels in diabetic rats for 3 to 4 days, 
which paralleled the rate of polymer erosion [132]. Clearly this technique of peptide 
incorporation was limited to polyanhydrides with low melting temperatures. In order to 
utilize the higher melting polymers, insulin has subsequently been incorporated into 
polyanhydride microspheres using a modified organic phase precipitation method involving 
only organic solvents [133]. However, insulin release was much faster than polymer 
erosion and 10% insulin loaded microspheres (50 -  300um) gave 4 - 5  days glucose control In 
diabetic rats [133].
The polyanhydrides, clearly, have advantages over polyorthoesters and P(LA-GA) polymers 
as potential drug delivery systems and on the basis of the above studies and further
biocompatibility studies of polymer implants in the brains of a number of mammals, FDA
has approved their experimental use in humans to treat glioblastoma multiforme, a 
universally fatal form of brain cancer [134].
Nevertheless, because of their highly reactive polymer bonds, polyanhydrides are
susceptible to hydrolysis on storage and can also lead to drug-polymer interactions 
especially at high fabrication temperatures [133]. Furthermore, the inability to use 
water during fabrication may prevent intimate mixing of water-soluble drugs into the 
polyanhydride matrix. The use of high temperatures and purely organic solvents may
significantly affect the stability of some peptides which may preclude their use in 
polyanhydride systems.
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1.3 Area of Research
As a consequence of recent advances in biotechnology, poly-D(-)3-hydroxybutyrate (PHB) 
and its copolymers with D( - )  -  3 -  hydroxyvalerate (P (HB -HV)) have emerged as a new set of 
candidates for use in drug delivery. These polymers are the most common in the more
general class of polyhydroxyalkanoates (PHA) which are produced by a number of
microorganisms as energy reserve materials.
The major advantage of these ’biopolymers’ is that they can be extracted from bacteria 
in a very pure form. This is in contrast to conventional synthetic thermoplastics, such 
as P(LA-GA) systems, which can contain inorganic catalyst residues even after extensive 
purification.
This study is concerned with determining the physico-mechanical properties of P(HB-HV)
copolymers and Investigating their potential for drug delivery.
The current literature available on P (HB-HV) biopolymers is reviewed in detail below.
The subject of crystallinity and crystalline properties is also introduced briefly and 
remains a major theme throughout this thesis.
1.4 P(HB-HV) Polyesters
P(HB-HV) biopolymers are optically active, stereoregular polyesters which are members of 
the general class of compounds known as polyhydroxyalkanoates (PHA). The structure of 
P(HB-HV) polyesters is compared with that of the P(LA-GA) copolymers in Figure 1.1 and 
some examples of other polymers within the PHA series of biopolymers are given in figure 
1.2.
1.4.1 Biosynthesis
The homopolymer PHB was first discovered in bacteria (Bacillus megatarium) by Lemoigne 
in the 1920 s [135-136]. It has subsequently been found in a number of different 
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Figure 1.1. Structure of biodegradable P(HB-HV) and P(LA-GA) 
polyesters.
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Figure 1.2. The general structure and some examples from the PHA 
class of biopolymers.
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algae [139] and microbially treated sewage [140]. Indeed its presence in bacteria has 
been used to taxonomically characterize the Pseudomonad species [141]. The major 
function of PHB in microorganisms is to serve as an intracellular energy and carbon 
storage product in much the same way as glycogen in mammalian tissue [137]. PHB is also 
thought to have minor roles in cellular functions such as sporulation [142], encystment 
[143] and gene expression [144], The polymer accumulates in discrete, membrane bound 
granules in the bacterial cell [145-146] from which It can be extracted directly with 
organic solvents such as chloroform [147], or by membrane rupturing techniques such as 
mechanical, chemical and enzymatic disruption of cell walls [148]. Figure 1.3 shows PHB 
polymer molecules coming out of a bacterial cell. The percentage of PHB in bacterial 
cells is normally low, from 1% to 30%, but under controlled fermentation conditions of 
carbon excess and nitrogen limitation, overproduction of polymer can be encouraged to 
yields of up to 80% of dry cell weight [137,140]. This fact has been commercially 
exploited by Marlborough Biopolymers Ltd (a subsidary of ICI Pic) who currently produce 
multikilogram batches of P(HB-HV) polymers (Biopol) from a glucose -  utilizing mutant of 
Alcaligenes eutrophus. The biodegradable polymers were largely developed by ICI as 
novel commodity plastics not dependent on the supply of petroleum [149-153].
The exact mechanism of biosynthesis and the elucidation of biochemical pathways involved 
In polymer accumulation/utilization in microorganisms has attracted much research 
interest over the years. The biosynthesis of PHB and other PHAs has been reviewed by
Senior and Dawes [137,154], Oeding and Schlegel [155] and more recently by Lafferty et
al [148]. However, because the biosynthetic pathway is still not fully understood, 
strong research interests remain in this area. Consequently, the majority of the 
literature available on PHB concerns its biosynthesis.
The exact nature of the enzymes involved in the synthesis and subsequent utilization of 
the energy reserve polymers are known to vary between microorganisms [137,148, 156]. The 
general pathway involved in the biosynthesis and degradation of PHB in Alcaligenes 
eutrophus In simplified form is represented in Figure 1.4. Essentially this scheme
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Figure 1.3. An electron micrograph showing the spilling out of 
polymer from a bacterial cell.
(Photograph courtesy of A. Webb, ICI, UK).
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(1) /MCetothiolase (/?-ketoacylthiolase, acetace- 
ty l-C oA  thiolase)
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Figure 1.4. A simplified biosynthesis and degradation pathway of 
poly -  D( - )  -  3 -  hydroxybutyrate in Alcaligenes eutrophus. 
(After ref. 137 and 148).
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represents the condensation of 2 molecules of acetyl-CoA to form acetoacetyl -  CoA which 
subsequently becomes structurally modified by acetoacetyl -  CoA reductase to form D ( - ) - 3 -  
hydroxybutyry!-CoA. This monomeric form of the polymer is then polymerized to form PHB 
by a synthetase enzyme (PHB synthetase, HB-CoA polymerase, PHB synthase). This 
polymerization does not occur directly but is thought to require a protein fraction A1 
located in the granule membrane [157]. Griebel and Merrick [157] have shown that 
following removal of this membrane bound protein fraction using a mild alkaline 
treatment, the extracted granules were essentially devoid of PHB synthetase activity.
Only on recombining this protein fraction was synthetase activity (and presumably PHB 
synthesis) restored [157]. The PHB synthetase enzyme is also thought to be physically 
located in the external membrane of the granule and is regarded as the key enzyme to 
explaining why Alcaligenes eutrophus is able to make different PHA’s depending on the 
substrate used [158]. The explanation may lie in the non -  specifity of the synthetase and 
other enzymes (such as ketothiolase) involved in the pathway but the exact mechanism 
has yet to be demonstrated.. This may not be possible until the structure of the 
synthetase enzyme is elucidated.
The synthesis half of the pathway in Figure 1.4 occurs during conditions of carbon 
excess whereas during balanced growth of the bacteria, the acetyl-CoA would normally be 
involved in other biochemical pathways (e.g. TCA or Krebs cycle) to produce energy and 
other cellular materials [137,148]. Consequently, PHB synthesis is regulated by all 
biochemical pathways producing or utilizing acetyl-CoA, the initial component in 
prokaryotic synthesis of PHB. PHB synthesis is also thought to be stimulated by 
conditions of oxygen, nitrogen and phosphorous limitation [137,148] (see Figure 1.5).
The reutilization of PHB proceeds within Alcaligenes eutrophus by hydrolase enzymes 
which depolymerize the polymer to initially its oligomeric and eventually, monomeric 
fractions. The monomer is converted to acetoacetate by 3 -  hydroxy butyrate dehydrogenase 
and the intracellular depolymerization is completed when acetyl-CoA is formed from 
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Figure 1.5. An overview of cellular conditions necessary for PHB 
synthesis. (After ref. 152).
available for Incorpoation Into energy producing biochemical pathways [137,148].
In Alcaligenes eutrophus, glucose has been found to the most efficient substrate for the 
commercial production of the homopolymer, PHB [151-152]. Other substrates such as 
methanol, sucrose, hydrogen, ethanol and acetic acid can also be used to produce the 
homopolymer [159-161]. Using various intracellular pathways such as the Hexose- 
Monophosphate pathway (HM), the organism is able to convert these substrates to the 
required acetyl-CoA. However, by modifying the substrate (carbon source) of Aeutrophus, 
other PHA’s can be produced. P(HB-HV) copolymers are produced using a combination of 
glucose and propionate [151-153]. By adjusting the composition of the carbon sources, 
copolymers with up to 47 mole% HV content have been produced [149-153]. P(HB-HV) 
copolymers containing up to 30 mole% HV content are available commercially. There had 
been suggestions that HV contents in excess of 50 mo!e% could not be produced because of 
a relatively fast metabolic pathway from propionyl-CoA to acetyl-CoA, but recently Doi 
et al [162] have been able to synthesise copolymers with up to 95 mole% HV from A  
eutrophus fed on pentanolc and butyric acid substrates. Doi and colleagues, who have 
carried out much work on PHA biosynthesis [162-173], have also shown that novel 
copolyesters of 3 -  hydroxybutyrate (3 -H B ) and 4-hydroxybutyrate (4 -H B ) can be produced 
from A. eutrophus when fed on nitrogen -  free cultures of either butyrolactone and butyric 
acid [172] or 4 -H B  and 4-chlorobutyric acid [169]. Doi et al [167] also found that by 
growing the organism on pentanoic and 4 -H B  acids, a novel terpolyester of 3 -  HB, 3 -  HV and 
4 -H B  could be produced.
The majority of biosynthetic P(HB-HV) and P (3 -H B -4 -H B ) copolymers have been shown by 
13C -N M R  to be statistically random [165,169,171,176,177], this suggests that enzymes 
responsible for P(HB-HV) synthesis are non-specific and can polymerize related monomers 
with equal efficiency. However, a recent report by Doi and colleagues [173] has shown 
that some of the polymers extracted from A. eutrophus (ATCC17699, NCIB11599) were 
actually mixtures of two or three random copolymers. Using a variety of substrates the 
organism was able to synthesise some P(HB-HV) copolymers whose sequence distributions,
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as determined by 13C -N M R , followed neither Bemoullan nor first-order Markovian 
conditions, Indicating that they were neither random nor block copolymers. With the aid 
of thermal analysis showing displaced melting endotherms, the authors were able to 
interpret the sequence distributions on the basis of a model of a mixture of two random 
copolymers [173]. It is now thought that because NMR can hardly discern beyond the triad 
level, the characterization of more complex sequences arrangements (such as partial 
blocks or higher order regularities) cannot easily be achieved without using 
complimentary techniques [174]. As a result alternative techniques such as Fast Atom 
Bombardment-Mass Spectrometry (FAB-M S) [174] and Pyrolysis-MS [175] have been
investigated for sequence determination.
One of the first reports pertaining to the natural existence of other PHAs was that of 
Wallen and Rohwedder [178]. The authors reported that physical blends of PHB and PHV 
(1:5) were accompanied by small quantities of C6 and C7 PHAs. Findlay and White [179] 
have reported the presence of at least 11 different PHA’s in the microbial mass of 
marine sediments. Witholt and coworkers [180] found that Pseudomonas oleovorons growing 
on octane as substrate were able to produce polyhydroxyoctanoate. Using the same 
organism Lenz and coworkers [181-182] have recently been able to use the sodium salt of 
a range of n-alkanoic acids as substrates to produce PHA s containing up to 12 carbon 
atoms. Although all the recovered polyesters were heteropolymers, containing up to 6 
different monomers, G C -M S analysis showed that the major monomer unit always had the 
same number of C atoms as the n-alkanoate substrate used. The authors also observed that 
when fed on C9 and C10 substrates, the next most abundant monomer contained 2 carbons 
less than the n-alkanoate used for growth [182]. This finding suggested that the PHA 
synthesising enzymes in P.oleovorons had higher specifity for certain long chain 
substrates. This is in sharp contrast to observations with those organisms 
preferentially synthesising P(HB-HV) even with long chain substrates.
The non -  specifity of the biosynthetic enzymes in polymer accumulating organisms has 
proved to be an advantage for it offers the potential of synthesizing unusual polymers
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not readily synthesized chemically. The potential for making biodegradable materials 
with specific and preselected properties has increased commercial Interests in PHA 
research over the last decade. This fact, coupled with advances in genetic engineering 
has led to studies which aim to manipulate the bacterial genes responsible for PHA 
synthesis in order to obtain increasingly more efficient synthesis and extraction.
Indeed Peoples and Sinksey [183-184] have suggested that PHB synthesis could be used as 
a model system for bioengineering purposes.
Peoples and Sinskey [183] have been able to isolate the genes encoding for the first two 
enzymes in the biosynthetic pathway for both Zoogloea ramigera and A. eutrophus. The 
authors have been able to characterize the genes and report to have developed enzyme 
overproduction systems [183-184]. Sinskey et at [185] are currently Investigating the 
location of the PHB polymerase structural gene(s) by subcloning experiments. 
Overproduction of PHB during the exponential growth of Azotobacter vinelandii UWD, a 
novel strain formed by transformation of the UW and 113DNA strains of A  vinelandii, has 
been reported by Page and Knosp [186].
Recently Friehs and Lafferty [187] have used genetic engineering methods to enhance the 
substrate spectrum of A  eutrophus H16. By using parts of the vector pMMB33 and a DNA 
fragment of the Bacillus subtilis chromosome, a plasmid was constructed bearing the gene 
for levanase, an enzyme able to hydrolyse various saccharides (cheap substrates). 
Transfer of this gene into A  eutrophus enabled the strain to hydrolyse sucrose but not 
to the desired efficiency. The limited growth on sucrose was attributed to inefficient 
transport of sucrose Into the cell and/or poor secretion of levanase into the medium 
[187].
The genes for the first two enzymes of the PHB biosynthetic pathway in A  eutrophus have 
also been cloned and expressed in Escherichia coli by Slater et al [188] and by Schubert 
et al [189]. The E.coli, which does not normally synthesise the polymer, has been 
reported to accumulate PHB to levels approaching 80% of the dry cell weight [188]. The 
biosynthetic pathway in E. coli is thought to be controlled in a manner similar to that
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found in A  eutrophus. The major significance of synthesising PHB in E. coli is that 
ail the genetic engineering principles that apply to this organism can now be utilized 
in optimising the production of PHB and other PHA s. There has been a recent report that 
a PHB synthesizing mutant of E. coli has been developed from which the polymer can be 
extracted by mild heat treatment rather than by expensive solvent extraction techniques 
currently employed [190]. This strain is thought to release the accumulated polymer by 
thermally induced cell lysis at a low temperature of only 42°C [190]. Clearl^this is an 
area of great commercial interest and will undoubtedly attract much further research 
Interest.
1.4.1.1 Morphology of PHB granules
PHB and other PHA’s accumulate in discrete spherical granules in the cell cytoplasm. 
Granules have a diameter in the range between 100 and 800nm [137,191] and are enclosed 
in a unit membrane approximately 2 -  4nm thick [191 -192]. The granules are typically 
composed of 98% polymer and 2% protein.
The granule was originally thought to consist of a solid, central polymer core, 
surrounded by a intermediate zone consisting of fibrils, lamellae and chains of PHB 
[137,191]. The polymer was thought to be In a crystalline state and led to the 
hypothesis that simultaneous biosynthesis and crystallization occurred [191]. The view 
that PHB is solid in vivo, was based on studies with freeze-dried granules and prevailed 
despite the fact that it leads to numerous difficulties in understanding the enzymology 
of PHB. The most obvious of these is the problem of how it is possible for the synthase 
and depolymerase enzymes to operate so efficiently on a close packed solid. Recent 
studies by Barnard and Sanders [193-194], using high resolution 13C -N M R  on live cells, 
have suggested that PHB is predominantly in a mobile state (but not in solution) within 
the storage granules of A. eutrophus and other organisms. The authors demonstrated that 
water was an integral part of the granule and acts as a plasticizer for the polymer 
[194]. The authors propose that the enzymes involved in the PHA biosynthetic pathway
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operate only on a mobile hydrated material and that the solid granules characteristic of 
dried cells are partially artifactual [194]. This work suggests that in vivo PHB is much 
more flexible and has an effective glass transition which is much lower than that of 
the solid state but the mechanism by which water plasticizes the polymer is not entirely 
clear. Interestingly, recent NMR studies of the analogous storage compound in humans 
have suggested that liver glycogen is also more mobile than previously thought [195]
1.4.2 Chemosynthesis
The chemical synthesis of PHB and similar polyesters has been reported by a number of 
authors [196 -  209]. From the early studies it was apparent that polycondensation of 3 -  
hydroxybutyric acid does not lead to high molecular weight polymers, since the acid 
readily dehydrates to crotonic acid [196]. Further studies on the synthesis of PHB from 
racemic p -  butyrolactone (BL) using various catalysts led to low molecular weight 
polymers with properties very different to those of bacterial PHB [197-199]. Agostini et 
al [201] were the first to report the synthesis of partially stereoregular PHB using a 
triethylammonium/water catalyst system. They found that by using racemic BL, a 
partially crystalline but optically inactive PHB (i.e. DL-PHB) could be obtained 
[200,202]. However, by using optically active BL (i.e. D (+ )-B L ) of 73% optical purity 
they were able to synthesize an optically active analog of the naturally occurring 
polymer [201]. Tani et al [203 -  204] also reported the synthesis of higher molecular 
weight PHB from racemic BL and were able to achieve increased crystallinity by means 
of solvent extraction. Both groups found that the X -ra y  diffraction patterns of 
synthetic PHB derived from racemic or partially active monomer were identical with that 
of bacterial PHB [200,209].
Racemic PHV (i.e DL-PHV) has also been chemically synthesized from racemic p -  
valerolactone (VL) by Tani and coworkers [204] when using the same experimental 
conditions as those for PHB synthesis. More recently Bloembergen et al [206] have used 
racemic BL and VL to prepare partially stereoregular PHB and PHV homopolymers. However 
by adjusting the mole ratio of the AIET3/H 20  catalyst system they were able to produce a
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high molecular weight polymer fraction with a high level of stereoregularity. This 
fraction was reported to be highly crystalline and XH -  NMR analysis showed that the 
fraction contained 85% to 87% isotactic diads [206]. The properties (melting 
temperature, heats of fusion and X -ra y  structure) of the synthetic homopolymers were 
reported as being similar to those of naturally occurring homopolymers [206].
In an earlier study, Bloembergen et al [207] were able to chemically synthesize 
statistically random P(HB-HV) copolymers from racemic BL and VL. The major significance 
of this was that copolymers containing the full composition range of up to 100% HV could 
be synthesized including those which are, as yet, commercially unavailable by 
biosynthesis. However, although the synthetic copolyesters were reported to be highly 
crystalline, they were not optically active and the low yield of stereoregular material 
(<25%  w /w  of total polymer) was considered to be a drawback. In a more recent study, the 
authors [208] were able to remove the atactic fractions by extraction with ethanol or 
acetone, to leave behind a high molecular weight polymer fraction with enhanced 
stereoregularity and sharp melting points.
Although the above synthetic studies were aimed at producing polymers identical to those 
found in bacteria, the less crystalline fractions may be preferable for some drug 
delivery applications providing they could be obtained in a pure form.
1.4.3 Crystalline properties
P(HB-HV) polyesters are semicrystalline polymers which have been reported to have very 
high degrees of crystallinity (60 -  80%) [149, 210-211]. The degree of crystallinity is 
one of the most important basic parameters characterizing semicrystalline polymers 
[212]. It affects virtually all other bulk properties of the polymer including 
mechanical, physical, thermodynamic and optical [213]. Pharmaceutically, crystallinity 
will influence polymer properties such as rate and mechanism of degradation, drug 
compatibility and drug diffusion and therefore drug release. The way in which these 
polymers crystallize from solution and from the melt has received great attention over
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the last few years [210-211,214-218]. The exceptional purity and chemical regularity of 
PHB (due to its biological origin) make it an ideal model substance for fundamental 
studies of polymer morphology, crystallization and nucleation [214], The crystallization 
of P(HB-HV) polyesters from the melt is a subject of this study and will be discussed in 
more detail in chapter 5. The basic concepts involved in polymer crystallization are 
given below.
1.4.3.1 Crystallization in polymers
Unlike conventional "small molecule" crystals, where crystallinity generally results 
from regular packing of ions or atoms, crystallinity in polymers results from regular 
packing of molecular chains. The pre-requisites for crystallization include that the 
polymer chains exhibit chemical and stereo -  regularity [219]. The isotactic nature of the 
side appendages on a linear backbone of P(HB-HV) polymer chains naturally lend 
themselves to ordering by satisfying some of the structural requirements for 
crystallization. Further details on structural requirements for polymer crystallization 
can be found in more general books and reviews [219-220].
1.4.3.2 Models of crystallinity
Although polymers were known to crystallize, failure to produce crystals of a 
macroscopic size for the majority of polymers suggested that they were not completely 
crystalline [219]. Indeed all macroscopic properties indicated that bulk polymers 
consisted of either microcrystals with large degrees of imperfection, or of an intimate 
mixture of microscopic crystalline and amorphous phases.
In fact, for many years, the latter was the accepted view of polymer crystallinity. The 
state of the bulk polymer was regarded as that of crystals of the order of several 
hundred Angstroms in size imbedded in an amorphous matrix. The polymer chains (which in 
a typical polymer are 0.1 -  10um in length) were viewed as threading their way through 
more than one crystallite (in which they were ordered) via amorphous regions (in which 
they were less ordered). This concept of polymer crystallinity is known as the ’fringed
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micelle’ model and is depicted in Figure 1.6 [221 -222]. The relative abundance of the 
two phases, crystalline and amorphous, is termed the degree of crystallinity.
The validity of the fringed micelle model of polymer crystallinity came into serious
question In the mid 1940 s, when it could not be successfully used to explain the
structure of the then newly discovered spherulites [223]. Spherulites are spherically 
symmetric collections of crystallites which commonly result when polymers are
crystallized from the melt and are discussed in more detail in chapter 5.
Then In 1957 [224 -  226] It was discovered that single crystals of polymers (polyethylene) 
could be grown from dilute solution. The type of structures observed in these early 
investigations can be represented by Figure 1.7 which shows single crystals of PHB. The 
crystals are sheet-like and often termed lamellae. Lamellae form because of the kinetics 
of nucleation and growth [220]: they can develop faster than crystals with alternative 
molecular conformations [227]. The discovery of lamellae was to radically change the 
concept of polymer morphology and its consequences. Keller [224] proposed that this 
discovery necessitated that a single molecule thread many times through the same
crystal, which it does by folding in the crystal surface. This marked the advent of the 
chain-folded concept of polymer crystallinity. The evidence from which Keller drew his 
conclusions on chain -  folding was supported by similar, independent observations of 
Fischer [225] and Till [226].
Knowing the crystal structure of polyethylene from the work of Bunn [226], Keller’s
electron diffraction experiments proved that the polymer chains were arranged
perpendicular to the large, fiat faces of the lamellar crystals. The thickness of the 
lamellar crystals was in the vicinity of 11-14nm  (depending on temperature of
crystallization) and this was far less than the contour length of polymer molecules 
(approximately 200nm). On the basis of this information, Keller concluded that the upper 
and lower surfaces of the single crystals consisted of chain folds.
Density measurements of polymer single crystals were somewhat lower than their
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Figure 1.7. Solution grown single crystals of PHB.
(Photograph courtesy of Lyn Welland, University of Bristol, UK).
Scale bar = 2nm. I------------------------------ \
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theoretical crystal densities (PHB is no exception) calculated from the dimensions of 
the unit subcell [219]. This density defect suggested that polymer single crystals were 
not 100% crystalline but contained amorphous regions which made them polycrystalline in 
nature. It is thought that the amorphous component causing the density defect results 
from the irregularity of the chain folded surface [229]. The chain folded model of 
crystallinity depicting varying amounts of irregularity in the folding of chains is 
given in Figure 1.8. Even when folding is regular (adjacent re-entry) there remains a 
density defect and for that reason the folds, themselves, have been regarded as the 
amorphous regions [229-230]. Although the chain-folded model of crystallinity is 
regarded as basically correct, there still remains some confusion over the exact reasons 
for the density defect and hence, the nature of the amorphous component Some 
investigators attribute practically the entire density defect in single crystals to 
surface roughness in the form of long loose folds, while others attribute it an an 
amorphous surface zone arising mostly from non-adjacent re-entry on a large scale. 
Furthermore, Hoffman et al [220] suggested that the amorphous zone may actually consist 
of independent polymer chains that are physically adsorbed on the fold surface.
Chain folding is not unique to traditional synthetic polymers but has also been reported 
to occur in a number of biological polymers including sonically degraded salmon sperm 
DNA [231] and synthetic peptides as exemplified by the calcium and barium salts of poly 
(L - glutamic acid) [232], There is also a suggestion that DNA of viruses may crystallize 
by chain folding when packed into the intact head of the virus [233]. Clearly, the 
phenomenon of crystallization with chain folding is a very common one.
1.4.3.3 Crystal structure of PHB and P(HB-HV) copolymers.
Historically, Marchessault and coworkers [234] made the first solid state investigation 
of PHB and to date Marchessault’s group has continued to study the crystalline 
properties of this polymer. In 1963 [234] they were the first to produce single crystals 
of PHB and were able to deduce, from x -ra y  diffraction data, that PHB had a fibre repeat
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Regular, adjacent re entry folds similar to those 
postulated as present in pyramidal crystals that 
have been grown from solution
B
Irregular, adjacent re-entry folds in which the ex­
tent or thickness of the irregular layer is sug­
gested to be proportional to the temperature
rf
Switchboard, or nonadjacent re entry model  
in which an even more nonordered amor- 
r '  phous layer is present on both sides of the 
lamellae than in the irregular model
Figure 1.8. The Chain Folded models of polymer crystallinity 
(from ref. 230).
of 0.59nm. Although Lundgren et al [147] found that PHB from different bacterial genera 
gave Identical X -ra y  diffraction patterns Irrespective of source, the crystal structure 
remained unknown.
The detailed crystal structure of the homopolymer, PHB, was first identified by Okamura 
and Marchessault in 1967 [235-236]. Using X -ra y  diffraction the unit cell (more 
accurately sub-cell) was identified as orthorhombic with the lattice parameters a=  
0.576nm, b= 1.320nm and c=  0.596nm (fibre axis) and is represented in Figure 5.3
(chapter 5). They proposed that PHB existed as a right handed helix with a two fold 
screw axis and that two anti -  parallel chain molecules pass through the sub-cell. The 
latter finding was in accord with the proven occurrence of chain folding in single 
crystals of PHB [234]. On the basis of the above findings, Okamura and Marchessault 
proposed that the space group for PHB was P212 121 and that the theoretical crystal 
density was 1.262 g/cm 3. The amorphous density was later proposed to be 1.171 g/cm 3 
[214]. Further structural studies on PHB using electron or x -ra y  diffraction by 
Marchessault and coworkers [237-239], Yokouchi et al [209] and recently by Bruckner et
al [240] have generally confirmed the original findings of Okamura and Marchessault 
[235].
The crystal structure of PHV is similar to PHB and was first reported by Yokouchi et al 
[205]. X -ra y  diffraction studies on melt-drawn samples of synthetic racemic PHV showed 
that the unit cell was also orthorhombic with the lattice parameters: a=  0.932nm, b=  
1.002nm and c=  0.556nm (fibre axis) and had the same space group as PHB [17]. The 
lattice parameters for the subcell of synthetic PHV were latter confirmed by Pundsack 
and Bluhm [241] using a specimen tilting technique to obtain 3 -  dimensional electron 
diffraction data of PHV single crystals.
Marchessault et al [242] showed that naturally occurring PHV had similar sub-cell 
dimensions to the synthetic racemic PHV except that the lattice parameter "a" was 
significantly higher at 0.952nm. The study was carried out on a polymer sample extracted 
from activated sludge [242] which was thought to a physical blend of PHB and PHV.
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However there was some uncertainty about the nature of the polymer sample and therefore 
the reported pure PHV crystals may well have been those of a heteropolymer.
It is thought that due to the similar crystal structures (and dimensions of the 
monomeric units) of PHB and PHV, in statistically random P(HB-HV) copolymers (synthetic 
and naturally occurring), the HB and HV units can co-crystallize within either sub-cell 
[208,210]. This is termed isodimorphism and the sub-cell chosen for crystallization 
depends on HV content. The PHB sub-cell is found at HV contents below about 30 mole%, 
above which the PHV sub-cell is used for co -  crystallization [210]. However, there had 
been earlier, a suggestion by Mitomo et al [243 -  244] that HV units were incapable of 
crystallizing and remained amorphous but this work has been subsequently reported to be 
inaccurate by the co-authors [245].
1.4.3.4. The degree of crystallinity of P(HB-HV) polymers.
Early workers reported that the homopoiymer was about 60-90%  crystalline [149]. This has 
been confirmed by more recent work [211,214] and is essentially correct. However, the 
early reports of copolymers being less crystalline [149,246,247] are now thought to be 
misleading. On the basis of their heats of fusion, Holmes and colleagues [149,247] 
reported that the crystallinity of P(HB-HV) copolymers decreased with increasing HV 
content and Owen [248] using wide-angle X -ra y  diffraction studies on melt-crystallized 
samples came to the same conclusion. However, because the heats of fusion for the 100% 
crystalline copolymers are not yet known and because of the unknown contribution of HV 
to the amorphous phase, a matter currently under investigation [249-250], the use of 
copolymer heats of fusion and their comparison with the heat of fusion of the 
homopolymer to determine the degree of crystallinity is not valid. It is now known that 
the rate of crystallization in the copolymers is slower than the homopolymer (chapters 4 
and 5) [211,251] and therefore after relatively short periods of time following 
fabrication the copolymers are known to be less crystalline than the homopolymer. It is 
thought that Owen did not allow samples to attain equilibrium crystallinity before
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assessing their degrees of crystallinity [250].
The present view is that the P(HB-HV) copolymers have similar degrees of crystallinity 
to PHB [211]. These results concurred with the opinion that P(HB-HV) copolymers are
isodimorphic [210]. However, a recent report showing that density of the copolymers 
decreases with increasing HV content [249], is incompatible with the previous 
suggestions that crystallinity remains constant independent of HV content and that there 
is equal concentration of HV in the crystal and amorphous phases [210-211]. It is
therefore likely that some exclusion of HV units from the P(HB-HV) lattice occurs during 
crystallization of copolymers and this may explain the fall in density with increasing 
HV content The overall degree of crystallinity may still remain essentially independent 
of HV content, but will be influenced by the degree of HV inclusion for each P(HB-HV) 
copolymer.
Crystallinity of the unusual copolyesters of 3 -H B  and 4 -H B  has been reported to decrease 
with increasing 4 -H B  content when determined by thermal methods [169]. Furthermore,
PHAs containing long side appendages (n-pentyl or greater), as produced by Lenz and 
coworkers [182] by growing P.oleovorons on long chain substrates, are also crystalline 
(melting range 45-61°C ; heat of fusion up to 8.3 cal/g).
1.4.4 Solubility and Conformation of PHB in solution.
P(HB-HV) polymers are soluble in a number of organic solvents [252-253]. The solubility 
of the homopolymer, PHB, in various solvents is summarized in Table 1.1. The 
solubilities are naturally dependent on temperature and polymer molecular weight 
Chloroform has been the most common solvent used for P(HB-HV) polymers. To achieve
complete solubilization at even modest concentrations (2%w/v polymer), the crystalline 
polymer can require refluxing in chloroform (~62°C) for up to 24 hours. No reports on 
the solution conformation of P(HB-HV) copolymers exist in the literature, but initial 
studies by Marchessault et al [254 -  255] suggested that the homopolymer, PHB, actually 
retained its solid-state helical conformation in solution following their studies with
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chloroform, trifluoroethanol (TFE) and ethylene dichloride. The authors based their 
conclusions on optical rotatary dispersion (ORD) experiments which showed a helix-coil 
transition for PHB when the temperature or the solvent composition was varied. However, 
they ignored their results from viscosity experiments which suggested a random coil 
conformation of PHB in chloroform [254]. Akita et al [256] using both viscosity and 
light scattering data concluded that the molecular conformation of PHB in what 
Marchessault et al [254-255] called helicogenic solvents was essentially random coil and 
the molecule was expanded by an unusually large volume exclusion. These authors used PHB 
samples with narrow molecular weight distributions in contrast to the studies of 
Marchessault et al [254] where samples used had polydispersities ranging up to 6. 
Further work on PHB by Fujita and coworkers [257-259] confirmed that an unusually large 
volume exclusion occurs in TFE. The more recent work of Doi et al [176], who used 13C -  
NMR to show that the PHB molecule in chloroform was not rigid but rather flexible, 
supports the random coil hypothesis.
Table 1.1. Solubility Properties of PHB (After refs. 148 and 252)
Highly soluble in:
Chloroform Ethylene carbonate Dimethylformamide
Dichloromethane Propylene carbonate Ethylacetoacetate
Di—, tri —, and Trifluoroethanol Triolein
tetra -  chloroethane Acetic anhydride Acetic acid
Dichloroacetate 1N Sodium hydroxide Alcohols (with more





Water Dilute mineral acids Ethyl acetate
Methanol Alkaline hypochlorite Ethylmethylketone
Ethanol Diethylether Tetrahydrofuran
Propan -1  -  ol Hexane Ethylformiate
Propan -  2 -  ol Benzene Butyl acetate




When extracted from different bacterial sources, the •homopolymer, PHB, has essentially 
similar properties [260]. Furthermore, the properties of PHB extracted from Alcaligenes 
eutrophus are thought not to vary with the nutrients used for fermentation [150].
Molecular weights of the polymer obtained have been reported to change with the 
bacterial source but there have been suggestions that the variation in molecular weight 
may due to the extraction process used [159]. The different extraction processes are 
thought to lower the polymer molecular weight to varying extent [159]. A recent report 
by Scandola et al [261] showed that PHB extracted from Rhizobium sp. using HCI (0.1 M) 
had a molecular weight of 60K but when extracted with acetone PHB samples had molecular 
weights of the order 106.
PHB is a crystalline thermoplastic with melting range of 160-180°C  depending on the 
molecular weight and thermal history of the sample [149,211,214,262 -  263]. It can be melt 
or solution processed into films, sheets and fibres [149,246]. P(HB-HV) copolymers are 
also semicrystalline thermoplastics but generally have lower (as low as 80°C [262]) 
melting points than the homopolymer depending on the HV content [262 -  263]. There appears 
to be a eutectic minimum In their melting points at about 30 mole% HV [210]. The 
eutectic minimum is a rare occurrence in normal copolymer systems where melting points 
usually continue to fall with increasing comonomer content [262]. Based on this eutectic 
minimum coupled with the facts that the degree of crystallinity appeared to be high (6 0 - 
80%) and independent of HV composition and that NMR analysis showed comonomer sequence 
distributions to be Bernoulian, Marchessault and colleagues [210,262] concluded that the 
P(HB-HV) polymers were isodimorphic. The crystal structures and dimensions of the unit 
cell, as mentioned above and according to Marchessault et al [210], further satisfy the 
criterion necessary for isodimorphism. However there remains some doubt as to the extent 
of HV inclusion within crystals and hence the relative distribution of HV into amorphous 
and crystalline domains [249-250].
The glass transition temperatures of PHB and P(HB-HV) copolymers have been reported by
Akhtar and Pouton [263] to lie in the range - 5  to +20°C  (as determined by differential 
scanning calorimetry) and appeared to be independent of copolymer composition but 
dependent on the thermal history of the polymer. This suggests that the amorphous 
regions of the polymers will exist in the rubbery state at physiological temperatures.
Baptist and Werber [260] were the first to report empirical data on the mechanical 
properties of the homopolymer. In a general paper outlining the isolation and 
characterization of PHB from Rhizobium sp., they noted the relatively brittle nature of 
the crystalline homopolymer and suggested that its properties may be improved by 
plasticization with a variety of esters, chlorinated hydrocarbons, polyglycols and some 
nitriles [260]. These compatible plasticizers were thought to lower the tensile modulus 
by suppressing or slowing down crystallization. However, no supporting evidence was 
given to confirm this statement
Akhtar et al [264] have shown, using static tensile tests on chloroform cast thin films 
(30-50um ), that although the homopolymer PHB is relatively hard and brittle, 
copolymerization with HV produces tougher, less brittle and more pliable polymers. It 
was suggested that in some cases, the copolymers may be preferable for manufacture and 
Implantation of biomedical devices [264]. These authors further noticed that the 
inclusion of a particulate drug (Sodium Fluorescein) modified (lowered tensile strength 
and elongation) the mechanical properties of these polymers [264]. The use of 
hydroxyapatite and other fillers in PHB has been used to modify the mechanical 
properties of the polymer for certain surgical applications [265-268].
Dynamic mechanical properties of P(HB-HV) polymers have been studied by several groups 
[248,261,269,275]. Using isotropic copolymer films cast from both chloroform and 
methylene chloride, Owen [248] showed that the modulus decreased with increasing HV 
content. Owen [248] used two P(HB-HV) copolymers, one containing 17 mole% HV but the 
other was quoted as having 2 5 -3 0  mole% HV. The latter sample is now thought to have 
contained only 20 mole% HV [270]. There have also been suggestions that mechanical
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properties change with time on storage [269]. The morphological changes on storage 
(ageing) have been examined in this study and are further discussed in chapter 4. The 
homopolymer, PHB, is thought to be thermally unstable at temperatures marginally above 
the melting point [247]. Barham et al [214] have reported that a PHB sample stored at 
190°C for 1 hour had degraded to half Its original molecular weight It is well known 
that the major pyrolysis product of PHB is crotonic acid [247,260,271] and that this was 
produced by the p -  elimination reaction [247,273]. Grassie et al [272], using Thermal 
Volatilisation Analysis (TVA) and subambient TVA (SATVA), showed that significant 
quantities of PHB oligomers and small quantities of isocrotonic acid were also evolved 
on heating the polymer to around 300°C. In addition, small amounts of carbon dioxide, 
propene, ketene, acetaldehyde and 3-butyrolactone were also reported to be evolved but 
the authors showed that these were secondary products formed by further decomposition of 
the primary products [272].
Billingham et al [247] have recently studied ways of improving the melt stability of 
synthetic and bacterial PHB. The degradation properties of the synthetic and naturally 
occurring polymers were similar once the catalyst residues were removed [247]. The 
authors found that PHB was, in practical terms, on the limit of melt processability but 
could be moulded and extruded satisfactorily within a small processing window of short 
residence times. They found that conventional stabilizers had little effect in 
preventing degradation of PHB. They were able to increase the thermal processing window 
of PHB by incorporating plasticizers. However, the amount of plasticizer that could be 
included into PHB was limited because of its high crystallinity and therefore this 
method was not as effective as in other polymer systems [247]. Although much
information is available on the thermal processing of PHB, little is known, as yet, 
about P(HB-HV) copolymers. Several reports have suggested that the copolymers are more 
stable and can be processed without significant degradation [247,262].
P(HB-HV) polymers are known to exhibit piezoelectricity [274 -  277]. The orthorhombic 
subcell of the crystalline polymers lacks symmetry and therefore mechanical deformation
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of the crystal in directions other than tension results in surface polarization or 
charging. Since electrical stimulation is thought to promote bone healing and repair 
[278], P(HB-HV) polymers have been suggested for use as bone pins and plates [149].
1-4-6 Biodegradation
1.4.6.1 Microbial degradation
The potential use of PHB and related polyesters as commodity plastics relies on their 
biodegradation in natural environments. Extracellular enzymes of a number of 
microorganisms have been reported to cause degradation of PHB [137]. Figure 1.9 shows 
the extracellular degradation of PHB by a mycelial fungus. Many soil bacteria are known 
to completely degrade PHB and utilize the polymer as a carbon source [137,148,279]. 
Merrick et al [280] showed that extracellular degradation of PHB by Pseudomonas sp. 
yields the dimeric 3 -  hydroxybutyrate, which was then later reported as being actively 
taken into the bacterial cell and hydrolysed to the monomer by the intracellular 
hydrolase [281,282]. The monomer can then participate in intracellular biochemical 
pathways providing energy for the bacterium. The exoenzyme is thought to be released 
during the growth phase of the organism but mainly at its cessation [281]. Further work 
by Lusty and Doudoroff [282] showed that the extracellular depolymerase of P. lemoignei 
actually consisted of two fractions, A and B. Fraction A converted the polymer to the 
monomer and dimer whereas fraction B of the depolymerase yielded the trimer. The 
extracellular depolymerase enzyme from Alcaligenes faecalis has been isolated and fully 
characterized by Tanio et al [283 -  285]. This organism was able to utilize PHB as the 
sole carbon source. The extracellular depolymerize when purified by Tanio et al [283- 
284] had a molecular weight of 48K (gel filtration) or 50K (polyacrylamide gel 
electrophoresis) and was optimally functional at a pH of 7.5. The depolymerase converted 
the PHB to predominantly the dimer but small amounts of the monomer were also detected 
[283 -  284]. The enzyme activity of this depolymerase was found to decrease when treated 
with trypsin [285]. This loss of activity was attributed to the removal of the 
hydrophobic site on the depolymerase by trypsin [285]. It is now evident that a broad
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Figure 1.9. A scanning electron micrograph showing extracellular 
degradation of a PHB film by a mycelial fungus. Note the etching 
of the polymer film adjacent to the fungus.
(Photograph courtesy of A. Webb, ICI, UK)
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spectrum of bacteria can depolymerize PHB and presumably other PHA’s. Table 1.2 
summarizes the biodegradation of PHB in soil and various other environments.
Table 1.2 Biodegradation of PHB in Various Environments (After refs. 148 and 246).
Environment Period for Dissolution 
of 1mm thick-section 
(weeks)
Average rate of 
surface erosion 
(u m/week)
Period for 100% weight
loss of 50um thick packaging 
film (weeks)
Anaerobic Sewage 6 100 0.5
Estuarine sediment 40 10 5
Aerobic sewage 60 7 7
Soil at 25° C 75 5 10
Sea water at 15°C 350 1 50
Doi et al [172] have recently reported that the P (3 -H B -4 -H B ) copolymer containing 
17mole% 4 -H B  degraded more rapidly in soil than pure PHB. However, no comparison was 
made with P(HB -  HV) copolymers. Although few (if any) reports are currently available on 
the degradation of other PHAs it is likely they too are degraded by microorganisms but 
possibly at different rates. Furthermore it remains to be seen whether mammalian enzymes 
can influence the degradation of P(HB-HV) and other PHA polymers.
1.4.6.2 In vitro and in vivo degradation of P(HB-HV) polymers.
In a manner similar to the microbial degradation, in vitro degradation of PHB is thought 
to proceed to the monomer, D (-)-3 -hydroxybutyric  acid. The acid is a normal constituent 
of blood and along with acetoacetate and acetone represents one of the three ketone 
bodies which are produced endogenously as a result of ketogenesis. It is therefore 
thought that PHB will be well tolerated in vivo. However, limited information is 
available, at present, on the hydrolytic degradation of P(HB-HV) polymers and even less 
(if any) on other PHAs.
Majid et al [286-287] have reported that the in vitro degradation of PHB proceeded 
relatively slowly when compared to P(LA-GA) polymer systems. Their studies on the
degradation of thin solvent cast films (85um) at 37°C and pH 7.4 suggested that the hatf 
life of these PHB films was about 152 weeks [287]. They found that the degradation rate 
of P(HB-HV) copolymers appeared to be more rapid but the relationship was not linear 
(Figure 1.10). The rate of hydrolysis (mass loss over a 50 week period) in these
polymers was reported to follow zero-order kinetics but the authors expressed some 
reservation because the degradation data from some copolymers could also be made to fit 
first-order kinetics [286]. Because water uptake into the polymers was too low to be 
measured precisely (less than 0.01%), the above results led the authors to conclude that 
in vitro degradation of P(HB-HV) polymers proceeded by a surface erosiorv mechanism. This 
was also confirmed by molecular weight analysis of degraded polymer samples. The 
molecular weight of PHB remained unchanged throughout the 50 week degradation period in 
which the polymer films incurred a 15% mass loss. Similar results were found for the 
copolymers under accelerated degradation conditions (0.1 N NaOH, 75°C) where mass losses 
of up to 87% for the copolymer containing 12 mole% HV, resulted in little or no
molecular weight loss [286-287]. This was in contrast to the bulk hydrolysing P(LA-GA) 
polymers in which mass loss during the degradation process was accompanied by large 
decreases in molecular weight [286-287]. A brief report by Gilding [54] also confirmed 
that no molecular weight loss of PHB samples was detected after 6 months of in vitro 
hydrolysis.
Tighe and coworkers [288-289] have also carried out extensive in vitro degradation 
studies with P(HB-HV) polymers. In their first study [288] they examined the effect of 
copolymer composition, molecular weight, fabrication technique, pH and temperature of 
the media together with effects of plasma on the hydrolytic degradation of P(HB-HV)
copolymers. Using a combination of techniques to assess bulk and surface erosion, such
as gravimetric and goniophotometric analysis, the authors found that degradation was 
enhanced when using alkaline media conditions, elevated temperature or low molecular 
weight polymer [288]. Also increasing HV contents of P(HB-HV) polymers up to 20 mole%, 
progressively increased degradation rates [288] which in principle was slightly 























HV content (mole %)
Figure 1.10. The in vitro degradation rates of P(HB-HV) 
polyesters. (After ref. 286).
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HV. Tighe and colleagues [288] also found that fabrication technique had a profound 
effect on the degradation rate of the polymer. In using four different fabrication 
techniques, the authors reported increasing stability to hydrolytic attack in the order 
cold compressed discs, solvent cast films, melt pressed discs and injection moulded 
devices [288]. The trend reflected, changes in porosity (compaction) and crystallinity 
which appeared to be the main determinants of polymer degradation.
The gravimetric data of P(HB -  HV) polymers obtained by Tighe and coworkers [288] is at 
variance with that reported by Majid et al [286-287]. Tighe and coworkers [288] found 
that although surface erosion does occur over the initial stages of the degradation, 
this is eventually superceded by the underlying bulk hydrolysis in the latter stages of 
degradation as indicated by rapid weight loss and increased porosity of the matrix. 
These results have been supported in a recent report by Knowles and Hastings [265]. The 
differences reported, both in the rate and mechanism of P(HB-HV) polymer degradation, 
may be explained by reference to the sterility of the release media used in the 
different studies. In the case of Majid et al [286 -  287] the media used for degradation 
studies was steam sterilized prior to use, thereby eliminating possible contamination 
with microorganisms. However, no sterilization of media in the other studies was 
reported. A preliminary study [290] in this laboratory has shown that by using non- 
sterilized distilled water as the hydrolysing medium, degradation of P(HB -  HV) polymer 
films (30-50um  thick) occurred within 2 -3  weeks, during which time all mechanical 
integrity of films was lost. The effect was more pronounced with copolymers. Subsequent 
microbiological analysis of the medium suggested the presence of pseudomonas sp., 
amongst others, as the contaminating agents [290]. Clearly much further work is 
necessary to to establish the role of both bacteria and mammalian enzymes on the 
degradation of P(HB-HV) polymers.
In contrast to the above studies, Miller and Williams [291 -  292] using mechanical 
property changes to monitor the in vitro and in vivo degradation of P(HB-HV) polymers, 
reported little or no degradation of PHB monofilaments. Although their failure to
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measure cross-sectional areas of some monofilaments before tensile testing, made 
interpretation of some their results difficult, they concluded that the homopolymer 
biodegrades in vivo (sub -  cutaneous implant in rats) only after pre-degradation with 
10Mrad gamma -  irradiation where the rate of degradation was much faster in vivo than in 
vitro. They found that increasing the HV content of P(HB-HV) copolymers (8 -1 7  mole%) did 
not enhance degradation but at elevated temperature conditions (phosphate buffered 
saline pH7.2 at 60°C or 70°C) increasing HV content actually retarded the degradation 
rate [291].
Doyle and Bonfield [268], using PHB (initial Mw range 0 .5 -1 .5  x 106) alone and in 
combination with hydroxyapatite found that injection moulded samples that had been 
sterilised by gamma-irradiation (2.5Mrad dose) showed significant hydrolytic degradation 
during a four month study period. Degradation was monitored by mechanical property 
changes of specimens immersed in sterile phosphate buffered saline pH 7.4 at 37°C. 
However, the authors did not measure the molecular weight of the polymer after melt 
processing or after irradiation sterilization and therefore the molecular weight of PHB 
samples used in the degradation were not known [268]. Furthermore, a recent report by 
Gerlach and Pesch [293] suggested that a P(HB-HV) copolymer containing 17mole% did 
biodegrade when specimens (25x3x2 mm), of an unknown physical form, were implanted 
subcutaneously into rats. The implanted copolymer specimens exhibited a progressive
decrease in both flexural strength and Youngs modulus during implantation (2.2% after 
1 month, 13.5% after 2 months and 18.5% after 3 months).
Other reports on in vivo degradation of PHB have included those of Kronenthal [294], who 
suggested that onset of degradation occurred within 8 weeks in an unspecified species, 
and Korsatko et al [1989] who suggested that in vivo degradation of PHB follows zero - 
order kinetics. However, in both these reports little data were presented to support
their conclusions on in vivo degradation of PHB.
Clearly the physical form of the polymer is a major determinant of the degradation rate.
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Although it was not entirely clear as to how the monofilament fibres of Miller and 
Williams [291] were processed , It is thought that they were most likely orientated 
fibres produced either by melt spinning or extrusion and consequently exhibited high 
crystallinity and low porosity which resulted in their relatively slow rates of 
degradation. Such devices which exhibit good stability to hydrolytic attack have 
advantages for use in surgical devices such as bone pins and plates. To this end, P(HB- 
HV) polymers are thought to be good candidates to fill the existing gap in the 
degradable polymer spectrum at the long term stability end [265].
In order to accelerate the degradation of P(HB-HV) polymers and thereby increase their 
applicability, Tighe and coworkers [289] have recently blended the polymers with a range 
of polysaccharides such as amylose, dextran, dextrin and sodium alginate. Using P(HB-HV) 
copolymers containing 12 and 20 mole% HV, they found that the degradation rate of these 
copolymers could be dramatically increased by varying the ratio and type of 
polysaccharide included [289]. The enhanced degradation with additives was attributed to 
the more rapid solvent uptake into the bulk of the matrix as the additive dissolved or 
leached out eventually causing matrix disintegration [289].
The use of additives (albeit biodegradable) has frequently been regarded as undesirable 
in biomedical polymers. Their use in implants will undoubtedly require toxicological and 
biocompatibility studies over and above those required for the virgin polymer. However, 
their use in drug delivery applications especially via the oral route may be more 
acceptable and undoubtedly offers greater control over degradation rate and possibly 
drug release.
1.4.7 Biocompatibility
The suitability of PHB and P(HB-HV) copolymers for inclusion in drug delivery or other 
biomedical applications will not only depend on the biodegradation properties but also 
on their biocompatibility. The term biocompatibility refers to the mutual acceptability 
of the polymer and its surrounding physiological environment Williams [295] has
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described biocompatibility as a two component phenomenon: the effects of the
physiological environment on the polymer and the effects of the polymer on that same 
environment The former will Influence polymer degradation and the second, the tissue 
response to the implanted polymers.
Early work by Korsatko et al [296] indicated the toxicological acceptability and 
biocompatibility of the homopolymer, PHB, as a compressed tablet implanted 
subcutaneously into the neck folds of mice. Further work by the same group [148] 
suggested that after an implantation period of 5 weeks, a connective tissue capsule 
containing many cells is formed around the PHB tablet. They did report a slight 
inflammation in the capsule zone during the implantation period in which the cell 
population of the capsule changed from mostly neutrophile granulocytes after 5 weeks to 
mostly lymphocytes after 20 weeks [148]. This reflected a change from an acute to a 
chronic inflammatory response by the mice to the PHB tablet and the authors suggested 
that this response was typical of any host reaction to a foreign implant No necrotic 
tissue was formed near the implant [148]. A recent report by Gerlach and Pesch [293] 
on the biocompatibility of a P(HB-HV) copolymer containing 17 mole% HV also suggested 
the formation of a connective tissue capsule but only after 2 weeks implantation into 
rats (implant site not mentioned). They found that all specimens (25x3x2 mm) produced an 
inflammatory response within the first week in that the reactive zone was limited to 
only a thin layer of polymorphonuclear leucocytes and occasional lymphocytes [293].
In vitro biocompatibility studies by Lafferty et al [148] showed that PHB did not 
affect cell growth or ceil metabolism, measured as glucose consumption and lactate 
production, when compressed PHB tablets were exposed to mouse fibroblast cells in 
culture.
The in vivo and in vitro biocompatibility of PHB and P(HB-HV) copolymers has also been 
carried out by Kennedy et al [297-299]. The in vivo biocompatibility was assessed by 
monitoring inflammation in male Wistar rats. Following intramuscular injection of 
polymer microspheres (20-40um ) into the rat thigh muscle, enzyme assays, using alkaline
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and acid phosphatase, were employed to monitor acute and chronic inflammation, 
respectively. Although an acute inflammatory response was noticed which was attributed 
to the initial trauma of injection, no chronic inflammation was observed [297]. The 
biocompatibility of the polymers was also evaluated using cell culture techniques. The 
effects of P(HB -  HV) polymers on the growth of CHO -  K1 (Chinese Hamster Ovary) cells in 
culture were monitored over a 60-hour period. The polymers, used as solvent cast films, 
did not inhibit growth of cells during this period, thereby suggesting good 
biocompatibility [298 -  299].
Juni and Nakano [300] have also studied the in vivo biocompatibility of PHB by 
injecting microspheres (100um) into the rat thigh muscle. The results were similar to 
the study of Kennedy et al [297] in that a transient acute inflammation was observed 
which terminated after 7 days post-injection [300]. The microspheres were further 
reported as being encapsulated by connective tissue during a 4 week post-injection study 
period [300]. Doyle and Bonfield [268,301], who have been investigating PHB for use in 
hip replacement, have carried out preliminary implantation studies in rabbits which 
showed good Integration between PHB and bone with no evidence of a chronic inflammatory 
response. They further reported that in vitro studies (unspecified conditions) with PHB 
and PHB -  hydroxyapatite composites suggested that the polymers were non cytotoxic [268].
Despite the initial acute inflammation observed in the various in vivo studies with 
P(HB-HV) polymers, which is probably in response to the trauma of implantation or 
injection, P(HB-HV) polymers show good in vitro and in vivo biocompatibility.
1.4.8 Biomedical applications
Although the potential of PHB for use in biomedical applictions (surgical sutures) was 
originally proposed in the early 1960 s [302], the commercial development by ICI in the 
1970 s was not primarily for these reasons. ICI had originally intended to use the 
bacterially produced thermoplastics as commodity plastics [149-152]. The principle of 
producing plastics from bacteria feeding on renewable resources such as sugar (glucose),
first occurred to ICI during the energy crisis of the early 1970 s. However the 
subsequent oversupply of oil and gas feedstocks in the 1980 s, made ICI’s original 
proposal economically unviable. It was then that the research interests into other 
applications of PHB and related polymers gained momentum.
1.4.8.1 Drug Delivery Applications
A number of authors have investigated the potential use of P(HB-HV) polymers for 
controlled or sustained drug delivery. Korsatko et al [148,303,304] have studied the in 
vitro and in vivo release of 7 -  hydroxyethyltheophylline (HET) in the form of a 
compressed tablet made from PHB (Mw 260K). They found that in vitro release was 
dependent on drug loading; with drug loadings of 60-80%  HET release was complete within 
24 hours but with lower drug loadings of 5 -30%  release of drug was extended for up to 50
days [303]. The authors reported that PHB has good compaction properties but varying
compaction pressure between 196.2 -  981 N/tablet did not influence release of 7 - HET. 
Drug release from tablets implanted subcutaneously into the neck folds of female mice 
was slower than in vitro release [148,304]. This was probably related to the smaller 
volume of release medium available during in vivo release.
Gould et al [305] have studied drug release from matrices produced by direct
compression of P(HB-HV) polymers for oral administration. The rationale of these
matrices was that not only do they have the benefit of simplified processing but, unlike 
polyvinylchloride, if they are retained inadvertently in the gut they will slowly erode 
by hydrolytic and enzymatic routes preventing retention and potential strictures on 
chronic dosing [305]. The authors using two copolymers containing 12 mole% (Mw 350K) and 
20 mole% HV (Mw 300K) found that release was dependent on matrix porosity, copolymer 
composition and on the molecular weight of the drug used. It was also concluded that 
drug release was independent of polymer molecular weight However, because of the 
similarity of the molecular weights used (300 and 350K) and the fact that molecular 
weight effects were compared across two different copolymer compositions such an
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interpretation becomes difficult The authors also found that increasing the copolymer 
composition decreased the rate of fluorescein (model drug) release from the compressed 
matrices. On the introduction of porosigens (such as microcrystalline cellulose and 
lactose) to increase matrix porosity , the authors found that drug release could be 
enhanced [305].
Brophy and Deasy [306] found that by increasing the polymer molecular weight, increased 
rates of sulphamethizole release were observed from irregularly shaped PHB 
microparticles (Mw 140K, 500K and 1000K). The authors were unclear as to the reasons for 
this finding but attributed it to uneven drug distribution which may have been worst at 
higher polymer molecular weights. The porous particles (1 0 1 .5 -1590um) were prepared by 
grinding a solvent evaporated polymer matrix containing the suspended drug. The particle 
size was controlled by the grinding time employed. The authors found that by decreasing 
particle size from 1590um to 101.5um, substantial increases in drug release were 
obtained because of the increased surface area of the drug-loaded particles. Particles 
prepared from P(HB-HV) copolymers (17 and 30 mole% HV) released drug more slowly than 
the homopolymer. The authors explained this in terms of improved matrix formation with 
copolymers leading to possibly better drug distribution. Release was biphasic and the 
burst effect observed in drug loaded P(HB-HV) particles could be eliminated by 
overcoating with polylactide [306]. However, release of drug was predominantly diffusion 
controlled and independent of polymer erosion. The in vivo absorption of orally 
administered PHB particles containing 50% sulphamethizole in greyhound dogs was reported 
to correlate well with the in vitro release profiles (0.1 N HCI, 37°C) [306].
The in vitro and in vivo release of an anticancer agent, lomustine (CCNU), from PHB and 
PLA microspheres has been studied by Bissery et al [307-309] as potential carriers for 
drug targetting. They found that 14C - labelled microspheres (1-12um ) injected 
intravenously accumulated mainly in the lungs, liver and spleen after 7 days post- 
injection [307]. The PHB microspheres, prepared by solvent evaporation (emulsion 
deposition), were a complex mixture of individual particles (1 -  12um) and assorted
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aggregates consisting of smaller particles irreversibly fused together [307]. Deviations 
from sphericity were most noticeable with PHB microspheres and was attributed to the 
highly crystalline nature of PHB [307]. Although both PLA and PHB microspheres were 
found not to contain surface pores, release of CCNU from PHB was more rapid (release 
complete within 24 hours) than from PLA (70% released after 90 hours). No explanation 
for the difference was offered by the authors [307]. In another report [309] the same 
authors stated that release of CCNU from PLA microspheres (median size 3um) was complete 
within 7 days. On the basis of particulate tissue distribution, they evaluated the use 
of PHB and PLA microspheres in Lewis lung carcinoma bearing mice. They concluded that 
CCNU loaded PHB microspheres had little effect on Lewis lung carcinoma and only PLA 
microspheres with the drug could increase the survival of carcinoma bearing mice over 
controls [309].
Juni et al [300,311 ^ 312] have studied release of anticancer agents such as aclarubicin, 
doxorubicin, bleomycin and 5-fluorouracil from PHB matrices. Contrary to the above 
results, Juni and colleagues [300,311-312] have found that the release of these 
anticancer agents occurred relatively slowly from PHB. For example, PHB microspheres 
(170um mean diameter) containing 13% aclarubicin hydrochloride released only 10% of the 
drug after 5 days in saline solution at 37°C [311]. The slower release may be due to the 
higher particle size used and/or to the nature of the drug. The authors were able to 
increase the rate of drug release by incorporating ethyl or butyl esters of fatty acids 
into the PHB microspheres. Esters of fatty acids with more than 10 or 12 carbon atoms 
were found to substantially enhance drug release [311]. There appeared not to be any 
significant change in the crystallinity of drug-loaded PHB microspheres upon inclusion 
of the additives and therefore, the authors, in a study of the mechanism involved in 
release enhancement, suggested release was facilitated by drug diffusion through 
channels formed by the additives in the PHB matrix [312].
Further work on microparticles has been carried out by Koosha et al [312-313] who have 
prepared PHB nanoparticles (170-210nm ) by a high pressure emulsification technique [312]
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and by Akhtar et al [314] who prepared PHB microparticles (20 -  40um) by spray drying. 
These authors reported relatively fast release of prednisolone [313] or Methyl Red (a 
model drug) [314] from PHB microparticles which was essentially complete within 48 
hours. Akhtar et al [314] found that release of the model drug from solvent cast films 
(30-50um  thick) occurred more slowly but was predominantly not erosion controlled in 
both films and spray-dried microparticles of PHB. The mechanism of release was thought 
to involve a combination of simple diffusion and aqueous channel formation [314] (see 
chapters 7 and 8).
Recently Deasy et al [315-316] have Investigated cold compressed PHB compacts containing 
physical dispersions of tetracycline and metronidazole for the treatment of peridontal 
disease in human volunteers. In a study with 12 human volunteers clinically diagnosed as 
having gingivitis, a compact (7.5mm diameter) containing 50% tetracycline was bonded to 
an upper molar tooth of each volunteer and was found to produce therapeutic levels of 
the antibiotic in saliva of patients throughout the 10-d ay  study period [315]. All 
patients showed clinical improvement but this was not maintained when the compact was 
removed. Metronidazole was found not to be as effective as tetracycline [316]. In vitro 
release studies in simulated saliva (pH 6.6; 37°C) showed that release was independent 
of compaction pressure in the range 106-318 kg/cm2. Decrease in PHB molecular weight or 
alteration to PLA tended to decrease drug release and increasing HV content of P(HB-HV) 
copolymers (17 and 30 mole%) tended to increase the initial drug release [315]. This 
was thought to be due to easier drug diffusion through the copolymer compacts [315].
There have also been reports of PHB matrices being used to deliver peptides [318-320].
In a veterinary application, Mcleod et al [320] have tested PHB implants for their 
efficacy to continuously release low levels of LHRH when administered subcutaneously, 
and thus to stimulate tonic LH secretion, promote preovulatory follicle growth and 
Induce ovulation in acyclic sheep. They found that PHB implants were superior to oil — 
based depot injections in prolonging release of hormone sufficient (2 -4  days) to cause 
ovulation in ewes. By using two LHRH-PHB (50ug /50mg or 40ug/15mg) implants per animal a
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success rate of up to 94% was obtained [320]. This success with PHB implants in
veterinary applications will undoubtedly stimulate further research with biodegradable 
PHA’s in drug delivery of macromolecules.
1.4.8.2 Other Medical uses
Although much research interest has been focused on drug delivery applications, P(HB-HV) 
polymers have also been considered in a number of other biomedical uses.
The fact that P(HB-HV) polymers have a chiral centre has initiated research into 
controlled degradation of polymers to produce products useful for synthesising 
enantiomerically pure compounds (EPC) [148-149]. Both pyrolysis and chemical degradation 
have been suggested for depolymerization [321-324]. Seebach and colleagues [322-324]
have been able to produce high yields (75 -  90%) of D (-)-3-hydroxybutanoates from PHB
depolymerized chemically in the presence of alcohols at 80-160°C  using a
tetraethoxytitanium catalyst [324]. Such optically active compounds cannot always be 
obtained in high yields from conventional synthetic routes and are thought to be useful 
starting reagents for the synthesis of EPC.
Webb and Adsetts [325] have suggested that PHB could be used in surgical dressings. A 
solution of polymer in chloroform could be applied to wounds directly. The polymer 
would form a transparent film which the authors claim would allow continuous monitoring 
of the affected area without removal of the dressing. Furthermore, the film would adapt 
to the contours of the affected area during evaporation of solvent [325].
Other uses of PHB reported have included using it has a medical dusting powder [326],
in fabrication of ostomy bags [327], nappy liners [327], and tampon e]ectors [328].
However, probably the most exciting application of PHB is in bone replacement therapy 
[149,266 -  267].
The homopolymer offers potential advantages over the currently used materials in bone 
replacement therapy in that its mechanical properties closely resemble those of cortical
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bone. Mismatch of mechanical properties such as Elastic Modulus has been a major problem 
with metals currently used in bone replacement [329]. The mechanical compatibility of 
PHB and PHB -  Hydroxyapatite composites has led to their investigation in hip replacement 
therapy [266-268,301]. Furthermore, Doyle and colleagues [268,301] have reported that 
PHB and its composites have superior integration properties with bone when compared to 
metals and other polymer systems such as polyethylene and polylactide. The reason for 
the superior integration properties remains unclear but may be due to the polymers 
piezoelectric properties.
Evidently P(HB-HV) polymers have considerable potential in both drug delivery and other 
biomedical applications. However, much further research and development is necessary 





The mechanical properties of a material are concerned with the effects of stress on that 
material. They provide information as to the behaviour of the material under this stress 
which can be indicative of the materials suitability for its intended purpose.
In order to assess the desirability of P(HB-HV) systems for biomedical applications, a 
knowledge of their mechanical properties is essential. Polymers with inadequate 
mechanical properties are unlikely to be used in biomedical applications such as bone 
pins or implants for long-term  drug delivery. Mechanical failure in such systems could 
result in potentially fatal consequences. Indeed, Hastings [330] has stated that 
polymers intended for surgical implantation must satisfy the double requirement of 
adequate long-term  mechanical properties and surface compatibility.
2.1.1 AIMS AND OBJECTIVES
In this study the mechanical properties of a range of P(HB-HV) copolymers have been 
examined using official static tensile tests. The aims and objectives for this 
investigation were:
1. To study the effect of polymer molecular weight on the mechanical properties of PHB.
2. To study the influence of composition on the mechanical properties of P(HB-HV) 
copolymers.
3. To study the influence of incorporating model drugs into polymers on their mechanical 
properties.
4. To evaluate the suitability of radiation and autoclaving as methods for sterilizing 
P(HB-HV) biopolymers.
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2.1.2 PRINCIPLES OF TENSILE TESTING OF POLYMERS
There are a bewildering number of mechanical tests which can be used to gain both
qualitative and quantitative information on the bulk mechanical properties of
materials. However, only some are recognised as official tests by either the American 
Society for Testing and Materials [331] or the British Standard Institute [332]. A list 
of mechanical tests relevant to polymers and plastics is given by Aulton [333] and an 
excellent review of published literature relating to both official and unofficial tests 
applicable to polymers can be found in a book by Lever and Rhys [334].
The tensile test is probably the most important single test [335] and certainly the most 
widely used of all the mechanical tests [336]. It has been used extensively to 
characterise polymeric materials for use in biopharmaceutical applications such as 
tablet film coatings [337-341], surgical implants [342 -  343] and surgical sutures [344- 
345]. A typical tensile test requires:
a) a test specimen, usually in a dum b-bell shape with a smooth gauge section between 
the enlarged ends
and b) a test machine that applies, measures and records various loads.
There are many types of tensile testing machines [346] available but the principle of 
them all is that the test specimen is held at one end by a fixed clamp or grip and the
other end by a movable one. The grips are then drawn apart and the tension in the
specimen is measured at various grip separation distances. A load cell usually relays 
the measured force-displacement profile onto a chart recorder which can be easily 
converted to the stress-strain profile of the material from a knowledge of testing 
variables and specimen dimensions.
Figure 2.1 gives a schematic representation of the Instron 1122 tensile testing machine 
used in the present study and Figure 2.2 shows a typical stress -  strain profile that can 
be obtained from such a machine. Superimposed on this figure are the material properties 
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Figure 2.1. A schematic diagram of the 
Testing machine.
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Figure 2.2. A typical stress -  strain profile from which mechanical 
properties of polymers were determined.
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A list of definitions for the mechanical properties as used in this study is given 
below:
Stress is defined as the ratio of the applied force on a specimen to its original cross- 
sectional area,
l.e. stress = applied force
original cross-sectional area
Tensile strength (TS) is defined here as that stress corresponding to the maximal load 
experienced by the test specimen during the tensile test. This may correspond to the 
breaking stress of brittle polymers which undergo little or no plastic deformation or to 
the yield strength of polymers undergoing considerable plastic deformation. Values of TS 
give an indication of the overall strength of a polymer but in isolation are not very 
important in predicting performance.
Percent Elongation (%E) is a measure of polymer ductility. It was taken as that strain 
corresponding to the maximal load or stress experienced by the specimen and is expressed 
as a percentage.
%E = increase in length X 100 
original length
Elastic Modulus (EM) is a measure of polymer stiffness or rigidity. It was calculated as 
the applied stress divided by the corresponding strain in the region of linear elastic 
deformation (Hookean behaviour) i.e. slope of the linear portion of a stress -  strain 
profile.
Toughness can be crudely estimated by measuring the area under the curve (AUC) of 
stress-strain profile. The AUC is a function of the work done (force x displacement) in 
deforming a material and as such closely resembles the polymer film toughness. 
Toughness has not clearly been defined; it is bound up with impact strength but this is
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only a guide. It is much more a function of stress, elasticity, and internal damping 
[333]. Toughness is expressed as Jm-3  from the following relationship:
Stress x Strain = N x m = Nm = Joules = Jm-3 .
m2 m m3 m3
2.2 MATERIALS
The homopolymer, PHB, and the P(HB-HV) copolymers were produced biosynthetically by the 
continuous fermentation of a glucose utilising mutant of Alcaligenes eutrophus and were 
purchased from Marlborough Biopolymers Ltd (a subsidary of ICI), Billingham, UK. The 
biopolymers were characterised as discussed below and their molecular characteristics 
are summarised in Table 2.1. All polymers purchased were of high purity medical grade.
Polyethylene (PE) of high density was purchased from BDH chemicals, Poole, UK. Batch 
No.1726200. Mw=400K.
Para-toluenesulphonic acid (PTSA) was purchased from Fisons, UK. Batch No.T/2500 43
Methyl Red: BDH Chemicals, Poole, UK. Batch NO.9898770F
Sodium Fluorescein: BDH chemicals ,Poole, UK. Batch No.5555630A1009
All solvents both HPLC and SLR grades and were purchased from Fisons,UK.
Table 2.1 Molecular Characteristics of P(HB-HV) Biopolymers.
Polymer Symbol Batch No. Nominal (ICI) 
HV content 
(mole%)




PHB PHB800K BX GV9 0 0 765K 506K 1.51
P(HB-HV) PHV6 BX 6.60 7.47 41 OK 267K 1.53
P(HB-HV) PHV12 BX PV12 12.60 11.99 1 293K 908K 1.42
P(HB-HV) PHV20 BX T -3 7  20.00 19.98 1 665K 770K 2.16
P(HB-HV) PHV27 BX PV13 27.00 27.79 - - -
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2.3 METHODS
2.3.1 Characterisation of materials
2.3.1.1 Determination of Copolymer composition
The HV content of P(HB-HV) copolymers was determined by 1H -N M R  according to the method 
described by Bloembergen et al [211]* This method was chosen in preference to the
Fourier transform infra-red (FTIR) method proposed by the same authors because of its
greater accuracy.
1H -N M R  spectra of 1%w/v solutions of P(HB-HV) copolymers in deuterated chloroform were 
recorded using a JEOL G X-270M HZ spectrometer in the pulse Fourier transform (FT) mode. A 
5.5 - s  pulse repetition was employed with a 3KHz spectral width, 32K data points and 100 
accumulations. The HV content (expressed as mole%) was calculated from the relative
magnitudes of the integrated areas of the methyl resonances in the side groups of HB and
HV monomeric repeating units. Examples of 1H -N M R  spectra for some P(HB-HV) copolymers 
are given in Figures 2 .3 -2 .5 .
Recently reports [347-348] have indicated that copolymer composition can also be 
determined from an optical rotation method. This method is based on a linear
relationship between the specific rotation of P(HB-HV) copolymers and HV composition.
However, this method is less accurate because it depends on calibration with samples of 
known HV contents determined by an alternative technique (NMR or FTIR). Furthermore, the 
optical rotation method has been reported to be less reliable for HV contents below 15 
mole% [348].
2.3.1.2 Determination of polymer molecular weight
The molecular weight distributions of the biopolymers were determined by gel permeation 
chromatography (GPC) according to the method described by Majid [286,349]. A schematic 
representation of the apparatus used is given in Figure 2.6. Briefly, 20uL polymer 
samples (1%w/v) in chloroform were injected into a M ixed-PL gel (5um) column, 0.3 x 








Figure 2.3. ^ H -N M R  spectrum of a P(HB-HV) copolymer containing 
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Figure 2.4. 1H -  NMR spectrum of a P(HB-HV) copolymer containing 
19.98 mole% HV. Chemical shifts are in ppm downfield from TMS 
(Me4Si).
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Figure 2.5. 1H -  NMR spectrum of a P(HB-HV) copolymer containing 
27.79 mole% HV. Chemical shifts are in ppm downfield from TMS 
(Me4Si).
Figure 2.6. A schematic representation of the gel permeation 














Labs,UK). A mobile phase of HPLC grade chloroform at 25°C was used and eluent detection 
was achieved using an infra-red spectrophotometer (Perkin Elmer 782) set at 1760cm-1 to 
detect the carbonyl (C = 0 ) resonance characteristic of P(HB-HV) biopolymers. PS detection 
was based on the C -H  stretch occurring at 2730cm-1 . Data were stored and analysed using 
a BBC Master microprocessor interfaced to the IR detector. Mark-Houwink constants used 
were K= 1.065 x 10-2 ml/g, a=0.728 for PS and K= 1.510 x 10-2 ml/g, a = 0.756 for PHB 
quoted by Majid [286,349].
2.3.2 Preparation of PHB samples with different molecular weights
A series of lower molecular weight polymer samples were prepared from high molecular 
weight PHB (PHB800K) by non-aqueous catalytic degradation [286].
PHB800K (2%w/v) was dissolved by refluxing in a methanokchloroform (1:5) mixture. The 
mixture was then cooled to ambient and the catalyst, PTSA (0.2%w/v), was added to the 
polymer solution and refluxed at 61 °C for timed intervals. The reaction was stopped at 
the appropriate time by pouring the refluxed mixture into excess iced water, in which 
the PTSA was soluble. The mixture was then continually agitated for 15 mins to effect 
removal of the catalyst before precipitating out the degraded polymer by the addition 
of excess methanol. The degraded polymer was then filtered through a Whatman No.52 
filter paper and the filtrate was washed with water and methanol to remove any traces 
of PTSA still remaining. The degraded polymer samples of different chain lengths were 
then further purified as described below and their molecular weights determined by GPC.
Table 2.2 gives the molecular weight details of the degraded polymers.
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Table 2.2. The molecular weight characteristics of PHB samples prepared by non-aqueous catalytic degradation.
Sample Reflux time (mins) 
(0.2%w/v PTSA)




1 0 765 506 1.51
2 10 513 324 1.58
3 15 384 226 1.70
4 20 250 167 1.50
5 30 236 152 1.56
6 45 204 159 1.28
7 60 193 136 1.42
2.3.3 Purification of biopolymers.
Although the ’as supplied’ polymers were of a medical grade, they were further purified 
as a routine procedure. Purification was achieved by refiuxing in chloroform (2%w/v), 
filtering the polymer solutions (Whatman No.52 filter paper) and recrystallizing with 
excess methanol. The recrystallized polymers were washed with water and methanol and 
dried in a vacuum oven at 45°C for 12 hours.
The polymers were then redissolved by refiuxing in chloroform to an initial 
concentration of 2%w/v. To achieve higher concentrations (4%w/v), suitable for casting 
films of the required thickness, the polymer solutions had to be further concentrated by 
evaporating chloroform in a rotary evaporator.
2.3.4 Addition of model drugs to polymer solutions
Sodium Fluorescein was used as a model water-soluble drug of low molecular weight. The 
particulate drug (Feret diameter 30 ± 15um, Mean ± S.D; n=200; Joyce-Loebl Magiscan 
Image Analyser) was accurately weighed and added to concentrated polymer solutions to 
achieve a range of drug loadings in the dried polymer films. Drug-polymer suspensions 
were sonicated in a sonic bath (Deakon FS100 Frequency sweep; Deakon Ultrasonics Ltd,UK) 
for 30 mins to obtain suitable mixing.
Methyl Red was used as a model chloroform-soluble drug of low molecular weight and
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incorporated into polymers in the same way as above. The chemical structures of the 
model drugs are given in Figure 2.7.
2.3.5 Casting of polymer films from solution
Films were cast onto dry, degreased glass plates using a Thin Layer Chromatography 
Applicator with an adjustable clearance. A suitable clearance setting was chosen to 
produce a dry film thickness of 3 0 -5 0  urn. A spirit level was used to ensure films were 
cast onto a flat, level surface.
2.3.6 Drying of films cast from solution
The resultant cast films were dried in two stages: a) initially overnight in a drying 
cabinet in which the films had been cast and b) in an oven at 45 ± 1°C for 1 2 -18  hours 
to ensure complete dryness.
2.3.7 Preparation of melt processed films
Purified polymer powders were melt pressed in a Moores model C194 (Birmingham, UK) hand 
melt press. Polymer powders were size reduced using a pestle and mortar and then placed 
In a mould consisting of two aluminium plates (20cm2) separated by four aluminium 
spacers of fixed thickness. The plates were lined with Mellinex polyester sheeting 
(Scott Bader, Bristol) to prevent the polymer from adhering to the mould. The polymers 
were pressed at 15psi pressure with top and bottom plattens at 165°C for 10 mins. The 
mould was then removed from the hot press and slowly cooled to ambient before films were 
peeled and stored.
2.3.8 Storage of polymer films
All film samples were stored at 25°C over silica gel for one week prior to testing.
2.3.9 Cutting of test specimens from polymer films
Test specimens were cut from films (melt processed and solvent cast) using a sharp
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Figure 2.7. Chemical structures of Methyl Red (A) and Sodium 
Fluorescein (B).
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scalpel and a dum b-bell shaped template of guage length 40mm and width of 6.5mm. All
specimens were visually inspected for cutting and film defects with only the best
specimens being used for testing. All defective specimens were discarded. The thickness
of each specimen was measured in 4 separate places along the gauge length and the mean
value used in calculations of cross-sectional area. In the case of solvent cast films a
minimum of 5 specimens from each film and two films for each poiymer or polymer-drug
mixture were taken for testing. For melt-pressed films a minimum of 5 specimens were
taken from a combination of different films. Properties or replicate films were not 
significantly different from each other (p > 0.05).
2.3.10 Static Tensile testing of films.
Static tensile tests were carried out using an Instron 1122 testing machine according to 
the ASTM D 882-8 0 a  standard test procedure. A strain rate of 5mm/min and ambient test 
conditions were employed in all cases. A calibration load of 500 grams and a load cell 
of 2000 grams force were used. Lightweight pneumatic grips were used to minimise local 
stress concentrations introduced by heavier grips.
2.4 RESULTS AND DISCUSSION
2.4.1 The effect of molecular weight on the mechanical properties of solvent cast films 
of PHB.
A minimum molecular weight (MW) of approximately 190K-200K was required to form a thin 
film specimen of PHB from solution. PHB samples of molecular weights below this 
threshold value did not form a mechanically intact film from chloroform solutions of
concentrations up to 10%w/v. Such samples were found to spread easily onto glass as
concentrated solutions and formed ’wet’ films on partial drying. However, on further 
drying these films shattered into small pieces of brittle polymer often leaving behind a 
mosiac pattern of dried polymer pieces on the glass plate.
The need for a minimum molecular weight to form a film is not peculiar to PHB but is
also characteristic of other crystalline polymers with glass transitions close to
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ambient temperature [336]. The reason for this threshold MW in crystalline polymers is 
similar to that given by Gent [350] for brittle amorphous polymers. Gent states that a 
minimum number of chain entanglements are required before the polymer becomes strong 
enough to carry a load or form a specimen. Similarly, very low molecular weight samples 
of crystalline PHB are very brittle and a minimum number of tie-molecules between 
crystallites are necessary to produce a mechanically intact specimen. Peterlin [351] has 
defined tie -  molecules as those which go from one crystalline domain to another and are 
responsible for holding these domains together. The threshold number of tie -  molecules 
provide sufficient cohesive energy to overcome the opposing shrinkage forces (solvent 
evaporation on drying) responsible for shattering the polymer into small pieces of very 
low strength.
Figures 2 .8 -2 .10  show the effect of MW of PHB on the tensile strength (TS), %e!ongation 
(%E) and elastic modulus (EM) of solvent cast films. The TS and EM followed the same 
trend in that above the minimum MW the properties increased rapidly with increasing MW 
to reach a limiting value or plateau between MW s of approximately 200K-300K. Although 
mean values of %E appeared to increase with Increasing molecular weight, the %E was not 
significantly different (p>0.05) for molecular weights above 300K.
The generally higher values of TS, %E and EM for molecular weights above the threshold 
was indicative of the increased toughness, strength and ductility of PHB at high 
molecular weights (>300K). At low MW’s PHB was extremely brittle and this was thought to 
be largely due to the accumulation of chain ends and low molecular weight fractions 
reducing the number of tie-molecules between crystallites. However even at high MW PHB 
was relatively hard and brittle as shown by the very high EM ( 1500 -  2000 MPa) and very 
low % E values (<2% ). The effects of molecular weight on the mechanical properties of 
PHB showed similar patterns to those reported for polyethylene [352], polystytrene [353- 
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Figure 2.8. The influence of polymer molecular weight on the 
tensile strength of solvent cast films of PHB (Mean ± S.D; n = 10).
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Figure 2.9. The influence of polymer molecular weight on the 
% elongation of solvent cast films of PHB (Mean ± S.D; n = 10).
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Figure 2.10. The influence of polymer molecular weight on the 
Elastic Modulus of solvent cast films of PHB (Mean ± S.D; n = 10).
2.4.2 The effect of P(HB-HV) copolymer composition on their mechanical properties.
2.4.2.1 Solvent cast thin films
Figures 2.11-2.13 show the effect of HV content of P(HB-HV) biopolymers on the TS, %E 
and EM of solvent cast thin films. The TS values in Figure 2.11, with the exception of 
PHV6, were not significantly different (p>0.05) for the range of copolymer compositions 
studied. Hence, it was concluded that TS changed little with composition for copolymers 
containing up to 27 mole% HV.
However, Figures 2.12 and 2.13 show that copolymer composition greatly influenced both
the ductility (%E) and rigidity (EM). The %E changed little for small increases in HV 
content up to 7 mole% when compared to the homopolymer. However, further increases in HV 
content produced a marked rise in the property culminating in over a 5 fold increase in
%E for PHV27 when compared to the homopolymer, PHB. The EM in Figure 2.13 showed
steady, almost linear decline In polymer stiffness with increasing HV content of P(HB- 
HV) biopolymers. For PHV27 the EM is approximately a third of that for PHB.
Toughness of polymers can be estimated from the areas under the curves of stress-strain 
profiles [333]. Table 2.3 gives toughness values of P(HB-HV) polymers estimated from 
stress-strain profiles from solvent cast films.








The toughness of P(HB-HV) copolymers progressively increased with increasing HV content 
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Figure 2.11. The variation in tensile strength with P(HB-HV)
copolymer composition (Mean ± S.D; n = 10).
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Figure 2.12. The variation in % elongation with P(HB-HV)
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Figure 2.13. The variation in Elastic Modulus with P(HB-HV)
copolymer composition (Mean ± S.D; n = 10).
2A2.2 Melt-pressed films
PHB is known to be thermally unstable at temperatures marginally above its melting point 
[247]. However, the P(HB-HV) copolymers are relatively more stable. Although they have 
lower melting temperatures the copolymers degrade at about the same temperature as PHB 
and therefore have larger windows for thermal processing (see chapter 3). To minimise 
thermal degradation of PHB, melt-pressed films (300 -  400um) were fabricated under 
pressure at 165°C. Because of their relative thermal stability, P(HB-HV) copolymers 
could also be processed at this temperature without degradation. Although molecular 
weight of samples was not determined to assess  ^degradation, no colouring of melt-pressed 
films was observed. In preliminary studies, PHB films processed at 190°C for 10mins 
became brown or off-w hite in colour due to thermal degradation and hence, the lower 
processing temperature was chosen to avoid polymer degradation.
The mechanical properties of melt-pressed P(HB-HV) polymer films followed the same 
trends as those seen In solvent cast films and are compared with high density 
polyethylene (HDPE) in Table 2.4.
Table 2.4 Mechanical properties of melt-pressed P(HB-HV) polymer films.
Polymer
Mechanical Property (Mean ± 
TS (MPa) %E
S.D; n = 5)
EM (MPa)
PHB380K 28.7 ±5.1 1.88 ±0.66 2543 ±180
PHV12 17.4 ±1.5 2.41 ±0.41 1154 ±322
PHV20 20.7 ±2.0 2.46 ±0.36 1086 ± 76
PHV27 17.5 ±1.3 7.88 ±0.84 475 ±179
HDPE 25.0 ±2.2 8.70 ±1.13 680 ±115
Although melt-pressed P(HB-HV) polymer films exhibited similar trends to those cast from 
solution, the values of the mechanical properties were not identical. Melt-pressed 
PHB380K films had slightly higher TS and EM values. The melt-pressed copolymer films had 
much lower values for %E when compared to those for solution cast films. This may have
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been partly due to the greater thickness of melt-pressed films or possibly due to some 
thermal degradation.
Of the P(HB-HV) polymers studied, the properties of PHV27 more closely resembled those 
of HDPE. Although polyethylene had a higher TS than PHV27, the %E and EM were not 
significantly different (p>0.05). Both polymers exhibited ’necking’ with similar 
elongations at fracture of about 90% in melt-pressed films. The mechanical properties of 
the homopolymer, PHB, have been reported to be similar to those of polypropylene [149].
According to the general polymer classification of Lever and Rhys [334] or Allcock and 
Lampe [394] (Figure 2.14), PHB was regarded as being hard and brittle and the copolymers 
with increasing HV content became progressively tougher, less rigid (softer) and more 
ductile. Indeed P(HB-HV) copolymer films with HV contents of 12mole% and above exhibited 
necking and ductile fracture.
The dependence of mechanical properties on P(HB-HV) composition cannot easily be 
explained by differences in their degrees of crystallinity. Bloembergen et at [211] have 
reported that equilibrium degrees of crystallinity are similar for copolymers 
containing up to 47 mole % HV. In this study it is proposed that differences in 
mechanical properties may be better explained by differences in crystalline morphology 
and this will be discussed in chapters 5 and 8.
On the basis of their favourable mechanical properties P(HB-HV) copolymers may be 
preferable for manufacture and implantation of surgical and drug delivery devices [264].
2.4.3 The effect of Sodium Fluorescein ( SF) as particulate drug inclusions on the 
mechanical properties of P(HB-HV) copolymer films.
Studies with model drugs were carried out with the P(HB -  HV) copolymer containing 20 
mole% HV (PHV20) because of its superior mechanical properties and film forming ability.
Drug loaded films had a uniform distribution of SF particles within the PHV20 matrix.
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Figure 2.14. Polymer classification on the basis of 
characteristic stress -  strain profiles (after ref. 334 and 394).
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Figure 2.15 shows that TS was markedly reduced upon the inclusion of particulate drug 
In PHV20 films. The addition of only 2%w/w drug gave rise to over 30% reduction in TS.
On comparison with the drug-free PHV20 films, drug loadings of 10%w/w lead to over 40%
loss in the property. The explanation for the reduction in TS of drug loaded polymer 
films was thought to be the induction of flaws or microcracks at the particle-polymer 
interface caused by the presence of SF. Such defects reduce the tensile strength 
according to Griffiths theory of crack propagation [358].
In Figure 2.16 a similar trend was seen for %E with increasing drug concentrations in 
PHV20 films. In this case, the incorporation of 2%w/w drug reduced %E by over 40% and 
over 50% reduction was observed for films containing 10%w/w drug. Nielsen [336] 
suggested that the main reason for a reduction Jn %E for polymers filled with rigid
particulates is that, although the film is part filler (drug) and part polymer, all the
elongation comes from the polymer. Therefore the actual elongation experienced by the 
polymer is much greater than that measured macroscopically [336,359]. However, Nielsen’s 
theory is complex and incomplete at present and the expected results depend upon the 
exact fracture mechanism [336].
Figure 2.16 also shows that EM values were not significantly different (p>0.05) for 
drug loadings up to 10%w/w when compared to drug-free PHV20 films. However, Aulton and 
Abdul-Razzak [338], working on tablet film coatings, have shown that the inclusion of 
titanium dioxide particles in hydroxypropylmethylcellulose films produced large 
increases in modulus. This effect was, however, more pronounced at concentrations 
greater than 10% and may also occur with the PHV20-SF systems at higher drug 
concentrations than those employed in this study. It should be noted that increases in 
modulus are dependant on the nature of the particulate filler or drug (eg rigidity of 
filler) and the strength of adhesion between filler and polymer [359]. These are 
variables which need to be addressed when assessing the mechanical properties of drug 
loaded polymeric implants and surgical devices.
Although the present work has shown that the inclusion of a particulate drug into
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Figure 2.15. The influence of drug concentration on the tensile 
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polymeric matrices reduces TS and %E, exceptions to these trends may occur with other 
drugs. A number of models have been proposed by Nielsen [336,359] and others [360-361] 
to predict the changes in properties of polymers on the inclusion of rigid particulate 
fillers but they must be used with caution as exceptions are not uncommon. One such 
exception in polymer science is the use of carbon black filler in rubber to actually 
increase the tensile strength of rubber [336].
2.4.4 The effect of inclusion of Methyl Red, a chloroform-soluble drug, on the 
mechanical properties of P(HB-HV) copolymers.
Methyl Red was soluble in the polymer solutions and resulted in films in which drug 
appeared to be homogenously distributed.
Table 2.5 shows that the mechanical properties of PHV20 were little affected by Methyl 
Red concentrations of up to 10%w/w and Is in contrast to the effects seen on inclusion 
of the particulate drug, SF. The reason for this was thought to be that Methyl Red 
formed a continuous phase with the polymer and did not induce the type of flaws in the 
polymer matrix caused by the particulate drug. However, it is thought that even 
chloroform soluble drugs may greatly modify properties at high concentrations when the 
drug is a major component of the composite. Indeed, mechanical properties are likely to 
closely resemble those of the pure drug as the proportion of the drug increases.
Table 2.5 The mechanical properties of Methyl Red loaded PHV20 biopolymer films.
(Mean ±S.D, n = 10).
Methyl Red Tensile Elongation Elastic
Concentration Strength (%) Modulus
(%w/w) (MPa) (MPa)
0 22.44 ±1.13 9.58 ±0.14 671 ± 97
1 19.08 ±1.42* 8.28 ±1.52* 653 ±132
2 21.02 ±0.78 9.25 ±0.30 694 ± 56
5 20.40 ±0.51 9.55 ±0.36 745 ± 64
7 19.30 ±1.02* 8.29 ±0.60* 707 ± 48
10 19.10 ±0.55* 7.92 ±0.56* 689 ± 35
* significantly different to control (p<0.05)
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2.4.5 The influence of radiation and steam sterilization on the mechanical properties of 
biopolymers.
Measurements of mechanical properties can be used to assess changes in bulk properties 
of materials. The correlation between mechanical properties and bulk properties has been 
used to indicate polymer-additive interactions [362 -  364], radiation damage [291] and 
polymer degradation [268,291-293]. In this section mechanical properties have been 
determined to assess any changes in bulk properties of polymer treated with either 
gamma -  irradiation (2.6Mrad dose) or steam sterilization (bench autoclave 121 °C for 
20 mins).
Table 2.6 shows the effect of sterilization treatments on the mechanical properties of 
PHV20 films. All batches of PHV20 films were prepared and stored under identical 
conditions. Two batches (n =5  per batch) of PHV20 films were used for irradiation 
studies and one batch was used for steam sterilization.
At the standard gamma -  irradiation dose of 2.6Mrad PHV20 films were unaffected in terms 
of tensile strength or Elastic modulus. However, %E was significantly lower (p>0.05) 
than the control value.
The effects of gamma-irradiation on polymers has been extensively Investigated in recent 
years [365-368]. Radiation is known to induce complex changes in polymers including 
random chain scission and cross-linking [366,377]. The reduced ductility of PHV20 films 
was presumably due to molecular weight changes induced by chain scission but these were 
not determined in this study.
Table 2.6 The effect of Sterilization Treatments on the Mechanical Properties of PHV20.
Sample Mechanical Property (Mean ±S.D, n=5)
Treatment T.S (MPa) %E EM (MPa)
Control PHV20 20.47 ±1.56 5.99 ±0.56 840 ±23
Gamma -  Irradiation Batch 1 18.08 ±1.12 4.73 ±0.18* 798 ±44
(2.6 Mrad dose) Batch2 19.60 ±4.95 4.95 ±0.14* 881 ±58
Steam Sterilization 11.41 ±1.75* 7.83 ±1.55* 375 ±61*
(autoclave 120°C 
for 20 mins).
* significantly different to control (p<0.05)
Miller and Williams [291] have recently shown that irradiation of P(HB-HV) copolymer 
monofilaments with doses up to 10Mrad progressively reduced tensile strength and 
extensibility and that a 20Mrad dose was sufficient to destroy all mechanical integrity 
of the specimens. The authors assumed that mechanical property changes induced by 
radiation were due to molecular weight loss but this was not confirmed. The authors 
neglected to measure cross-sectional area and hence, were unable report values for TS 
and EM of the unirradiated polymer which made interpretation of some of their results 
difficult [291].
Table 2.7 The effect of steam sterilization on the mechanical properties of PHB films.
Sample Mechanical Property ±S.D.
Treatment T.S (MPa) %E EM (MPa)
Control PHB 21.84 ±2.74 1.95 ±0.32 1537 ±379
Steam Sterilization 21.41 ±1.75 1.93 ±0.55 1475 ±161
(autoclave 120°C 
for 20 mins).
Steam sterilization did not affect the mechanical properties of the homopolymer, PHB, 
(Table 2.7) but significantly modified those of the PHV20 copolymer. As shown in Table
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2.6 the TS and EM of PHV20 were reduced by approx 50% but the %E was increased I 
approximately 30%. The melting range of PHV20 (see chapter 3) is close to the 
sterilization temperature and consequently the partial melting of films resulted in 
gross mechanical property changes. The use of high temperature steam sterilization will 
only be applicable to the homopolymer or P(HB-HV) copolymers with softening points 
greater than the temperature of sterilization.
2.5 CONCLUSIONS
A minimum MW of 190 -  200K was required to form a thin solvent cast film of PHB. Above 
this threshold MW for mechanical integrity of a specimen, the mechanical properties of 
PHB improved until a critical MW (approximately 300K) was reached beyond which the 
properties remained stable.
PHB was relatively hard and brittle and copolymerization with HV produced tougher, less 
brittle and more pliable polymers. These may be preferable for manufacture and 
implantation.
The inclusion of drugs may adversely affect polymer properties. The effects may be 
marked even at low concentrations with particulate drugs.
Steam sterilization may be used for P(HB-HV) biopolymers with melting temperatures well 
above those employed in autoclaving but may induce gross changes in mechanical 
properties for those that have lower melting ranges.
Gamma-irradiation at the recommended 2.6Mrad total dose was sufficient to induce changes 
in mechanical properties of PHV20 films. The loss in properties must be taken into 
account, if this method is to be employed for sterilizing biomedical devices fabricated 
from P(HB-HV) biopolymers. However the magnitude of the changes caused by the 2.6Mrad 
total dose would probably not be great enough to preclude the use of sterilization by 






3.1.1 PRINCIPLES OF DIFFERENTIAL SCANNING CALORIMETRY (DSC)
Differential Scanning Calorimetry (DSC) and Differential Thermal Analysis (DTA) are 
related techniques used to monitor enthalpy changes of a sample as a function of 
temperature. The Nomenclature Committee of the International Confederation for Thermal 
Analysis have defined DSC as [369]:
"A technique in which the difference in energy input into a substance and a reference 
material is measured as a function of temperature whilst the the substance and reference 
material are subjected to a controlled temperature programme".
DTA is essentially the same as DSC but in DTA differences in temperature between 
reference and substance are measured as a function of temperature [370].
General reviews on DTA and DSC include those by Smothers and Chiang [371], Mackenzie 
[372], Murphy [373], Wunderlich [374] and Schultze [375]. However more specific reviews 
on polymer characterization using these techniques include those by Turi [376], Chiu 
[377], Smith [378] and Barrel and Johnson [379].
DSC is mainly used for studies of physical transitions [380] and is the technique used 
in this investigation. Polymer features such as moisture interactions, glass 
transitions, melting temperatures, compatibilty and crystallinity may be determined by 
this technique [364].
The equipment used in both DTA and DSC is similar. The arrangement of temperature 
sensors (platinum) in a typical DSC instrument are shown in Figure 3.1. Sample and 
reference materials are usually held in crimped aluminium pans. In the event of a 
transition occurring, thermal energy is added or subtracted from the sample or reference 
in order to maintain isothermal conditions. The energy is precisely equivalent in 
magnitude to the energy absorbed or evolved in the particular transition and is 


















Figure 3.1. The arrangement of temperature sensors in a typical 
DSC apparatus (after ref. 390).
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Figure 3.2. A hypothetical DSC trace representing some common 
transitions observed in polymers.
representing physical transitions commonly seen in polymers. A DSC trace is often termed 
a ’thermogram’ in the pharmaceutical literature and although the former is the most 
accurate both are used interchangeably in this report.
3.1.2 PRINCIPLES OF THERMOGRAVIMETRIC ANALYSIS (TGA).
Thermogravimetric analysis (TGA) is a dynamic technique which monitors the weight 
changes in a sample as a function of temperature. The technique is considered to be the 
most important method for studying polymer stability and degradation [377] but can also 
be used to provide useful information on moisture interactions and residual solvent 
[364].
General reviews on TGA of polymers include those by Chiu [380], MacCullum [381], and 
Thompson [382].
Experimentally a polymer sample is placed in a furnace while being suspended from one 
arm of an automatic-reading, precision electrobalance. The change in sample weight is 
recorded as a function of temperature during the programmed heating of the sample. A 
typical TGA curve is represented in Figure 3.3.
TGA is basically a means for studying polymer behaviour and not an absolute 
identification tool [380]. Therefore it is often used in combination with DSC to provide 
information on weight changes occurring during transitions detected by the DSC. It
has: also been used in combination with other analytical techniques including mass
spectrometry (MS) [383-384], gas chromatography (GC) [385] and G C -M S  [386].
3.1.3 AIMS AND OBJECTIVES
1. To study the melting behaviour and glass transitions in P(HB-HV) polymers using DSC.
2. To study the thermal degradation of P(HB-HV) polymers using TGA.





T E M P E R A T U R E
Figure 3.3. A hypothetical TGA trace representing a two stage 
weight loss.
3.2 MATERIALS
P oly-L-lactide (PLA) of 300,000 Mw was purchased from Polysciences, UK.
Poly L -  lactide -  co -  glycolide), P(LA-GA) 90:10, and 10:90 were gifts from Cyanamid of 
Great Britain Ltd, Gosport, UK.
PHB43K and PHB380K (the numbers indicate the Mw) were purchased from Marlborough 
Biopolymers Ltd. Quinine was purchased from Fisons, UK.
All other materials used were identical to those given in Chapter 2.
3.3 METHODS
3.3.1 Differential Scanning Calorimetry (DSC)
Melt-quenched amorphous samples were prepared by cooling molten polymers rapidly in 
liquid nitrogen. This was carried out to erase previous thermal history of polymer 
samples before determination of melting and glass transition temperatures.
DSC scans to determine glass transitions (Tg), melting points (Tm) and heats of fusion 
Hf ) of polymers were recorded on a Dupont DSC 910/9900 Thermal Analyser. AH other
DSC scans were obtained using a Perkin Elmer D S C -7/P E  7700 Thermal Analysis System.
Instruments were calibrated with indium (Tm = 156.4°C, / \H f = 28.47 KJ/Kg) at the required 
heating or cooling rates prior to use. Standard heating rate was 20K/min and typical 
sample mass used was 3 -5m g  in lightly crimped aluminium pans with inverted lids. 
Reference in all cases was an empty aluminium pan crimped as above.
3.3.2 Thermogravimetric Analysis (TGA)
Polymer samples (3-5m g) were heated at a programmed heating rate of 20K/min, unless 
otherwise stated, in a Perkin Elmer TG A -7/P E  7700 Thermal Analysis System.
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3.4 RESULTS AND DISCUSSION
3.4.1 Melting behaviour of P(HB-HV) biopolymers.
The melting of polymer crystals is essentially the reverse of crystallization, but is 
more complicated than the melting of low molecular weight materials. Characteristically, 
polymers do not have sharp melting points but the melting takes place over a range of 
temperatures [387-388]. The melting range is further classified by the onset and peak 
melting temperatures as shown in Figure 3.4.
The onset melting temperature is defined as the intersect on the baseline of a tangent 
drawn to the leading edge of the main peak [380]. The difference between the onset and 
peak temperatures provides a measure of the range over which melting occurs. The range 
and shape of the melting curve contains information on the size and order within 
crystallites and in general the quality of the crystallinity [389]. However, the onset 
and peak temperatures are often not distinguished and sometimes used synonymously in the 
literature.
The melting range is influenced by a number of factors including the programmed heating 
rate within the DSC. Daniels [390] gives a detailed account on the influence of 
operating parameters, including sample mass, on DSC traces. The sample mass in this 
study was kept constant within the range of 3 -5m g . Table 3.1 shows the relationship 
between heating rate and peak melting temperature for PHB380K. Increasing the programmed 
heating rate from 5K/min to 20K/min produced a corresponding 4°C  rise in peak Tm.
Table 3.1. The effect of DSC heating rate on the melting points of PHB380K 
(Mean + Range; n = 2 )
Heating Rate Melting Temperature (°C)
Kmin-1 Onset Peak
5 161.5 ± 0.1 170.0 ± 0.1
10 162.0 ± 0.2 172.3 ± 0.4
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Figure 3.4. A DSC melt endotherm showing the onset and peak 
melting temperatures of a polymer.
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As a result of Tm varying with heating rate, it has been suggested [389] that the 
definition of Flory [391] for melting points should be used. Flory [391] has defined the 
melting point as that temperature at which crystallinity just persists. This implies 
that melting of the most stable crystallites is determined rather than a less precise 
measure of average melting point [389]. In the DSC this is usually determined by 
extrapolation to zero mass or zero heating rate. Extrapolation of Tm values for PHB to 
zero heating rate gave a peak melting point of 169°C. However values obtained in such a 
manner are thought to be dependent on the heating rates chosen for extrapolation and the 
concept has been replaced by the determination of equilibrium melting temperature [389].
This is further discussed in chapter 5.
Table 3.2 shows the effect of molecular weight (MW) on the melting behaviour of PHB. 
Molecular weight fractions were prepared by non-aqueous catalytic degradation as 
described in chapter 2. In general the peak melting point increased with increasing 
molecular weight of PHB. The melting temperature of PHB23K was significantly lower 
(p<0.05) than of PHB molecular weights in the range 250K-800K. This was thought to be 
due to the higher proportion of chain ends in the low MW polymer which are responsible 
for introducing crystal defects and lowering Tm. However, the effect of molecular 
weight on melting temperatures of PHB within the molecular weight (Mw) range of 250K -  
800K was weak. This finding is not unusual and the influence of MW on melting point has 
been reported by Young [392] to be weak when the MW of the polymer is sufficiently high 
to have useful mechanical properties. For PHB the mechanical properties stabilised at 
about MW 300K, which is in close agreement with the melting point data. Mechanical 
properties were thought to stabilize when the cohesive forces within the bulk polymer 
were strong enough for the polymer to have useful properties (see Chapter 2). The heat 
of fusion appeared to be variable and no correlation with molecular weight of PHB could 
be established.
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Table 3.2. The melting behaviour of PHB molecular weight fractions prepared by n o n -  
aqueous catalytic degradation (Mean + Range; n = 2 )
Molecular Weight (x 1000) Mw/Mn Melting Temperature (°C ) Heat of Fusion 
Mw Mn Onset Peak
23 13 1.8 160.1 ± 0 .3 168.2 ±0.3 87.5 ±2.1
250 167 1.5 164.4 ±0.1 173.8 ±0.2 101.5 ± 9 .5
384 226 1.7 165.0 ± 0 .2 174.8 ±0.4 96.1 ±9 .3
513 324 1.6 165.9 ±0.1 177.3 ±0.1 86.2 ±3 .2
765 506 1.5 166.5 ±0.1 176.8 ±0.1 99.5 ±1.1
Figure 3.5 shows DSC melt endotherms of ’as supplied’ P(HB -  HV) copolymers to highlight 
the relationship between copolymer composition and melting temperature. Melt endotherms 
were recorded at a programmed heating rate of 20K/min. The data on the melting behaviour 
of P (H B -H V ) biopolymers is summarized in Table 3.3
Table 3.3. Data on the melting behaviour of P (H B -H V ) polyesters (Mean + Range; n =  2  
Heating rate 20kmin_1).
Polymer Melting Temperature (°C ) Heat of Fusion ( j / g )
Onset peak
PHB380K 163.4 ±0.1 174.1 ±0.1 91.7 ±0 .3
PHV6 129.8 ± 0 .4 150.0 ±0.1 77.2 ±2 .9
PHV12 111.4 ± 0 .5 135.9 ±0.1 66.6 ±0 .6
PHV20 79.1 ± 2 .4 115.0 ±0 .4 54.1 ±7 .3
PHV27 41.7 ±0.1 83.8 ±0.1 51.3 ±0 .3
The melting point or range of P (H B -H V ) copolymers was dependent on HV content. PHB380K 
melts at a peak melting temperature (peak Tm) of 174°C but as the HV content was
increased the peak Tm was progressively lowered to a value of 83°C  for PHV27. A similar
trend was seen for their heats of fusion ( / \  H f ). The results are shown graphically in 
Figures 3.6 and 3.7.
The heats of fusion of a polymer can be indicative of the mass fraction degree of
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Figure 3.6. The variation in onset and peak melting temperatures 
with P(HB-HV) copolymer composition.
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Figure 3.7. The variation in heats of fusion with P(HB-HV) 
copolymer composition.
(Mean, n = 2; data from Table 3.3)
crystallinity of that polymer if the value for the heat of fusion of the 100%
crystalline polymer is known [389]. The heat of fusion estimated for the 100% 
crystalline PHB has been reported by Barham et al [214] to be 146 J/g« The values
obtained in this study suggest that the ’as supplied’ PHB800K was up to 69% crystalline.
However contrary to the assumption of Holmes and colleagues [149,247], the progressive 
decrease in heats of fusion values for P(HB-HV) copolymers cannot be taken to represent
a corresponding decrease in their degrees of crystallinity. This is mainly due to the
fact that the values for the 100% crystalline copolymer will be different at each HV 
content, possibly because of crystal defects. There is also recent evidence [249-250] 
to suggest that there may be some exclusion of HV units from the common crystal lattice 
of these polyesters. The exclusion of HV units may explain why density measurements and 
heats of fusion values do not relate to the crystallinities determined by X-raY
diffraction techniques.
The depression in melting points of copolymers with increasing HV content was thought to 
be due to HV units acting as impurities within the PHB matrix. In addition, the extra 
methyl group of HV introduced into the side-chain of the PHB polymer may introduce 
crystal defects in copolymers to lower Tm. The PHB crystalline lattice is thought to 
accept the ethyl group of HV, but less readily than the PHV lattice accommodates the 
smaller methyl group of HB [208]. The introduction of the ethyl group of HV within the 
PHB lattice, therefore, may only occur at the expense of introducing crystal defects and 
imperfections. This is manifested in a progressive increase in the range or breadth of 
the melt endotherm with increasing HV content This can be seen from the melt endotherms 
of the copolymers in Figure 3.5 and can also be deduced from the progressive increases 
in the differences between onset and peak temperatures shown in Table 3.3. The melt 
endotherms for the P(HB-HV) polymers also show double melt endotherms. The existence of
multiple peaks in polymer melting is a common but complex phenomenon which may be
explained by a distribution of crystallite sizes [393] and is further discussed in 
chapter 4.
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The Tm of copolymers would normally be expected to fall progressively until the melting 
point of pure PHV is attained. The literature value for the melting point of pure PHV is 
105-108°C [205]. However, a recent report by Marchessault and coworkers [210] has shown 
that bacterial P(HB-HV) polyesters from Alcaligenes eutrophus exhibit eutectic -  like 
minima in their melting points and heats of fusion at approximately 30 mole% HV content.
In a more recent report, Marchessault and coworkers have shown a similar eutectic-like 
minimum for synthetic P(HB-HV) copolymers [208]. These P(HB-HV) copolymers were 
chemically synthesized by ring opening polymerization of mixtures of p -  butyrolactone and 
p -  valerolactone using a stereoselective alumoxane catalyst The melting temperatures of 
synthetic copolymers were found to be similar to those determined by the authors for the 
biosynthetic copolymers. However, the heats of fusion were consistently lower for the 
synthetic copolymers and these were attributed to calibration differences between the 
two separate DSC instruments used in their study [208]. The authors reported that the 
synthetic P(HB-HV) copolymers exhibited eutectic-like minima in melting points and 
heats of fusion at approximately 30 mole% [208,210]. However, closer examination of 
their data over the full composition range, suggests that the minima for the synthetic 
P(HB -  HV) copolymers occurred at about 40mole%. The results of this study on the melting 
data for bacterial P(HB-HV) polymers containing up to 28 mole% HV correlate well with 
those reported by Marchessault and coworkers [210].
This phenomenon of a melting point minimum is not normally seen in most copolymer 
systems [210]. However in the case of P(HB-HV) the eutectic -  like minima may be explained 
by the fact that the statistically random P(HB-HV) copolymers exhibit isodimorphism.
Both the HV and HB components of the crystalline P(HB-HV) copolymers are thought to c o -  
crystallize within the same unit cell because of their similar main-chain conformations 
and molecular dimensions [208,210].
3.4.2 Glass transitions in P(HB-HV) biopolymers.
The glass transition represents the rather sharp change that occurs from the glassy to
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the rubbery or flexible thermoplastic states in nearly all linear-type polymers [394].
It is characteristic of a polymer and related to its structure. In fact, the glass 
transition temperature (Tg) varies with the type of skeletal atoms present, with the 
types of side groups, and even the spatial disposition of the side groups [394]. A 
knowledge of the glass transition of a polymer is not only useful for identification but 
also provides information of the polymers properties and molecular structure [395]. In 
biomedical applications of polymers, a knowledge of the Tg will indicate whether the 
polymer exists as a brittle glass or as a flexible thermoplastic with enhanced chain 
mobility at physiological temperatures. Information on polymer chain mobility will be 
important in drug diffusion and controlled drug release properties of polymers.
The Tg strongly depends on the thermal history and crystallinity of polymers [393] and 
for that reason samples were standardised to an amorphous morphology for Tg 
determinations. Amorphous samples of PHB could only be produced if the quenching 
(cooling) rate was equal to or greater than 40K/min. Slower cooling rates allowed the 
PHB to recrystallize. The presence of the amorphous state was confirmed, on a subsequent 
heating cycle in the DSC, by the presence of an exotherm of crystallization with a heat 
of crystallization close to the heat of fusion (within 50-70%  of the heat of fusion; see 
section 3.4.3). Completely amorphous polymers were not obtained in this study. This 
was expected since the presence of some order even in amorphous states has been observed 
for crystalline polymer systems [396]. The absence of an exotherm of crystallization 
would suggest that the sample had crystallized and was no longer amorphous. P(HB-HV) 
copolymers could be quenched to an amorphous state at slower rates of cooling than for 
PHB (Table 3.4) because the rate of crystallization was slower in copolymers and was 
dependent on HV content (see chapter 5).
109







Melt-quenched amorphous P(HB-HV) copolymers were heated from subambient temperatures, 
usually -1 5  or -20°C , to melt in a Dupont DSC apparatus at 20K/min. Figure 3.8 shows a 
typical DSC trace for PHB from which glass transitions were determined using the Dupont 
DSC data analysis software. The onset temperature was the chosen method for Tg 
determination. The Tg results are summarized in Table 3.5.
Table 3.5 Glass Transition Temperatures of P(HB-HV) polyesters.
Polymer Tg range (°C)
PHB380K - 5 to + 8
PHV6 0 to + 5
PHV12 - 5 to + 3
PHV20 + 10 to + 18
PHV27 + 15 to + 20
PLA + 56 to + 59
P(LA-GA)90:10 + 55 to + 58
P(LA-GA)10:90 + 35 to + 38
The glass transition temperature varied between - 5  to 20°C for the range of P(HB-HV) 
copolymers containing up to 27mole% HV content but the relationship was not linear. 
These values were much lower than those determined for P(LA-GA) systems (included in
Table 3.5). The experimental values of Tg for P(LA-GA) polymers were in agreement with 
those cited in the literature [92,97,403]. However the values found in the literature
for P(HB-HV) polymers vary considerably and are dependent on the method used for Tg 
determination. Holmes and colleagues [159] have reported that the homopolymer has a Tg 















Figure 3.8. A typical DSC trace from which the glass transition 
onset temperature was calculated.
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increasing HV content to a value of -6 ° C  for a copolymer containing 25 mole% HV. Barham 
et al [214] have reported that PHB has a Tg in the range -1  to +4°C  determined by 
dilatometry whereas dynamic mechanical analysis by Owen has suggested the homopolymer 
has a Tg value of 7°C and a copolymer containing 17 mole% HV has a Tg of -1 °C . The 
discrepancies are mainly due to the highly crystalline nature of P(HB-HV) biopolymers 
which makes detection of Tg difficult and imprecise. For the same reason the Tg of 
polyethylene is a matter of some dispute [392] and values have been quoted between 140°K 
and 270°K (-1 3 3  to -3 °C ).
The relatively low Tg of the homopolymer, PHB, is due mainly to the flexibility of the 
polymer backbone allowing easy rotation about the main bonds. Structural considerations 
suggest that the Tg for P(HB-HV) copolymers should progressively decrease with 
increasing HV content as is confirmed by the findings of Holmes and colleagues [159]. 
However, this was not found to be the case in this study but the results may have been 
complicated by differences in the molecular weights of the copolymers used. The Tg of 
polymers is found to increase with increasing molecular weight and the behaviour has 
been approximated by Young [392] to an equation of the form
T’g = Tg + K/M
where T’g is the value of Tg for a polymer sample of infinite molar mass and K is a 
constant dependent on polymer free volume.
As discussed earlier the Tm of P(HB-HV) polymers is also dependent on similar structural 
factors as those outlined for Tg because both Tm and Tg are controlled principally by 
main-chain stiffness. It is not surprising, therefore, that a correlation is found 
between Tm and Tg for polymers undergoing both transitions. Boyer [397] found that when 
expressed in Kelvins the value of Tg is between 0.5 and 0.8 Tm The Tg values of P(HB- 
HV) polymers as shown in Table 3.5 suggest that the correlation approximates to about
0.6 Tm and falls within the limits predicted by Boyer [397].
The possibility of predicting polymer properties from their chemical structure has been
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investigated [398] and reviewed by Askadskii [399]. He illustrates how a number of 
polymer properties including Tm and Tg can be predicted from information on Van der 
Waals’ volumes of atoms and suggests that this makes synthesis of polymers with 
accurate predefined properties a practical reality [399].
The onset of the Tg marks a significant change in the physical properties of the 
polymer. A glassy polymer will lose its stiffness and have a tendency to flow above Tg.
The glass transition temperatures of the P(HB-HV) copolymers are close to ambient and 
suggest that at body temperature the biopolymers will certainly be above their Tg values 
and in the rubbery state. The added chain mobility at the higher temperatures is likely 
to modify polymer properties from those at ambient It is recommended, therefore, that 
whenever possible polymer properties should be evaluated at the temperature of use. The 
changes in polymer behaviour above Tg may greatly influence polymer permeability and 
drug release.
3.4.3 Crystallization exotherms and the influence of drugs.
When a melt-quenched amorphous sample of a crystalline polymer is re-heated to melt in a 
DSC It first undergoes a glass transition followed by a crystallization exotherm and 
finally an endotherm for the remelting of crystals. A representative DSC thermogram 
showing such transitions for PHB43K is given in Figure 3.9. The crystallization 
exotherm for PHB43K occurred at 63°C at a heating rate of 20K/min. Studies with PHB 
380K showed that peak exotherm temperature was dependent on the DSC heating rate (39,43 
and 51 °C at programmed heating rates of 5, 10 and 20 Kmin-1 respectively) [400]. Typical 
values for the heat of crystallization of PHB on heating melt-quenched samples was in 
the range "48 -  62 j / g  (53-68%  of the heat of fusion). Typically for P(HB-HV) 
copolymers, the heat of crystallization was also approximately 50-70%  of the respective 
heat of fusion. Using the assumption that crystallization is essentially the reverse of 
melting then the value for the heat of crystallization, for each polymer, should be the 










Figure 3.9. A DSC trace for PHB43K showing the glass transition, 









occurs within the DSC heating programme. However, the heat of fusion for PHB and P(HB- 
HV) copolymers was generally greater than the heat of crystallization suggesting that 
some order existed within the amorphous PHB and P(HB-HV) polymers prior to the DSC 
heating cycle. This may have been as a result of rapid crystallization of polymers 
outside of the DSC cycle or due to intrinsic local order within the amorphous polymer 
[396].
Recrystallization of polymer also occurred when PHB was cooled from the melt at a
temperature below the minimum rate for obtaining an amorphous state, The
crystallization exotherm for PHB43K cooled at 20K/min occurred at peak temperature of 
82 +_ 1°C. Typical values for the heat of crystallization of PHB43K were-50 +_ 6 J/g and 
a representative DSC thermogram on cooling is shown in Figure 3.10. The crystallization 
exotherm temperatures were less reproducible than the endothermic melting temperatures 
for P(HB -  HV) polymers. The major causes for variation in results were thought to be 
impurities such as dust particles which can induce surface nucleation in polymer 
samples. They can act as nucleating agents and at a given temperature, initiate 
crystallization at a rate faster than would be seen for a pure sample .
The inclusion of drugs in polymers may act in a similar way to impurities such as dust
The influence of a number of model drugs on the glass transition, crystallization 
exotherm and melting temperature is shown in Table 3.6.
Table 3.6. The effect of model drugs on the DSC transitions of PHB43K at programmed 
heating rate of 20K/min.
Model Drug Concentration ___________Temperature (°C)_________________
(%w/w) Tg crystallization melting
_________________  (onset)_(peak)_____________(peak)
PHB43K alone 6.5 63.4 176.6
+ 1% Methyl Red 4.3 53.9 173.4
+ 10% Methyl Red 4.5 76.6 167.7
+ 1% quinine 2.0 53.9 163.2
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The inclusion of all drugs lowered the peak Tm of PHB. However, the magnitude of the 
effect was dependent on the concentration (10% Methyl Red depressed Tm by a greater 
amount than 1% of the same drug) and the nature of the drug (Sodium Fluorescein had a 
greater effect than quinine which had a greater effect than Methyl Red in depressing Tm 
of PHB43K). The presence of drugs in PHB lowered the Tg in the same way as Tm but the 
effect on the crystallization exotherm was variable. The effect of drugs at low 
concentration (1%) was to reduce the peak crystallization temperature but Methyl Red at 
higher concentrations (10%) actually increased this value. This may have been due to the 
higher concentration of drug in polymer reducing thermal conductivity in the sample and 
thereby introducing a temperature lag.
3.4.4 Thermal stability of P(HB-HV) biopolymers by TGA.
The classic way of assessing thermal stability of polymers is by thermal gravimetric 
analysis (TGA). This technique detects mass losses within a sample as volatile 
decomposition products are evolved. The degradation process is characterised by the 
onset degradation temperature (Td) [399]. This is determined from the intersect of 
tangents drawn on the degradation profile as shown for PHB380K in Figure 3.11. For PHB 
380K, Td was approx. 310°C and 100% mass loss was complete within a temperature range of 
about 50°C at a heating rate of 20K/min. Results from TGA were found to very 
reproducible and typically, were within +_ 2°C.
The decomposition of PHB can also be monitored by DSC. Programmed heating of PHB380K up 
to 500°C is represented in Figure 3.12. The peak at around 300°C following the endotherm 
of melting (175°C) was associated with the evolution of volatile degradation products 
from PHB. The peak temperature associated with degradation of PHB in the DSC was in 
agreement with the corresponding Td values from TGA.
The reaction mechanism for the thermal degradation of PHB has been studied by Grassie et 
al [273]. The authors found that following the initial esterification of the terminal 
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Figure 3.12. A DSC trace showing thermal degradation of PHB380K.
ester linkages. Grassie et al [272] found that the major volatile products for PHB 
were, in decreasing amounts, the dimer, crotonic acid, trimer, tetramer and isocrotonic 
acid. In addition, small amounts of carbon dioxide, propene, ketene, acetaldehyde and p -  
butyrolactone were also reported to be evolved but the authors showed that these were 
secondary products formed by further decomposition of the primary products.
Although a single stage mass loss of PHB was registered over a temperature range of
approximately 300 -  350°C, thermal degradation of the polymer to non-volatile breakdown
products may have occurred at lower temperatures without corresponding mass loss. 
Indeed, Grassie et al [401] have reported that although no significant weight loss 
occurs up to 190°C, molecular weight losses indicating degradation in PHB do occur even 
in this temperature range. The magnitude by which molecular weight changed at a 
particular temperature was dependant on the length of time the material was held at that 
temperature [401].
3.4.4.1 Effect of heating rate
The degradation profile and the Td are dependent on the heating rate used in the TGA
apparatus. Figure 3.13 shows that Td for PHB43K increased with increasing heating
rate. Increasing the heating rate from 5 to 20K/min resulted in a 20°C rise in the Td.
The explanation for this effect is the same as in DSC, where it was less pronounced, and 
is related to the residence time of the sample at a given temperature being shorter as 
the heating rate is increased.
3.4.4.2 Effect of polymer molecular weight
Figure 3.14 shows TGA curves for different molecular weights of PHB. The Td increased 
from PHB 140K (Td = 298°C) to PHB380K (Td = 309°C). However the value of 308°C for the 
of PHB43K was not significantly different from that of PHB380K. The explanation for 




















- 10.0- 10 .0
375.0 400.325.0 350.0275.0 300.0225.0 250.0200.0
♦Temperature
Figure 3.13. The effect of TGA heating rate on the degradation 
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Figure 3.14. TGA traces showing the effect of polymer molecular









3.4.4.3 Effect of copolymer composition.
The Td for P(HB-HV) copolymers is given in Table 3.7. The results showed that for up to 
12 mole% HV the Td decreased with increasing HV content Figure 3.15 shows the TGA curve 
for PHV12 compared to that of PHB43K. However, the Td values for higher HV content 
copolymers were similar to those found for PHB.








The DSC thermograms for the degradation of P(HB-HV) copolymers were similar to those 
obtained for the homopolymer. Figure 3.16 shows a representative DSC thermogram for 
PHV20. It was noted that although PHV20 had a much lower melting temperature than PHB no 
such difference was found in either Td determined by TGA or the peak temperature of the 
DSC degradation endotherm. This may be due to their similar degrees of crystallinity 
[210- 211].
Although the Td was around 300°C for all the P(HB-HV) polymers studied, the progressive 
fall in their melting points (chapter 2) suggested that the window for safe thermal 
processing increased with increasing HV content Materials which do not degrade until 
temperatures are very much above the melting point are preferable for manufacture by 
melt-processing. The copolymers therefore offer potential advantages of greater
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Figure 3.16. A DSC trace showing thermal degradation of PHV20.
3AAA  Comparison with poly-L-lactide (PLA).
Figure 3.17 shows TGA degradation profiles for PLA and PHB. The degradation profile of 
PLA consisted of a single stage mass loss (as for PHB) and this was consistent with the 
findings of Gupta and Deshmukh [402] and Gilding and Reed [97]. Lactide has been 
reported to be the major decomposition product of PLA [97].
The value of Td for PLA (303°C) was lower than PHB (309°C) but the major difference in 
the TGA degradation profile of the polymers was in the range over which mass loss 
occurred. Complete mass loss occurred for PHB within a range of approximately 50°C 
whereas for PLA, mass loss occurred over a wider temperature range of approximately 
100°C. This suggested that the rate of thermal degradation of PHB (and P(HB-HV) 
copolymers) was much faster than that of PLA. Gupta and Deshmukh [402] have proposed 
that, under isothermal conditions, PLA degradation kinetics follow the Avrami-Erofeev 
equation for solid gas equilibria:
[-ln(1 - a ) ] 1/n = kt
where a is the fractional weight loss, n is an exponent and k is the rate constant The 
authors report that the Avrami -  Erofeev equation kinetics suggest that the decomposition 
of PLA is due to nucleation and growth of decomposition sites [402].
The above results suggest that PHB has a similar temperature range for melt-processing 
as PLA. Both polymers melt and degrade at similar temperatures but once degradation is 
initiated or nucleated then degradation appears to more rapid in PLA than in PHB. This 
may be advantageous in melt processing of PHB but needs to be further investigated at 
temperatures close to the melt which are more likely to be used during thermal 
processing.
126
1 1 0 . 0  - 110.0
100.0 100.0
90 .0  - 90 .0
80 .0  J 80 .0
70 .0 70 .0
60 .0  n 60 .0
50 .0  - 50 .0
40 .0  - 40 .0
30 .0  J 30 .0
20 .0  - 20.0
10.0  *1 10.0
0.0
- 10.0  - -  - 10.0
200.0 225.0 250.0 275.0 300.0 325.0 350.0 375.0
Temperature (*C)
Figure 3.17. TGA traces comparing thermal degradation behaviour 
of PHB380K and PLA.
3.5 CONCLUSIONS
Results from both TGA and DSC were Influenced by the programmed heating rates of the 
instruments.
The peak melting temperature was dependent on P(HB-HV) copolymer composition.
The glass transition temperatures for P(HB-HV) polymers were variable over the range - 5  
to 20°C and no correlation was established between Tg and HV content. The Tg values of 
P(HB-HV) polymers studied were all lower than body temperature.
Thermal degradation of P(HB-HV) polymers occurred over a narrow range (approximately 
50°C) from around 300°C. The values for Td were influenced by molecular weight and HV 
content but the relationships were not linear. PLA also degraded at around 300°C but 






Physical ageing of polymers refers to changes in their physical properties with time 
following manufacture. Ageing has been reported to occur in a number of materials and 
significant changes in both their physical and mechanical properties have been reported 
on storage [404 -  407].
Physical ageing has been widely studied by Struik [404 -  406] and in recent years ageing 
has been reported to occur in both amorphous and crystalline polymers [405]. Ageing has 
been demonstrated in a number of commercial semicrystalline polymers, including 
polypropylene and high density polyethylene, at temperatures above and below their glass 
transitions [405].
Physical ageing is a phenomenon characteristic of the glassy state because of its non- 
equilibrium character. In the glassy state (below Tg for semicrystalline polymers) 
residual short range mobility of molecules exists which produces molecular 
rearrangements that drive the thermodynamic variables closer to their equilibrium 
values. With increasing ageing time the free-volume, for instance, decreases and all 
physico -  mechanical properties dependent on this variable will also change with time. The 
changes are faster at short rather than long ageing times because ageing is a self- 
delaying process in which the state of equilibrium (zero mobility) is reached 
asymptotically [269,404 -  405].
At temperatures above Tg in semicrystalline polymers, Struik [404 -  405] has shown that 
part of the amorphous phase remains glassy and consequently these polymers continue to 
exhibit ageing at temperatures above Tg, a behaviour not normally observed in purely 
amorphous polymers. Struik [404 -  405] also proposes that in semicrystalline polymers the 
crystalline phase reduces segmental motion of amorphous regions close to the crystal 
surface but the bulk amorphous regions remain undisturbed. Therefore, the amorphous 
phase no longer has a single Tg but a Tg -  distribution. This may therefore explain the 
variations in the Tg values for P(HB-HV) and other polymers reported in chapter 3 and
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the dependence of Tg on ageing and thermal history of the material.
The change in physical properties of polymers with time following fabrication or ageing 
will be an important consideration in determining the potential applications of such 
materials. Furthermore, knowledge of the behaviour of polymers on storage at specified 
conditions following manufacture (from solution or melt) will be important in 
determining methods of accelerating ageing and thereby producing devices with stable or 
at least known properties. Indeed, recent work by Kandil et al [407] on the effects of 
ageing on the mechanical properties of dental polymeric composite materials enabled the 
authors to develop a simple equation to predict the strength of composites when aged 
over a limited range.
Ageing properties of research materials are not always fully investigated and can often 
become an additional but unknown variable. A clear example of where this can occur is in 
the use of mechanical properties to monitor in vitro or in vivo degradation of polymeric 
materials. In such cases if the polymeric material is not allowed to age sufficiently 
(i.e. to a storage time when properties reach equilibrium) then any changes detected in 
the mechanical properties will not be solely due to the degradation but also a function 
of ageing. Clearly the ageing properties of polymers need to investigated if erroneous 
interpretations of results are to be avoided.
4.1.1 AIMS AND OBJECTIVES
1. To investigate the effect of physical ageing on the mechanical and crystalline 
properties of P(HB-HV) polymers.
4.2 MATERIALS
P(HB-HV) copolymer containing 16 mole% HV (PHV16; Mw = 41K) was purchased from
Marlborough Biopolymers Ltd, UK.
All other materials used were identical to those given in chapters 2 and 3.
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4.3 METHODS
4.3.1 Preparation of films
P(HB-HV) polymer films (30-50um) were prepared by solvent casting as in chapter 2. 
Polymer films cast from chloroform were initially dried under ambient conditions for 1 
hour in a level drying cabinet. Films were removed from the glass after this period and 
then stored either at 25°C over silica gel or at 65°C in a vacuum oven before analysis 
at timed intervals. In all cases, only films within a narrow thickness range (40 ±10um) 
were used such that thickness of films could effectively be eliminated as a variable In 
the interpretation of results.
4.3.2 Mechanical testing
Mechanical properties of polymer films were determined using static tensile tests (ASTM 
882-80a) as described in chapter 2.
4.3.3 Differential Scanning Calorimetry (DSC)
Bulk crystallinities of ageing films were monitored by DSC as described in chapter 3. A 
programmed heating rate of 20K/min was used unless otherwise stated.
4.3.4 X -ra y  diffraction studies
Polymer films (30 -  50um) were cast onto a glass slide and periodically analysed by X -  ray 
diffraction (CuK-alpha source) as a function of time over a diffraction angle of 4 -3 0 ° .
A Philips PW 1820/00 computer controlled vertical goniometer with a Philips PW1710 
diffractometer control was used. Intensity measurements were made using a Xenon 
proportional counter (Philips PW1711/10) with graphite monochromator and automatic 
divergence slit assembly. For the crystallinity index, the instrument was programmed to 
provide a step scan acquisition of data. Intensity data were acquired by scanning for 
10s at 0.2° steps in diffraction angle over the range 10-30°. Data acquisition was 
carried out using the COMSTAR software package run on a BBC Master Microprocessor 
interfaced with the X -ra y  diffractometer.
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4.4 RESULTS AND DISCUSSION
4.4.1 Mechanical Properties
In the course of the earlier investigation on the mechanical properties of P(HB-HV) 
polymers (chapter 2), It was found that mechanical properties of films varied with time 
following solution casting. In the present chapter, mechanical properties of P(HB-HV) 
polymer films were monitored at 25°C over a 42 day period following casting from 
chloroform solution.
The mechanical properties of all P(HB -  HV) biopoiymer films stored at 25°C appeared to 
change at first but stabilised to equilibrium values within 14 days. The Elastic Modulus 
(EM), a measure of polymer rigidity, changed rapidly at first before reaching 
equilibrium value for all polymers within 3 - 5  days ageing (Figure 4.1). The %Elongation 
(%E), a measure of polymer ductility, stabilised within a similar period of time (3 -5  
days) for all polymers except PHV12 which reached equilibrium within 14 days (Figure 
4.2). The anomalous behaviour of PHV12 may be due to secondary crystallization following 
reorientation of polymer chains in crystallites or crystal domains.
The equilibrium %E and EM values for P(HB-HV) copolymers were dependent on the copolymer 
composition. The EM decreased and the %E increased with increasing HV content of
copolymers at equilibrium. Their respective values at equilibrium were similar to those 
reported in chapter 2 (Figures 2.12 and 2.13).
The tensile strength (TS) of ageing P(HB-HV) films (Table 4.1) reached an equilibrium 
value for all polymers within 166 hours (approximately 7 days). There was some evidence 
to suggest that time taken to reach stable TS values was a function of HV content The 
TS data for PHB380K and PHV12 exhibited large standard deviations and appeared to
stabilise within approximately 2 days (46 h) whereas PHV20 and PHV27 stabilised within 
approximately 5 days (122 h) and 7 days (166 h) respectively. The equilibrium TS values 












Figure 4.1. The effects of ageing at 25°C on the Elastic Modulus 








Figure 4.2. The effects of ageing at 25°C on the % Elongation of 
solvent cast films of P(HB-HV) polyesters (Mean ± S.D; n = 5).
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The rapid changes in mechanical properties over the first few days following film 
casting were thought to be due to primary crystallization during solvent evaporation. 
Although all the films had dried sufficiently after 1 hour for them to be removed from 
the glass plate, crystallization was thought not to be complete until the majority of 
the solvent had evaporated from the polymer film. This was thought to have largely 
occurred within 3 - 7  days for films aged at 25°C. Small amounts of residual solvent, 
which may have remained trapped within the film matrix, could contribute to secondary 
crystallization processes allowing limited chain mobility and reorganization of polymer 
chains within the formed crystallites. This may have explained the delayed stabilization 
of %E in PHV12.
Table 4.1. The tensile strength of P (H B -H V ) polyesters stored at 25°C  as a function of 
ageing time.
Time Tensile Strength (MPa); (Mean ±S.D; n =  5).
(hours) PHB380K PHV12 PHV20 PHV27
21 19.3 ±4.4 19.2 ±1.1 17.9 ±0.8 12.4 ±0.2
46 23.5 ±2.0 25.6 ±0.4 19.6 ±0.5 13.8 ±0.4
122 21.0 ±7.8 27.5 ±0.8 22.3 ±0.4 14.6 ±0.3
166 22.4 ±4.0 25.8 ±0.9 — 15.9 ±0.6
240 20.3 ±1.9 23.8 ±5.1 — - -----
336 20.5 ±5.3 25.1 ±2.1 22.0 ±1.1 16.5 ±0.6
The effect of film storage at a higher temperature (65°C) on the mechanical properties 
of P (H B -H V ) films is shown in Figures 4 .3 -4 .5 . A temperature of 65°C  was chosen because 
it represents a temperature in excess of the boiling point of chloroform (62°C) and 
would accelerate solvent evaporation. It was found that mechanical properties had 
stabilised to equilibrium values within 24 hours. This suggested that ageing effects 
could be accelerated by controlling the temperature of storage.
4.4.2 Differential Scanning Calorimetry 
4.4.2.1 Solvent cast films
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Figure 4.3. The effects of ageing at 65°C on the % Elongation of
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Figure 4.4. The effects of ageing at 65°C on the Elastic Modulus
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Figure 4.5. The effects of ageing at 65°C on the Tensile Strength
of solvent cast films of P(HB-HV) polyesters (Mean ± S.D; n = 5).
intervals.
Figure 4.6 shows the variation in the heat of fusion for PHV27 on ageing. The heat of 
fusion, a measure of bulk crystallinity, initially increased rapidly with time but 
reached an equilibrium within 3 - 5  days for PHV27. This suggested that the degree of 
crystallinity of PHV27 increased to stable values within 3 - 5  days and largely mirrored 
mechanical property changes at 25°C. However Figure 4.7 shows that the shape of the DSC 
thermograms for PHV27 stabilised after longer periods of storage. The shape of DSC 
thermograms can be indicative of crystalline morphology in polymers [389]. The 
crystalline morphology is concerned with the size and arrangement of polymer crystals 
[408]. According to Shalaby [393] the shape of the DSC trace is determined in general by 
two competing processes: melting of the sample according to type, size and perfection of 
crystallites and reorganization of the sample as it is heated up during the scan. The 
results for PHV27 suggested that, although bulk crystallinity changed little after 
approximately 3 - 5  days storage at 25°C, the morphology of polymer crystals continued to 
change for longer periods of time. DSC thermograms for PHV27 stabilised within 31 days.
It was noted that DSC thermograms of PHV27 exhibited a double melt endotherm and these 
were seen in all P(HB-HV) copolymers (see chapter 3; Figure 3.5). The phenomenon of 
multiple melting endotherms in polymers is complex and attempts to explain their 
occurrence have been based on many hypotheses including variable crystallite sizes 
[393,413], different polymer morphologies [409 -  410] and melting and recrystallization 
of a single polymer morphology [411-412]. Double melt endotherms in bulk Nylon 66, 
polystyrene and poly(ethylene terephthalate) (PET) have been interpreted as a result of 
conversion of kinetically favoured lamellar crystals to thermodynamically favoured 
extended chain crystals [416-418]. The confusion over the best explanation for multiple 
melting peaks in polymers has recently been highlighted in a series of conflicting 
papers on the Interpretation of multiple melting peaks in poly(ether ether ketone)
(PEEK) [409-415]. The ongoing, and as yet unresolved, debate over the interpretation of 
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Figure 4.6. The variation in the heats of fusion for solvent cast
films of PHV27 during ageing at 25°C. (Mean ± S.D., n = 2)
Figure 4.7. The variation in the shape of DSC traces for solvent 
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endotherms seen in P(HB-HV) polyesters and a number of other polymers [419-420].
In the case of P(HB-HV) polyesters, the two melting peaks were thought to represent 
recrystallization of a single morphological form during the DSC heating program because 
this has been the most favoured of the hypotheses in studies with PEEK. This has been 
supported by observation of double melting peaks for isothermally crystallised P(HB-HV) 
polymer samples consisting of spherulites of the same size (one morphological form). 
Figure 4.8 shows that double melt endotherms were observed for P(HB-HV) spherulites 
isothermally crystallized at 60°C. Spherulitic crystallization is examined in more 
detail In chapter 5.
Ageing of PHV27 films at 25°C altered the shape and relative proportions of the two 
melting peaks until equilibrium was attained. Initially, peak II (the peak associated 
with melting at higher temperature) was the most prominent but on continued storage peak 
I (melting at a lower temperature) became the most prominent and appeared to be, 
thermodynamically, the more stable. The variation in peak melting temperatures for each 
peak (or crystal population) is shown in Figures 4.9 and 4.10. Peak I stabilised to a 
peak melting temperature of approximately 83°C (Figure 4.9) and peak II stabilised to 
approximately 110°C (Figure 4.10). A difference of approximately 27°C in the melting 
temperatures of the two peaks was observed at equilibrium.
Figure 4.11 shows changes in the relative proportions of the two peaks (or crystal 
populations) on ageing at 25°C. The relative proportions were calculated from the heats 
of fusion of each peak relative to the total heat of fusion for PHV27 and expressed as a 
percentage. Accurate results could not be obtained because the software did not allow 
deconvolution of the melt endotherms. However, estimates of the relative proportions of 
the two peaks were made using the Dupont thermal analysis software package which involved 
separating the two peaks by a perpendicular drop from the extrapolated baseline. 
Initially, peak II constituted 80% of the total melt endotherm. However this changed 
progressively over the first 4 - 6  days with peak I becoming more prominent Note the 
cross over point at about day 2, which represents the time when both peaks (or
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Figure 4.8. DSC traces showing double melt endotherms for P(HB- 
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Figure 4.9. The variation in the melting temperatures of Peak I
for solvent cast films of PHV27 during ageing at 25°C.












Figure 4.10. The variation in the melting temperatures of Peak II
for solvent cast films of PHV27 during ageing at 25°C.
























Figure 4.11. The variation in the relative proportions of the two
melting peaks for solvent cast films of PHV27 during ageing at
25°C (Mean ± S.D; n = 2).
morphologies) were equal in magnitude. At equilibrium, the situation had reversed and 
peak I constituted about 80% of the total melt endotherm.
Table 4.2 shows that PHB films achieved stable values for the heat of fusion within 24 
hours storage at 25°C. Figure 4.12 shows that the DSC thermograms of PHB also stabilised 
within a similar period of time. These results showed that the heat of fusion and shape 
of DSC thermograms for PHB stabilised more rapidly than PHV27 and also PHV12 (see Figure 
4.13). In the case of PHV12, DSC traces stabilised within 19 days of ageing at 25°C. 
These results were in general agreement with those reported by Bloembergen et al [211] 
who showed that solution crystallization of P (H B -H V ) copolymers occurs more slowly than 
in PHB. Crystallization of P (H B -H V ) polymers from the melt showed similar results (see 
chapter 5). The explanation for the slower rates of crystallization was thought to be 
due to the additional methyl group in HV retarding crystallization kinetics in 
copolymers.
Table 4.2. Heats of Fusion for PHB380K as a function of ageing time.
Ageing Time Heat of Fusion (Jg_1)
(Mean + Range; n = 2)
4 hr 61.2 ± 5.1
8 hr 74.3 ± 4.3
11 hr 81.6 ± 2.3
1 day 89.5 ± 1.7
4 days 90.6 ± 1.0
6 days 89.6 ± 0.9
17 days 87.4 ±  2.0
The DSC thermograms of aged PHB films (solvent cast) also exhibited double melt 
endotherms. The double melt endotherm was characteristic of aged samples prepared from 
both melt and solution.
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Figure 4.12.The variation in the shape of DSC traces for solvent 
cast films of PHB380K during ageing at 25°C.
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Figure 4.13. The variation in the shape of DSC traces for solvent 
cast films of PHV12 during ageing at 25°C.
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4.4.2.2 Ageing of melt quenched PHB.
The immediate remelting of melt quenched samples of PHB resulted in a single melt 
endotherm following complete recrystallization during the DSC heating program. However 
if melt quenched PHB samples were aged at 25°C before remelting, then a double melt 
endotherm would result on melting (Figure 4.14a and e).
At 25°C, PHB was above its glass transition temperature (Tg) and sufficient mobility of 
chains existed for the polymer to rapidly crystallize by chain reorientation. In the DSC 
the crystallization process at 25°C for PHB was monitored by the progressive 
disappearance of the crystallization exotherm at around 50°C. As crystallization 
progressed during the ageing process, the heat of crystallization progressively 
decreased from an initial maximum value, of approximately 70% of the heat of fusion, to 
zero when the crystallization process was complete. Using this method of monitoring 
crystallization, PHB was found to crystallize rapidly at 25°C and crystallization was 
usually complete within 2 hours. The crystallization of melt quenched PHB samples aged 
at 25°C Is represented by the DSC thermograms in Figure 4.14. The copolymers were found 
to crystallize more slowly (Table 4.3).
Table 4.3. Overall Crystallization times for P(HB-HV) polymers as estimated from DSC 
measurements.
Polymer Overall Crystallization
Ageing of poly- L -  lactide (PLA) at 25°C did not produce any crystallization outside of 
the DSC run and the heat of crystallization, which occurred at around 116°C, remained 
essentially constant for the entire study period of 60 days (Figure 4.15). The value for 
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Figure 4.14. DSC traces showing crystallization and ageing 
effects in melt -  quenched PHB380K samples as a function of time. 
(A = 1 min, B = 30 mins, C = 65 mins, D = 2 hours, E = 7 days).
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Figure 4.15. DSC traces for melt -  quenched samples of PLA as a 
function of time during ageing at 25°C.
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fusion (54 ± 4 Jg"1). This was in contrast to findings with P(HB-HV) polymers where
heats of crystallization were typically 50 -  70% of the heats of fusion for the range of
copolymers studied (see chapter 3). The absence of crystallization for PLA at 25°C was 
due to its high Tg (56-59°C ). At 25°C PLA was well below its Tg and existed in the
glassy state. The polymer was, therefore, unable to crystallize because of insufficient
chain mobility in this frozen glass. However, the glass transition for PLA, as shown in 
Figure 4.15, became more pronounced with time suggesting some stress relaxation or 
mobility of polymer chains on ageing. The position of the Tg was maintained within the 
range 56-59°C  throughout the 60 day study period.
This DSC method detects the overall crystallization of the polymer which is a 
combination of both nucleation rate and spherulite growth rate. A more comprehensive 
report of the crystallization growth rates determined from polarized light microscopy 
measurements is presented in Chapter 5.
4.4.3 X -ray  Diffraction
X -ra y  diffraction traces of ageing P(HB-HV) polymer films (solvent cast) changed with 
time when stored at 25°C. A representative trace showing changes with time for PHB is 
given in Figure 4.16. The amorphous state is characteristic of films cast from solution 
that have not completely dried. As crystallinity of the films progressed the sharp 
peaks, indicative of crystalline order, developed on the amorphous halo. The peak 
heights continued to change until equilibrium crystallinity was attained. At equilibrium 
the X -ray  diffraction traces for P(HB-HV) polymers were similar in appearance (Figure 
4.17) but this per se does not necessarily mean similar crystallinities. The amorphous 
component of each polymer needs to be assessed and for the degree of crystallinity to 
be independent of copolymer composition, the amorphous component must also be similar in 
each case. Although preliminary assessment of the amorphous components of the copolymers 
using X -ray  diffraction on melt-quenched samples suggested that crystallinity was 
indeed similar for the copolymers, this can only be a tentative suggestion and further 
work is required in this area.
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Figure 4.16. The variation in the shape of X - ra y  diffraction 
traces for solvent cast films of PHB380K during ageing at 25°C.
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Figure 4.17. X - ra y  diffraction traces for equilibrium aged P(HB 
HV) solvent cast films.
A = PHB380K
B = PHV6 
C= PHV12 
D = PHV20 
E= PHV27
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4.4.3.1 The crystallinity index
In order to quantify the changes in crystallinity observed for P(HB -  HV) polymers during 
storage, a crystallinity index was developed. It is obvious from even a cursory 
inspection of the physics of diffraction from polymers that calculation of an absolute 
crystallinity value from X -ray  data is a formidable task and and one which is prone to 
errors [421-422]. If an absolute value is determined, it is frequently open to debate as 
to whether certain assumptions that were used are actually valid [421]. It is often 
adequate to calculate a reproducible value from the X -ra y  data, which will compare, on 
an arbitrary basis, the crystallinity of different samples of the same polymer. Such a 
relative evaluation is termed a ’crystallinity index’. This approach of assessing 
crystallinity was suitable for this investigation in which degrees of crystallinity were 
being compared after samples of the same polymer had been aged for varying periods of 
time.
The differential intensity measurement method of Statton [421] was used in this study 
because of the advantages it offered over other methods of quantifying crystallinity. It 
is applicable to polymers having complex scans with several strong reflections [422].
The method requires no resolution or estimates of amorphous and crystalline scatter.
The method involved scanning two reference samples or standards between set limits of 
diffraction angle. One standard was for a highly crystalline sample and the other for a 
very amorphous sample. The unknown sample was then also scanned between the selected 
limits of the diffraction angle. The three scans were then normalized to the same total 
intensity between the selected limits of diffraction angle. An example of these scans 
for PET is reproduced from the original work of Statton [421] and is shown in Figure 
4.18.
In the case of P(HB-HV) polymer films, the crystalline standard was the equilibrium aged 
(> 2  months at 25°C) solvent cast film (30-50um) of the respective polymer. The amorphous 
standard was a 4%w/v chloroform solution for each of the respective polymers. By default
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Figure 4.18. Representative X - ray  diffraction traces for 
polyethylene terephthalate showing the principles involved in 











Figure 4.19. A typical plot of X - ray  intensity data for PET from 
which the crystallinity index value is obtained (after ref. 421).
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the standards represent 100% and 0% crystallinity respectively. The set limits for 
diffraction angle were 10 -30°. At increments of 0.2°, the differences between the 
intensity values were determined: (lu -  la) and (lc -  la); where I is the intensity 
value and the subscripts represent the unknown sample (u), amorphous standard (a) and 
the crystalline standard (c). The increments were carefully chosen to coincide with the 
maximum height of peaks seen in the X -ra y  traces and at the same time to provide 
sufficient data for a statistically accurate result. The Philips diffractometer control 
was programmed to carry out a step scan at 0.2° with a 10s time interval for intensity 
accumulations. Increments of 0.2° yielded 100 data points from each X -ra y  diffraction 
trace.
According to Statton [421] there are two different methods of handling the data obtained
from such scans. The first method results in an ’integral’ crystallinity index and is
calculated from
X = (L -  U  (x 100)
0c -  «a)
However, this method was quite sensitive to errors in experimental technique and Statton 
found lower precision for PET samples using this technique compared to the slope or 
correlation index method [421]. The latter is the second method and that used in this
study. In this second method, the data were treated to obtain a ’correlation’
crystallinity index from a linear regressional analysis of the expression
(lu -  la) = X(lc -  la) + B
The plot of (lu -  la) against (lc -  la) for a series of diffraction angle increments is
expected to yield a straight line. Figure 4.19 shows the results obtained for PET by 
Statton [421]. By linear regression, the slope of the straight line was the 
crystallinity index (X). Although more calculations are required in this method it is
preferred over the ’integral’ crystallinity index method.
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Figure 4.20. A typical plot of X - r ay  intensity data for PHB380K
from which the crystallinity index was determined.
obtained using the above method. There was a large degree of scatter between the points 
and regressional analysis of the data gave values of r2 consistently below 0.97.
Table 4.4 summarizes the crystallinity results for PHB380K, PHV12 and PHV27 on storage
of films at 25°C. Contrary to the findings with the mechanical properties, the
crystallinity of all polymer films (solvent cast) studied using X -ra y  diffraction, 
appeared to stabilise within 24 hours of fabrication. It appeared that crystallization 
was progressively retarded on increasing HV content. The crystallinity index reached 
equilibrium within approximately 2 - 4  hours for PHB380K, 4 - 8  hours for PHV12 and 12- 
hours for PHV27. No significant changes in the index were noted after this period but 
results may have been complicated by the large scatter of the acquired data. This was 
largely attributed to a greater variation in final film thickness (20-50um) of polymers 
used in the x -ra y  diffraction study.
Bloembergen et al [211], who used solvent cast films of an unknown thickness, have also 
studied ageing of solvent cast films. Using FTIR (Fourier Transform Infra-Red
Spectroscopy) to measure crystallinity, they found that copolymer films stored at 
ambient stabilised more slowly than the homopolymer. The authors found that
crystallinity of copolymers containing 7 -4 7  mole% HV had not stabilised after 3 weeks of 
storage. They attributed this to the slower crystallization of copolymers which may 
involve secondary crystallization processes [211].
Table 4.4 Variation in Crystallinity Index as a function of ageing time for 
P(HB-HV) polymers.
Ageing Time Crystallinity Index (Mean + Range; n = 2)
(hours) PHB380K , PHV12 PHV27
0.33 0.30 ±0.29 0.27 ±0.21 0.13 ±0.10
0.67 0.65 ±0.14 0.45 ±0.33 0.42 ±0.12
1.00 0.48 ±0.11 0.85 ±0.24 0.25 ±0.22
2.00 0.91 ±0.17 0.74 ±0 21 0.55 ±0.31
4.00 0.97 ±0.52 0.90 ±0.11 0.65 ±0.21
8.00 1.10 ±0.21 0.98 ±0.20 0.74 ±0.15
12.00 1.01 ±0.44 1.11 ±0.10 0.67 ±0.41
24.00 0.92 ±0.46 1.12 ±0.22 0.94 ±0.21
48.00 1.00 ±0.20 0.99 ±0.13 1.10 ±0.10
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The fact that polymer properties stabilized more rapidly when measured by X -ra y  
diffraction than those measured by DSC or mechanical testing may be explained by the 
fact that X -ra y  diffraction is primarily detecting surface properties whereas the other 
two techniques are concerned with the bulk. The surface of the polymer film crystallized 
more rapidly than the bulk because drying proceeds from the surface inwards. The results 
are therefore consistent with the drying process.
These results have highlighted the fact that crystallinity must be determined by more 
than one technique for the results to be meaningful. Furthermore, bulk properties of 
P(HB-HV) polymers were found to change for longer periods than surface properties during 
ageing.
A recent report by Scandola et al [269], who investigated the ageing phenomenon in melt 
processed PHB by monitoring dynamic mechanical properties with time at 30°C, found that 
the dynamic mechanical spectrum (DMS) of PHB in the glass transition region continued to 
change throughout the 720 hour study period. At the same temperature the DMS for a 
copolymer containing 30 mole% HV continued to change throughout a 1120 hour study period 
[269].
Clearly ageing can occur in P(HB-HV) polymeric devices fabricated from both solution and 
melt and must be accounted for in biomedical and other applications of these polymers. 
Significant ageing effects were not evident in PLA when stored at 25°C and this may be 
due to its high glass transition temperature (56-59°C ), which is well above room 
temperature. DSC traces for PLA stored at 25°C remained essentially unchanged but the 
glass transition became more pronounced with increasing ageing time.
4.5 CONCLUSIONS
The crystalline and mechanical properties of P(HB -  HV) polymer films changed with time 
following fabrication. The bulk crystallinities and mechanical properties of P(HB-HV) 
films appeared to stabilise within 3 -5  days, whereas surface crystallinities stabilised
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within 24 hours for the polymers studied. These changes may have been related to either 
solvent evaporation and/or secondary crystallization effects.
Despite PHV20 and PHV27 films having stable crystallinities (DSC and X -ra y  diffraction) 
after a maximum of approximately 7 days, the morphology of these films, as detected by 
DSC, continued to change for up to 19 and 31 days respectively. These results suggest 
that some chain reorganizaion or stress relaxation may be occurring during storage. The 
reason why this occurred with the copolymers and not PHB remains unclear but may be 
related to the slower rates of crystallization observed in the copolymer. There was some 
evidence in terms of TS, stabilization of DSC traces and crystallinity index data from 






A knowledge of the crystalline properties of polymers is important because they 
influence all other bulk properties (thermodynamic, physical, mechanical and optical)
[213] and in order to explain bulk properties fully it is essential to have a clear 
understanding of the nature and extent of crystalline regions. The degree and rate of 
crystallinity and the morphology of polymer crystals will be important parameters when 
considering the processing of semicrystalline polymers. In the biomedical and
pharmaceutical applications of such polymers, the way In which these properties are 
modified on incorporation of drugs or additives will influence not only the manufacture 
but also the potential uses of the material. Furthermore, in drug delivery applications, 
the way in which drugs are trapped and distributed within the semicrystalline polymer 
and the way in which this influences polymer morphology may provide valuable information 
on the rates and mechanisms of drug release.
Polymer morphology concerns the shape and arrangement of crystals [408]. However,
semicrystalline polymers in their solid state are reported to have very complex
morphologies [219]. This is attributed to the chainlike nature of their constituent 
molecules, which leads to crystallization behaviour and morphologies that are in most 
aspects only rarely encountered in more traditional "small molecule" solids, and in 
other aspects are unique to polymers [219].
Evidently, the study of polymer morphology has a great deal to offer but, despite major 
advances in the last thirty years, with one or two notable exceptions, its full impact 
has yet to be realized. This applies especially to melt-crystallized polymers, i.e. many 
commercial products, whose morphologies have hardly been established or may still be 
controversial [423]. The morphology of crystalline polymers has been the subject of a 
number of reviews including notably those of Keller [6], Bassett [227,424], Geil [425], 
Vaughan and Bassett [229] and Khoury and Passaglia [219].
Many such reviews also consider morphology and crystallization behaviour from dilute
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polymer solutions. The principles of which have been briefly covered in chapter 1. This 
chapter is primarily concerned with the crystallization and morphology of polymer melts.
The crystalline morphology of polymers crystallized from the melt is thought to closely 
resemble that seen in polymers crystallized from concentrated solutions [220]. However, 
crystals grown from dilute solution are thought to be more perfect than polymer crystals 
produced from the melt [219,229]. Studies on crystalline morphology have shown that 
polymers do not attain perfect crystalline order [229] and even polymer single crystals 
are not 100% crystalline [425].
Closely related to polymer morphology is the subject of crystallization kinetics and 
this has also been reviewed by a number of authors including Hoffman et al [220], 
Bassett [424], Sanchez [426] and Ross and Frolen [427].
One of the simplest and direct methods of studying both morphology and crystallization 
kinetics In polymers is from bulk or melt crystallized samples. Polymers crystallize 
from the melt most commonly in the form of spherulites, which, as described later, are 
symmetrical arrays of chain-folded lamellae. The study of the morphology of polymers 
crystallized from the melt is therefore predominantly concerned with the determination 
of fine structure of spherulites and of the mechanism of growth [219,227].
5.1.1 Spherulitic Crystallization
Crystallization is the process whereby an ordered structure is produced from a 
disordered phase, usually a melt or dilute solution [408]. Crystallization from the melt 
to form spherulites is called "spherulitic crystallization". When the temperature of the 
melt is reduced to the melting temperature there is a tendency for the random tangled 
molecules in the melt to become aligned and form small ordered regions. This process is 
known as nucleation and the ordered regions are called nuclei. These nuclei are only 
stable below the melting temperature of the polymer since they are disrupted by thermal 
motion above this temperature [408]. Nucleation has been classified as either 
homogeneous or heterogeneous [408]. During homogeneous nucleation in a polymer melt (or
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solution) it is envisaged that small nuclei form randomly throughout the melt (i.e. on 
the polymer itself). Although the process has been analysed in detail from a theoretical 
viewpoint [220,426] it is thought that in the majority of cases of crystallization from 
polymer melts (and solutions), nucleation takes place heterogeneously on foreign bodies 
such as dust particles or the surfaces of the containing vessel.
The second step in crystallization is growth whereby the crystal nuclei grow by the
addition of further chains. In polymers it is recognised that the growth kinetics result 
not from diffusion of material away from the growing interface, but rather from a
nucleation process occurring at the tip of the lamellar crystal [428-429].
Crystallization is therefore a process which takes place by two distinct steps, 
nucleation and growth, and these are often considered separately. Barham [215] has 
investigated the nucleation behaviour of PHB polymer melts and for that reason this 
study will primarily be concerned with spherulitic growth and its kinetics. Only 
qualitative observations on nucleation have been made where relevant
Spherulitic crystallization is not confined to polymers but also occurs in minerals 
[430]. Spherulites in polymers superficially appear similar to the mineral counterparts 
but are generally smaller. Although in special cases, such as PHB, where polymer 
spherulites up to a few millimetres have been grown, they are usually of the order of 
100um or less in diameter [219,424]. Examples of PHB spherulites observed in thin films 
under the optical microscope with crossed polarizers are shown in Figure 5.1. The three 
essential minimum attributes of spherulites can be inferred from their appearance [424].
The bright contrast derives from birefringence and indicates a crystalline entity. 
Superimposed on this is the black Maltese cross with arms lying parallel to the 
extinction directions of the polarizer and analyser. When the specimen is rotated in its 
own plane the cross remains stationary. This implies, as will be explained later, that 
all the radii are crystallographically equivalent to the resolution employed.
Historically, Bunn and Alcock [223] were the first to report the presence of spherulites 
In synthetic polymers in 1945. They also showed by birefringence measurements that the
167
Figure 5.1. A optical photomicrograph showing PHB spherulites.
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chain axes were perpendicular to the spherulite radius. Further early work on their 
structure was performed using a microbeam X -ra y  diffraction technique by, amongst 
others, Point [431] and Keller [432]. These studies showed that in polymeric 
spherulites the unit cell orientation is such that the molecular chains are normal to 
the radial direction, or nearly so, and that a crystallographic direction is parallel to
the radius, and this cleariy demonstrates the spherical symmetry of the spheruiite. In
many cases including polyethylene [432] and PHB [214] the molecular chains are normal to 
the radius and according to Khoury and Passaglia [219], no polymer is known , other than 
in the case of some species of polypropylene spherulites, for which the molecular axis 
makes an angle of less than 60°C with the radius. For this reason the molecular 
orientation in spherulites is said to be "tangential". In the exceptional case seen in 
certain species of spherulites of the alpha-monoclinic form of polypropylene, Binsbergen 
and De Lang [433] have observed twinning of chain folded lamellae within the fibrils.
This twinning leads to the development of daughter lamellar branches at approximately 
right angles to radially orientated lamellae. Consequently, the molecules in the 
daughter branches are orientated with the chains parallel to the radius.
The tangential orientation of molecules in spherulites defied explanation by the then
existing fringed micelle model and was not fully understood until Keller’s [224] 
discovery of chain-folded polymer crystals in 1957. Fischer [225] was the first to 
clearly show the existence of lamellar structures in melt-crystallized polymers. 
However, the question as to whether these lamellae contained chain -  folding was not 
answered. Perhaps, the most direct evidence for the presence of chain-folded lamellae 
came from the etching experiments on polyethylene by Palmer and Cobbold [434] and 
Keller and Sawada [435]. Microscopic fragments of a lamellar appearance were formed by 
selective oxidation using fuming nitric acid. Electron diffraction studies of these 
fragments showed that the chain molecules had similar orientations relative to the 
surface of the fragments as with molecules in chain-folded lamellae grown from solution 
[434 -  435]. Although the selective oxidation technique etched out the folds of the
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molecules In the fragments, the experiments provided strong evidence that in the 
untreated solid polymer, the lamellae in the spherulites existed as chain-folded 
crystals.
Although no extensive etching studies have been performed on melt-crystallized PHB, 
Keller et at [436] have recently used gaseous methylamine to selectively degrade 
surface folds in freeze-dried solution -  grown crystals of PHB. The authors have used the 
technique together with gel permeation chromatography to determine fragment lengths and 
therefore, fold lengths in solution -  grown crystals. More recently, a preliminary report 
by Organ and Barham [437] suggests that this etching technique can also be successfully 
applied to melt-crystallized PHB and offers great potential for examining the underlying 
microstructure of P (H B -H V) polymer spherulites.
Clearly, the structure of spherulites remains an area of intense study. However a 
summary of the current knowledge suggests that spherulites consist principally of radial 
arrays of chain-folded lamellae that are highly elongated in the radial direction. The 
stacks of lamellae radiating from a central nucleus have somewhat the appearance of 
fibrils. This is represented schematically in Figure 5.2. In Figure 5.3 the crystal axes 
are superimposed on a PHB spherulite and a diagram of the molecules in the PHB unit cell 
are given for completeness.
5.1.2 Theory of optical extinction patterns and polarized microscopy
The study of spherulites by the polarizing microscope is the most common [219] and 
historically, the oldest of methods [223]. A great deal has been learned about the 
grosser features of spherulitic structure from its application and when coupled with 
the fine details observed by electron microscopy, it serves as a unified picture of the 
structure of polymer spherulites.
The polarizing microscope itself is a standard instrument fitted with a pair of 
polarizing filters, one above and one below the specimen. When the two polarizers are in 
the crossed position with their permitted vibration directions orthogonal, then no light
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Polymer spherulite with chain-folded lamellae 
(schematic). Spherulite consists of chain-folded lamellae 
radiating from central point. Polymer chain axes in 
lamallae are more or less perpendicular to radius of 
spherulite. Branching causes spherulite to become 
spherical in shape after sufficient growth. Noncrystal- 
lizable material (not shown) when present accumulates 
between lamellae and at outer boundary. Twist of 
lamellae when present causes rings in optical extinction 
patterns
Figure 5.2. A diagramatic representation of a polymer spherulite 





a = 5*76 A 
b=  13 20 A 
c =  5 9 6  A 
(Fiber axis)
Figure 5.3. A diagram indicating the crystal axes in a PHB 
spherulite. Above, the crystal axes are superimposed on an 
optical micrograph of a spherulite; below, a diagram of the 
molecules in the unit cell of PHB is reproduced 
(after ref. 214 and 235).
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passes through the microscope in the absence of a specimen, or if the specimen is 
isotropic. Inserting a doubly refracting (birefringent) specimen gives rise to beam 
splitting and interference phenomena which allow light to pass through the instrument 
Such specimens will appear bright, even coloured, against a dark background [438].
The utility of the observations with the polarizing microscope stems from the fact 
polymer crystals are anisotropic with respect to their optical properties. The 
polarizability in the direction of the chain axis is usually different from that normal 
to the chain direction [439-440]. This results from birefringence, which is defined as 
the difference between the refractive indices of light with its electric vector parallel 
to the chain axis and light with its electric vector normal to the chain axis.
The interpretation of the characteristic extinction patterns for spherulites viewed 
between cross polars has had an important bearing on the determination of their
structure [219]. In favourable cases the sign and magnitude of birefringence can provide 
information on the molecular orientation [227]. The sign of birefringence is usually 
determined using an accessory plate (1 or 1/4 wavelength optical path difference) which 
is inserted into the microscope above or below the specimen. A spherulite is considered 
positive in sign If the radial refractive index is higher than the tangential [438].
This is done by observing the change in polarizing colours produced. Barham et al [214] 
have found that PHB spherulites are negatively birefringent and the derived 
crystallographic axes have been shown in Figure 5.3.
The simplest and most common extinction pattern seen in spherulites is the Maltese cross 
with its arms parallel to the polarizer and analyser vibrational directions. This is 
usually superimposed on the ’fibrillar’ texture of spherulites. The fact that in some 
cases spherulites exhibit more complex extinction patterns was first reported in 1952 by 
Keller [441]. These are of four types: 1) a pattern in which, in addition to the Maltese 
cross, concentric extinction rings with regular periodicity are seen, 2) a pattern as 
above but with rings paired so that there is double periodicity, 3) a pattern in which
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the Maltese cross Is replaced by a zig -zag , and 4) a pattern In which concentric 
extinction rings are seen in addition to the zig -zag.
The patterns were originally explained by Keller [441] and by Point [431] to arise from 
a periodic variation in the orientation of the constituent birefringent structural units 
along the radius. This was not a novel explanation and the concept had been suggested 
and discussed many years earlier by, for example, Wallerant [442] in the case of
nonpolymeric spherulites. However following the discovery of chain -  folding in polymer
crystals, the patterns were fully analysed and explained in a set of interesting papers 
published simultaneously in 1959 by Keith and Padden [443 -  444], Price [445] and by 
Keller [446]. The explanation, substantiated by electron microscopy observations, 
showed that the concentric extinction rings arise because the crystal orientation 
rotates about the radius in progressing from the centre of the spherulite outward. This 
was due to the fact that fibrils twist as they grow. Even more remarkable was the fact 
that neighbouring fibrils twist with the same period and same phase, that is, they twist 
cooperatively. Keith and Padden [444] found that the hand, however, may be different 
along different radial paths and at rather well defined radial boundaries the hand
changes discontinuously from right to left
Cooperative twisting and the resultant complex extinction patterns have been observed in 
various polymers including polyethylene, poly(ethylene adipate) and poly(ethylene 
terephthalate), and while it has been extensively studied, its origins remain one of the 
unsolved problems of polymer morphology [219]. The reason for the twisting of chain 
folded lamellae is still unclear. In the same polymer it sometimes occurs and sometimes 
does not Point [431] found that at relatively high undercoolings in polyethylene, 
ringed (or banded) spherulites were formed but at higher temperatures, unringed 
spherulites were formed.
The period of twist (ring or band spacing) depends upon the temperature of 
crystallization [431] and has been found to increase with increasing temperature 
[440,478]. In polyethylene, the ring spacing varies from about 1um to some tens of
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micrometres [219]. Various mechanisms have been proposed to explain twist [447] but it 
is fair to say that none of them account convincingly for the experimental findings 
[219].
5.1.3 Formation and evolution of spherulites
The formation of spheulites is a feature of crystal growth which is still not well 
understood [229]. Precisely how a spherulite develops depends, in the first instance, on 
how it is nucleated. A common progression, but not essential, is that shown in Figure 
5.4, beginning with a fibre or a single crystal and evolving through sheaf-like embryos 
(bundles) before attaining a sphericle envelope [424]. Following the discovery of chain 
folding, studies by Bassett et al [448] showed that these sheaf-like precursors were 
multilayered, chain-folded structures akin to the crystalline objects which had been 
variously and collectively referred to as axialites and/or hedrites. The latter are 
formed when polymers are crystallized from concentrated solution and from the melt at 
low undercoolings (undercooling refers to the difference between equilibrium melting and 
crystallization temperatures of the sample) [219]. The term axialite was first coined by 
Bassett, Keller and Mitsuhasl [448] to apply to multilayered objects grown in relatively 
concentrated solutions of polyethylene in xylene. The lamellae in these objects formed 
diverge apparently from a central axis and the objects exhibit polygonal or sheaf-like 
appearances, depending on the direction in which they are viewed. The term hedrite was 
first coined by Geil [425] to distinguish polygonal objects formed in melt-crystallized 
polymers from the more common spherulites. The reason as to why these structures diverge 
and fan out to form spherical entities remains unclear. Khoury and Barnes [449] have 
suggested that the lamellae are intrinsically curved and that the sheaving in axialites 
is a phenomenon of curved crystal formation but this has not been fully examined.
The spherulite growth sequence given in Figure 5.4, represents, according to Keith and 
Padden [428 -  429,450], successive stages in the evolution of an initially formed 
lamellar chain-folded crystal which degenerates progressively as it grows under the
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Figure 5.4. Schematic development of a spherulite from small 
fibres through sheaving outlines to the mature form (from ref. 
227)
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influence of impurities (such as low molecular weight polymer fractions) rejected at its 
lateral growth fronts. This classic theory of Keith and Padden [428 -  429] is based on 
diffusional segregation of impurities at interfaces and between lamellae. It has been 
used to account for the radiating fine fibrillar texture seen in fully evolved
spherulites. According to the theory, the fibrillar texture develops from the sheaf-like 
objects because of a change in the habit of the lamellae [428 -  429]. This change in 
habit, from the polygonal single crystal habit to the fibrillar habit has been explained 
by Keith [451] as being a consequence of cellulation at the periphery of the polygonal 
lamellae during the early stages of spherulitic growth and is due to diffusional 
segregation of impurities. Although the theory of Keith and Padden [428 -  429,450] was 
developed almost 30 years ago and based primarily on optical observations, it has
commanded widespread support, not least for the subtlety of textures for which it could 
account [227]. However, modern techniques of etching coupled with the greater detail of 
the fine structure now possible with electron microscopy has led to some modifications 
to the original theory [227]. A recent report by Vaughan and Bassett [229] suggests that 
the internal fibrillar texture is due to a spherulitic framework of individual dominant 
lamellae which branch and splay. This is qualitatively different from the cellulation 
model of Keith and Padden [428 -  429,450]. Furthermore, Vaughan and Bassett [229] have 
concluded that there is no clear evidence in favour of habit changes due to cellulation.
This subject and the theory of Keith and Padden will be further discussed in relation to
drug distribution in melt processed polymers (section 5.5.7).
5.1.4 Kinetic Growth Theory and Crystallization Kinetics.
The kinetics of polymer crystallization can be divided into three aspects [219]: a) the 
overall crystallization kinetics of the transformation of liquid to solid; b) the radial 
growth rate of spherulites; and c) the interfacial kinetics concerning the molecular 
details of the kinetic processes that occur at the crystal growth front (as described 
later).
There have been many attempts to develop theories to explain these important aspects of
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crystallization but to date, none are thought to have been completely successful [452].
The two approaches used most commonly for analysis of crystallization data are those 
described by Avrami [453 -  454] and by Hoffman and coworkers [220,455].
5.1.4.1 Avrami equation
The overall crystallization kinetics of polymers in bulk is invariably treated using the 
Avrami approach which considers the evolution of the volume fraction crystallized [456].
Avrami published two papers relating to the kinetics of phase change in general [453- 
454]. His fundamental relationship as applied to the crystallization process was:
X = 1 -  exp ( -  Ktn)
where X is the degree of crystallinity, K is the crystallization rate constant, t is the 
elapsed time and n is the Avrami exponent, usually an integer, characteristic of the 
type of nucleation and crystallization mechanism.
However, the Avrami model was not intended for polymers [457] and depends on a large
number of assumptions which severely limit its applicability. These assumptions, as 
given by Grenier and Prud’Homme [457] include: constancy of shape of the growing 
spherulite: constant rate of radial growth; lack of induction time; complete
crystallinity of the sample; random distribution of nuclei; primary nucleation process 
(no secondary nucleation); and absence of overlap between the growing crystallization 
fronts.
Obviously, all these assumptions cannot be met simultaneously and some of these can
hardly be met at all for polymers [457]. Consequently, it has often been found that, 
contrary to theoretical predictions, nonintegral values of n are obtained [457]. Serious 
deviations from the Avrami expression can be found particularly towards the latter 
stages of crystallization because secondary crystallization often occurs and there is 
usually an increase in crystal perfection with time [452].
Although the Avrami analysis is still regarded as fairly successful in explaining the
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phenomenology of crystallization it does not give any insight into the molecular process 
Involved in the nucleation and growth of polymer crystals [452]. For the reasons given
above and because this study was concerned primarily with the kinetics of growth and not
overall crystallization, the Avrami approach was not used in this study.
5.1.4.2 Kinetic Growth Theory
The kinetic theories of crystallization lead naturally to predictions of the temperature 
dependence of the growth rate of a crystal [424]. The most widely accepted of the 
kinetic theories Is that of Hoffman, Lauritzen and others [220,447] which has been used 
to explain nucleation and growth of polymer crystals (from solution and melt). Providing 
the spherulites are formed through the process of heterogeneous nucleation, the primary 
nucleation is developed from a solid surface such as a dust particle. It is then
postulated that growth of polymer crystals takes place by a process of secondary
nucleation on the pre-existing crystal surface. This process is similar to primary 
nucleation but differs somewhat because less new surface per unit volume of crystal is 
created than in the primary case and so the activation energy barrier is lower [452].
The first step in the secondary nucleation is the laying down of a portion of the 
polymer molecule on an otherwise smooth chain-folded lamellar crystal surface to form a 
stable folded nucleus. However, the manner in which this initial polymer stem is laid 
down is a matter of controversy. It still remains unclear as to whether the stem is 
attached onto the growth surface in a single process as a whole unit or in successive 
segments (or flexibility units) [458]. Following the formation of such a nucleus the 
rest of the long chain molecule is "reeled in", crystallizing with a fixed, temperature- 
controlled fold distance. This type of nucleation-controlled growth seems very 
consistent with the current knowledge of the fibrillar growth of spherulites [229,427].
The basic thrust of the theory is that the rate of formation of a chain-folded surface 
nucleus, i.e. the net flux, simultaneously governs the crystal growth rate and the 
initial lamellar thickness and has been outlined by Hoffman et al [220]. Applying the
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flux equation approach to the theoretical Idea of Turnbull and Fisher [459] on the 
crystallization kinetics of small molecules, Hoffman [220,455] has given the linear 
growth rate (G) of polymer spherulites as:
G = G0 exp l-U V R C T -T J ] x exp [-K g .5.2
where G0 is a constant, U* is an activation energy for transport of molecules to the 
growth front, R is the gas constant, T is the crystallization temperature, Too is the 
temperature below which molecules become immobile, / \T  is the supercooling,
where T °m is the equilibrium melting temperature (melting temperature of infinitely 
thick, defect-free crystal), k is the Boltzmann constant, b0 is the monomolecular 
layer thickness, / \H f is the heat of fusion, ooe is the product of the lateral and end 
surface free energies, and K may have the value of 2 or 4 depending on the growth 
mechanism.
Hoffman et at [220] originally proposed two different growth regimes in polymer crystals 
depending on the relative rates of formation and spreading of new secondary nuclei at 
the growth front (Figure 5.5). Regime I is thought to occur at low supercoolings when 
the rate of spreading is so large compared to the rate of nucleation that a nucleus once 
formed spreads right across the growth front. Regime II occurs at higher or intermediate 
supercoolings when several secondary nuclei form and spread across the growth front 
together, the separation between them decreasing as the supercooling increases.
More recently, Hoffman [460] has proposed a third regime of growth in polymer crystals. 
Regime III is thought to occur at sufficiently high supercoolings when the separation 
between secondary nuclei is of the order of a molecular width and no more spreading 
takes place. The three regimes may be distinguished by the value of the constant K in 
the equation for Kg (equation 5.4); in Regimes I and III it takes the value 4 and in
also where f = 2T/(T°m + T) .5.3
and Kg =  Kb0 ooeT0m/k /\H f .5.4
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Growth front morphology for regime I and regime II growth 
(schematic). Regime I : diagrams at left. Single nucleus forms on surface, 
rapidly completes new layer. Folds are all parallel to edge of crystal; 
K g =  4bcraeTm0/(Ahf)L Regime II:  diagrams at right Many new surface 
nuclei form before previous layer is complete, leading to reentrant or 
crenelated growth front Some folds are now parallel to direction of 
overall growth; K g =  2baaeTm°/(Ahf)k.
Figure 5.5. A schematic diagram of growth regimes in polymer 
crystals (from ref. 220).
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Regime II it takes the value 2. The derivation of the equations, which involves complex 
mathematics based on the thermodynamic flux theorem, can be found in the work of Hoffman 
and others [220] or in the book by Bassett [424] and will not be included here.
The type of growth exhibited by a polymer system can be determined by converting 
equation 5.2 into a linear plot. The use of the equation for the data on spherulitic 
growth of P(HB-HV) polymers is described in the discussion (section 5.5.6).
The kinetic theory of Hoffman and coworkers [220] (also known as HL theory) has largely 
been based on knowledge from solution -  grown crystals but continues to be used for m elt- 
crystallized polymers in ways analogous to those for solution crystallization [424].
Much of the reason for this has been the considerable difficulty in producing firm facts 
to show how the behaviour differs in the two cases [424]. Although the theory is still 
widely used it has been modified on several occasions [220,461 -  462] since the original 
work [463]. Major criticisms of the HL theory have been made by Point [458,464 -  465] and 
by Sadler [466] who have proposed alternative theories to explain crystallization. In a 
very recent paper Point and Dosiere [465] have radically questioned the validity of the 
HL theory and concluded that regime I does not exist in practice and is completely 
hypothetical. The authors suggest that even the latest version of the HL theory [462] 
cannot account for kinetic crystallization data on polyethylene, the interpretation of 
which was a keystone in developing the original HL theory of polymer crystallization.
They report that various characteristic lengths (such as the mean persistence length,
Lp) are inconsistent with the modern versions of the HL theory and thus highlight some 
conceptional shortages of the kinetic theory [465]. It is thought that with the current 
advances in bulk polymer morphology, further modifications of the theory may result from 
renewed theoretical activity in this important area.
5.1.5 Theory relating to equilibrim melting temperature
The equilibrium melting temperature (T°m) of a polymer has been defined as the melting 
temperature of an infinitely thick crystal [467] or a crystal with no surface [408] or
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the melting of a large perfect crystal in an extended -  chain configuration [427]. The 
concept of T °m was introduced because of the variability in the melting behaviour of 
polymers [408] (see chapter 3). The experimentally derived melting point is usually much 
lower than this value because of the thinness of the polymer crystals [427] due to chain 
folding. This is particularly disturbing because accurate values of T °m are required to
test the theories of crystallization quantitatively, for example undercoolings are taken
from T°m.
T°m can, however, be determined by a number of extrapolation methods [467]. The most 
commonly used method is that described by Hoffman and coworkers [220,468]. These authors 
showed that the lamellar thickness, I, of polymer crystals is a function of the 
temperature of crystallization. They also showed that when such crystals remain at the 
crystallizing temperature their initial lamellar thickness, lg*, increases by a factor, 
y, to the final thickness, I, according to equation [468] :
I = yig*
They found that, with certain simplifying assumptions, the melting of thickened crystals 
could be represented by the following equation [220]:
Tm = T °m [1 — (1 /y)J + (Tc/y) .....................5.5
where Tm = the experimentally determined melting point
Tc =  temperature of crystallization 
Equation 5.5 shows that the observed melting is always greater than the crystallization 
temperature and that a plot of Tm against Tc is always linear. Since Tm can never be 
lower than Tc the line Tm = Tc will represent the lower limit of the melting behaviour.
The point at which extrapolation of the upper line meets the Tm= T c line then represents 
the T °m.
An interesting melting point relationship which requires fewer assumptions and that has 
a straightforward theoretical basis is the following [469]:
Tm = T °m [1 -(2 o e/l / \H f )J  5.6
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where oe = end surface energy 
/ \H f = heat of fusion 
I =  lamellar thickness
Typically from equation 5.5 a plot of Tm against 1/1 will result in a straight line. The 
intercept of which gives an estimate'of T °m_ However, because I needs to be determined 
from complex procedures involving small angle diffraction or electron diffraction this 
method was not used in this study. The extrapolation of a plot of Tm against Tc to the 
Tm= T c line is a much simpler approach and is that used in this study.
5.2 AIMS AND OBJECTIVES
1. To study the crystallization kinetics and morphology of melt-crystallized P(HB-HV) 
polymers.
2. To study the effect of molecular weight and HV content on crystallization growth 
curves for P(HB -  HV) polymers.
3. To study the effect of model drugs on crystallization kinetics and morphology of 
P(HB-HV) polymers.
5.3 MATERIALS
P(HB-HV) containing 16mole% HV (PHV16; Mw=41k) was purchased from Marlborough
Biopolymers Ltd, UK.
All other materials were Identical to those given in chapters 2 and 3.
5.4 METHODS
5.4.1 Measurement of radial growth rates of P(HB-HV) spherulites by polarized light 
microscopy
All polymer samples were used as solution cast films except for PHB43K and PHV16 which
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were used in purified powder form.
Samples (2-3m g) of PHB and P(HB-HV) copolymers were heated to melt between two thin 
glass slides at 195°C for 30 -  60 seconds on a Monotherm hot plate (Rodwell Scientific 
Instruments Ltd). Polymer samples were then rapidly transferred to a Mettler FP82 hot 
stage linked to a Mettler FP80 central processor programmed for isothermal heating at a 
chosen crystallization temperature, T c. The hot stage was connected to a polarizing 
optical microscope (Vickers) and radial growth of spherulites was recorded onto video 
tape (Scotch, Magnetic Media Division/3M, UK) using a Hitachi colour video camera with a 
V102 Vertical enhancer (Hitachi Denshi Ltd, Japan) and a Panasonic AG6200 VHS video 
cassette recorder. Spherulite radius, R, was measured directly from a calibrated flat 
monitor screen as a function of time, t  Radial growth rates, G, were then calculated 
from the relationship:
G =  6R/5t
The value for G was, therefore, derived from the slope of the linear plot of R versus L
5.4.2 Preparation of PHB samples containing model drugs
P(HB-HV) polymer films containing Methyl Red were prepared by solvent casting as 
described in chapter 2.
5.4.3 Melting points of crystallized samples in the estimation of the equilibrium 
melting temperature
Isothermally crystallised spherulites of polymers were heated to melt in the Mettler 
FP82 hotstage at a programmed heating rate of 10K/min. The point at which birefringence 
just disappeared was taken as the melting point of the sample.
5.4.2 DSC of isothermally crystallized P(H B -H V) spherulites
Polymer samples (2-3m g) were placed in DSC aluminium pans and heated to melt in a 
Mettler hot stage at 195°C for 30 -  60 seconds.
The samples were isothermally crystallized at the different crystallization temperatures
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until crystallization was complete. The spherulites thus obtained were subsequently 
heated to melt at 20K/min in a Dupont DSC 910/9900 Thermal analyser.
5.4.3 X -ra y  diffraction of isothermally produced spherulites
Solvent cast films (3cm x 1cm; 30-50um ) of polymers were heated to melt on a glass slide 
at 195°C for 30 -  60s and isothermally crystallized in a Mettler hot stage as before. The 
glass slide containing the film of spherulites was then analysed by X -ra y  diffraction 
(CuK-alpha source) over a diffraction angle of 4 -3 0 ° . A Philips PW 1820/00 computer 
controlled vertical goniometer with a Philips PW1710 diffractometer control was used. 
Intensity measurements were made using a Xenon proportional counter (Philips PW1711/10) 
with graphite monochromator and automatic divergence slit assembly.
5.5 RESULTS AND DISCUSSION
5.5.1 Linear radial growth rates of spherulites
Spherulites nucleate and grow radially from a central nucleus until impingement occurs.
They form by nucleation at different points in the sample and grow as spherical 
entities. Figure 5.6 shows the progressive growth of PHB spherulites under isothermal 
conditions. Note that they lose their spherical outline on impingement, at which point 
it becomes polyhedral. The type of outline or shape of spherulites on impingement is 
governed by the relative nucleation rate of adjacent spherulites. If neighbouring 
spherulites are nucleated simultaneously then they will have a planar interface, 
otherwise a common boundary will be a hyperboloid of revolution. As a result of 
variations in shape, morphology of spherulites was characterized in terms of their 
average size and internal fine structure.
Figure 5.7 shows the linear growth rate of PHB spherulites crystallized isothermally at 
90°C. The rate of growth (or velocity of radial advance) of spherulites prior to 
impingement was remarkably linear with time at a constant temperature. This is a common 
finding in polymers and deviations from linear radial growth have only been detected 
when spherulites near impingement or when the viscosity of the melt is deliberately
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Figure 5.6. A series of optical micrographs showing the 
progressive growth of PHB spherulites under isothermal conditions 
as a function of time (A -F ) over a period of 30 s at 75°C.
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Figure 5.7. Linear growth rate of PHB380K spheulites grown 
isothermally at 90°C (Mean; n = at least 2).
(S.D = less than 5% of Mean)
reduced [424]. It was pointed out by Keith and Padden [450] that this constant growth 
rate was inconsistent with the solution to the diffusion equation for an expanding 
sphere. It was therefore concluded that the long-range diffusion of molecules to the 
growing spherulite cannot control its development If it did, then the radius would 
increase with the square root of crystallization time. On the contrary, the observed 
linear isothermal growth implies that conditions at the crystal/melt interface remain 
constant and must be influenced by local diffusion fields. Indeed, the radial advance of 
spherulites remains as one of the most precisely measurable, and measured, morphological 
quantities [470].
5.5.2 Variation of spherulitic growth rates and morphology with temperature
The radial growth rate of PHB spherulites, as is common with other polymers, was 
dependent on the crystallization temperature. Figure 5.8 shows the variation in growth 
rates for PHB 380K spherulites isothermally crystallized at various temperatures.
It was found that the radial growth rate (G) for PHB 380K was relatively low at 
crystallization temperatures just below the melt (0.02um/s at 140°C), but as the under-  
or supercooling was increased there was a rapid increase in G. The increase in G 
continued to a peak at a crystallization temperature of about 90°C (G = 4.5um/s) and 
further increases in undercooling resulted in a reduction in G (0.64um/s at 47°C). The 
reason for the peak in the growth rate-temperature curves of polymers is thought to be 
due to two competing effects [408,220]. The thermodynamic driving force for 
crystallization increases as the temperature is lowered. But as the temperature is 
reduced further, the viscosity of polymer melt also increases and transport of material 
to the growth point becomes more difficult. Hence G peaks and eventually decreases as 
the temperature is reduced even though the driving force continues to rise. The detailed 
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Figure 5.8. Growth rate -  temperature profile for PHB380K 
spherulites (Mean; n = at least 2).
(S.D = less than 5% of Mean)
Changes in growth rate of PHB 380K spherulites also resulted in changes in their 
morphology. The variation in the internal, fine structure of PHB 380K spherulites with 
temperature of crystallization is shown in a series of optical micrographs in Figure 
5.9. Similarly, Figure 5.10 shows the variation in spherulite morphology with 
crystallization temperature for PHB800K. Figure 5.9 (A and C) clearly shows that the 
polymer forms ringed or banded spherulites. The band spacing or the period of twisting 
of chain-folded PHB lamellae has been reported to increase with temperature [214]. The 
average band spacing for PHB spherulites at selected temperatures is shown in Table 
5.1. The results of this study were broadly in agreement with the findings of Barham et 
al [214]. However at low undercoolings (at 120-140°C ), banding was less obvious and PHB 
spherulites exhibited a fibrillar morphology (see for example Figure 5.10 (D)).
Table 5.1. The Variation in Band Spacing and Spherulite Size for PHB380K at Different 
Crystallization Temperatures (Mean ±S.D, n = 20)
Temperature Average Band Average Spherulite
(°C) Spacing (urn) Radius (mm)
60 11 ± 5 0.22 ± 0.05
70 15 ± 4 0.53 ± 0.10
80 17 ± 4 0.61 ± 0.15
85 29 ± 6 0.77 ± 0.13
110   1.34 ± 0.20
The average size of PHB spherulites also increased with increasing temperature (Figures 
5.9 -  5.10 and Table 5.1). The reason for this was that nucleation rate and density
decreased with increasing temperature. The size of the spherulites formed was dependent 
on the nucleation density which, in turn, was also dependent on temperature. At higher 
temperatures of crystallization (low undercoolings) nucleation was sporadic and during 
melt crystallization of PHB, a relatively small number of large spherulites were 
formed. However, at lower temperatures many more nuclei formed (higher nucleation rate 
and density) and a large number of smaller spherulites were obtained. A reduction in the 
rate of nucleation was also found to decrease with increasing temperature, thereby
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Figure 5.9. Optical micrographs of PHB380K spherulites 
isothermally crystallized at various temperatures
(A = 60°C, B = 90°C and C = 110°C).






Figure 5.10 Optical micrographs of PHB800K spherulites 
isothermally crystallized at various temperatures
(A = 42°C, B = 60°C, C = 95°C and D = 135°C).
Scale bar (A -D ) = 1mm.
193
reducing overall crystallization time, but this was not quantified.
At low undercoolings, nucleation of PHB spherulites was, in this study, found to be 
heterogeneous. This was confirmed by spherulites reappearing at the same sites following 
melting and recrystallization of PHB. Barham and coworkers [214-215] have carried out
preliminary studies on the nucleation and crystallization behaviour of PHB spherulites.
The results on spherulite size and nucleation from this study are in agreement with the 
findings of Barham and coworkers [214-215].
It should be noted that, unlike polyethylene [424], a complete growth rate profile could 
be obtained for PHB. For polyethylene, growth is so fast that only for the higher end of 
the curve (low undercoolings) can growth rates be accurately measured. Other polymers 
for which the whole curve can be measured include isotactic polypropylene and isotactic 
polystyrene [424]. This fact, coupled with the highly pure nature of bacterial PHB 
resulting [n large spherulites (up to several millimetres at low undercoolings), make
it an ideal model for studying polymer crystallization [214]. The large spherulite size 
can be disadvantageous because it confers brittleness to specimens but the size can be
controlled by the addition of suitable nucleating agents [215].
5.5.2.1 X -ra y  diffraction and DSC of spherulites
X -ra y  diffraction and DSC were used to assess changes in the crystalline nature of
spherulites with the temperature of crystallization. Crystallinity clearly increases as
the spherulites form and grow but this study was concerned with examination of fully 
formed spherulites, i.e. at impingement and when all the available space in sample had 
been occupied.
Figure 5.11 shows the X -ra y  diffraction traces for PHB samples fully crystallized
(where spherulites occupied all available space in sample) under isothermal conditions 
at 60, 90 and 110°C. The peaks in X -ra y  diffraction traces become sharper with
increasing temperature suggesting the presence of greater order at the higher 
temperatures. This was confirmed with increases in heats of fusion of PHB samples from
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Figure 5.11. X -ra y  diffraction traces for PHB380K spherulites 
isothermally crystallized at various temperatures.
(A = 60°C, B = 90°C and C = 110°C).
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DSC studies (Table 5.2). Although these results suggested that the degree of 
crystallinity increased with increasing temperature, they may also be interpreted to 
indicate an increase in the perfection or quality of crystals. This perfection was 
primarily thought to be due to increases in lamellar thickness and although not 
determined in this study, it has been found to increase with other polymer systems 
crystallized or annealed at elevated temperatures [471-472].
Table 5.2 Heats of fusion for melt crystallized PHB380K as a function of crystallization
temperature (Mean + Range; n = 2)
Temperature Heat of Fusion
(°C) (Jg-1)
60 87.7 ± 2.2
90 90.3 ± 1.4
110 93.1 ± 1.1
5.5.3 The effect of molecular weight of PHB on spherulitic growth rates
Figure 5.12 shows the growth rate -  temperature profiles for three different molecular 
weights of PHB. The curves appear to be similar for the molecular weights of PHB employed 
(43K, 380K and 800K). However, the maximum growth rate (Gmax) for PHB43K spherulites was 
significantly higher (p<0.05) than the two higher molecular weights (see also Table 
5.3). This may be due to a lower viscosity of PHB43K providing less resistance to the 
radial advance of spherulites.
The polydispersity or molecular weight distribution of polymers has an interesting 
significance in crystallization in that at a given temperature below the equilibrium 
melting temperature, the larger molecules tend to crystallize more rapidly than the 
smaller ones [220]. The polydispersity of the PHB samples used in this study was about 2 
but in some polymers, possibly where polydispersity is greater, separation of molecules 
on the basis of molecular weight can occur during the crystallization process [428]. The 
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Figure 5.12. The influence of polymer molecular weight on growth 
rate -  temperature profiles for PHb spherulites (Mean; n -  at least
2) (S.D = less than 5% of Mean)
boundary [428].
The morphology of spherulites for the different molecular weights of PHB were found to 
be different The morphology of PHB43K, PHB380K and PHB800K spherulites crystallized at 
90°C is compared in Figure 5.13 (A -C ). Furthermore, the morphology of PHB380K and 
PHB800K at different temperatures can be compared in Figures 5 .9 - 5.10. The findings of 
this study do not agree with those reported by Barham et al [214] who compared 
morphologies of PHB samples with different molecular weights. Although Barham et al 
[214] did not compare growth rates for different molecular weights of PHB they did make 
the following observation, as quoted from their paper, "In general we may say that the 
lower molecular weight polymer gives a similar morphology to that obtained at higher 
crystallization temperatures, when using a higher molecular weight'. No examples of 
spherulites grown at different temperatures for the different molecular weights were 
given by the authors in support of this conclusion. However, the results from this study 
over the full temperature range indicated that this relationship does not exist
Table 5.3. Maximum radial growth rates of P(HB-HV) polymers (Mean ±S.D, n= at least 2),
Polymer Gmax Tc at Gmax
sample_________________ (um/s)__________________ (°C)
PHB43K 4.92 _+ 0.09 90
PHB380K 4.50 _+ 0.07 90
PHB800K 4.47 +_ 0.04 85
PHB380K
+ 2%w/w MR 3.61 +_ 0.06 90
+ 8%w/w MR 2.66 +_ 0.05 80
PHV6 1.42 +_ 0.04 80
PHV12 0.48 _+ 0.02 75
PHV16 0.24 +  0.02 70
MR = Methyl Red
5.5.4 The effect of P (H B -H V) copolymer composition on spherulitic growth rates
Figures 5.14-5 .15 show the growth rate -  temperature profiles for P(HB-HV) copolymers. At 
any given Tc, the rate of spherulite growth was progressively lowered as the HV content 
was increased.
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Figure 5.13. A series of optical micrographs comparing the 
morphology of spherulites isothermally crystallized at 90°C.
A = PHB43K 
B = PHB380K 
C = PHB800K 
D = PHV6 
E = PHV12 
F = PHV16
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Figure 5.14. A comparison of the growth rate -  temperature profiles 
for PHB380K and P(HB-H V) copolymer spherulites (Mean; n = at 
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Figure 5.15. Spherulitic growth rate-temperature profiles of 
P(HB-HV) copolymers (Mean; n = at least 2).
(S.D = less than 5% of Mean)
Figure 5.16 shows the variation of Gmax as function of HV content. The relationship was 
not linear and Gmax decreased to 32% for PHV6, 11% for PHV12 and 5% for PHV16 when 
compared to Gmax in the homopolymer, PHB380K. In addition to the reduced rate of 
spherulitic crystallization, Gmax was also achieved at progressively lower
crystallization temperatures with increasing HV content in copolymers (Table 5.3). The
peak in the growth curve for PHB occurred at 90°C whereas for PHV16 the growth curve
reached a peak at 70°C. This reflects the depression in equilibrium melting point in the 
copolymer (see section 5.5.5) and emphasizes the fact that Gmax is governed by the 
undercooling (as postulated by Hoffman et al [220]). Figure 5.17 shows growth rates of 
copolymers plotted as a function of undercooling. Gmax or the peak in the growth profile 
of all the copolymers occurred at a similar undercooling to that observed for the 
homopolymer PHB380K (Figure 5.18).
The progressively slower crystallization for P(HB-HV) copolymers with increasing HV 
content was thought to be due to the retarded incorporation of the HV components into 
the common crystal lattice. This was thought to be largely due to the slower transport
of chain segments containing HV components to the crystal growth front, possibly because
of the larger molar mass of this component resulting from the additional methyl group in 
the side chain. However the extent to which HV components are incorporated into the PHB 
crystal lattice remains unclear. Although Marchessault and coworkers [210] suggest that 
P(HB-HV) copolymers are isodimorphic and therefore the HV components would be expected 
to be equally distributed between the amorphous and crystalline domains, recent evidence 
has questioned this hypothesis [249-250]. If the degree of crystallinity of the 
copolymers is similar then equal distribution of HV components between crystal and 
amorphous domains cannot account for the decreasing density of copolymer samples with 
increasing HV content [249]. There may be some exclusion of HV from crystals. This would 
not be unexpected. If the theory of Keith and Padden applies in this case, then HV units 
may be regarded as impurities and may become, to some extent, segregated and therefore 
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Figure 5.16. The variation in maximal growth rate of polymer
spherulites as a function of copolymer composition (Mean; n = at
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Figure 5.17. Spherulite growth rates as a function of 
undercooling for P(HB-HV) copolymers (Mean; n = at least 2).
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Figure 5.18. Spherulite growth rates as a function of
undercooling for PHB380K (Mean; n = at least 2).
(S.D = less than 5% of Mean)
of growing spherulites.
At a constant crystallization temperature, the morphology of the copolymers varied with 
HV content. Figure 5.13 compares the spherulite morphology of P(HB-HV) polymers 
crystallized isothermally at 90°C. The nucleation rate and density was also 
progressively reduced on increasing HV content and is reflected in the size of 
spherulites (Figure 5.13 (D -F )). As a result, at constant temperature the overall 
crystallization time decreased with increasing HV content but this was not accurately 
quantified.
5.5.5 Estimation of the equilibrium melting points for P(HB -  HV) polymers
Estimation of equilibrium melting temperature (T°m) was made from extrapolation of 
linear plots of Tm against Tc to intersect with the Tm= T c line. Such a plot is shown for 
PHB380K in Figure 5.19 and for the copolymers in Figure 5.20. Each datum point 
represents the mean of two replicate experiments. A summary of the values for T°m are 
given in Table 5.4.
Table 5.4. Equilibrium melting temperatures of P(HB-HV) polymers.
5.5.6 Thermodynamic parameters from spherulitic growth kinetics
The equation of Hoffman given below and in section 5.1.4.2 governs the spherulite growth 
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Figure 5.19. A plot of equilibrium melting point data for
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Figure 5.20. A plot of equilibrium melting data for P(HB-HV)
copolymers (Mean; n = at least 2).(S.D = less than 5% of Mean)
The rise in growth rate as the undercooling is increased is governed by the expression 
exp [- Kg(1 /T /\T f) and the fall after Gmax is controlled by the opposing factor 
e x p I-U V R fr -T J ] [220,427].
The value for Kg reflects the type of growth occurring at the crystal interface. The 
growth regime, according to Hoffman et al [220], can be determined experimentally by 
fitting growth rate data to equation 5.2.
The data represented in the growth curves for P(HB-HV) polymers crystallized at high 
temperatures (beyond Gmax) were used in an attempt to fit Hoffman’s equation. In order 
to model this equation values of T °m, U*, and Tro needed to be estimated. T °m values 
were deduced from Tm v Tc plots and are summarized in Table 5.4. Estimates of Kg and 
hence an insight to the molecular mechanism of growth for PHB and P(HB-HV) copolymers 
were made by obtaining best linear fits for the growth data when plotted in the form: 
log G + U 7R C T -T J  against 1/T/yTC. Hoffman et al [220] found that for a fairly large 
number of polymers values of U* in the vicinity of 1000-1400 cal/mol and T* values about 
30°K below Tg give excellent fits. Values of T . of about 20 -  50°C below Tg and values of 
U* in the range 0.9 -  1.20KJ/mol gave good fits for P(HB-HV) polymers and the results 
are summarized in Table 5.5.
Table 5.5. B est-fit values for various parameters in equation 5.2.




PHB380K 1.20 230 470 -  1.62 0.9852
PHV6 1.00 250 460 -  1.82 0.9802
PHV12 1.00 260 446 -  2.90 0.9901
PHV16 0.90 265 440 -  1.91 0.9791
The best-fit plots derived from the above parameters are plotted according to the 
Hoffman equation in Figure 5.21. The slope or Kg value derived for P(HB-HV) polymers 
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Figure 5.21. Best fits of crystallization data for P(HB-HV)
polyesters plotted according to the Hoffman equation to determine
growth regimes (see also Table 5.5).
crystallizes according to Regime II. Barham et al [214] found that PHB (Mw 358K) 
crystallized according to Regime III when crystallized at temperatures below 128°C and 
by Regime II at crystallization temperatures above 135°C. It was therefore concluded by 
the authors that PHB undergoes a Regime II -  Regime III transition within the 
approximate temperature range 128-135°C  [214]. Results from this study suggested that 
for PHB380K Regime II may actually' extend to the lower crystallization temperatures used 
in this study (as low as 110°C). Regime I has not, as yet, been observed in PHB. This 
finding may lend support to the idea of Point and Dosiere [465], who in a recent paper, 
conclude that Regime I, as postulated by the HL theory [220], is hypothetical and does 
not occur in practice. Furthermore, the authors have severely criticised the use of In G 
versus 1 /T /y r plots to establish Regime I and thereby have questioned the validity of 
the HL theory [220]. Clearly the theory needs to be reassessed in the light of comments 
made by Point and Dosiere [465].
In the case of P (HB-HV) copolymers, PHV6 and PHV16 exhibited similar Kg values to the 
homopolymer and therefore It must be concluded that they crystallized according to the 
same regime as PHB380K. However, the Kg value for PHV12 suggested that it may be 
crystallizing according to Regime III.
Attempts to fit the whole growth curve data for P(HB-HV) polymers according to Hoffman’s 
equation (5.2) using curve fitting software (MINSQ; Micromath Scientific Software, USA 
and INSTAT; University of Reading, UK) were unsuccessful. The main problem was that G0
estimates were very different for the different growth regimes (as predicted by HL
theory) and no suitable estimate of the parameter gave a good fit This further
highlights the shortfalls of the HL theory which is clearly not ideal In explaining 
crystallization of polymers.
5.5.7 The effect of drug incorporation in P(HB-HV) polymers on spherulitic growth rates.
Methyl Red was used as a model crystalline drug which Is chloroform soluble. Figure 5.22 
shows that pure Methyl Red also crystallised from the melt as spherulites. The
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Figure 5.22. An optical photomicrograph of Methyl Red 
spherulites.
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spherulites exhibited a weak extinction cross and were difficult to detect Consequently 
no growth rate data were obtained for pure Methyl Red. In the presence of PHB, Methyl 
Red did not crystallize as separate spherulites suggesting that the drug remained 
amorphous and was mixed at a molecular level. The Methyl red was thought to be entrapped 
within spherulite boundaries and within the interlamellar fibrils. A similar conclusion 
has been derived for blends of PHB'and poly(ethylene oxide), PEO [217]. Although PEO is 
crystalline it fails to crystallize in the presence of PHB and is thought to remain 
amorphous and possibly trapped within the interlamellar regions of PHB spherulites 
[217].
Figure 5.23 shows the growth rate-temperature curves for PHB380K loaded with 2 and 8%w/w 
of Methyl Red (MR) as a model drug. The Gmax was substantially reduced on increasing 
drug concentration. Loadings of only 2% w /w  Methyl Red reduced Gmax to 80% of that for 
pure polymer and at 8% w /w  loading the Gmax was only 59% of that for the pure 
homopolymer. An 8% loading of Methyl Red was sufficient not only to reduce the growth 
rate of PHB but also to cause a shift in peak to a lower crystallization temperature 
(Table 5.3). Again, this was related to the depression in the T°m of PHB380K containing 
8% Methyl Red and therefore a function of the undercooling. For PHB380K containing 8% 
MR, a T °m of 189°C was obtained (determined as in section 5.5.5). The undercooling at 
which Gmax occurred for PHB380K and PHB380K containing 8% MR was, therefore, similar.
The morphology of PHB spherulites was also influenced by the addition of Methyl Red. 
Figure 5.24 compares spherulite morphologies of PHB380K containing 2 and 8%w/w drug 
loadings at a crystallization temperature of 90°C. There were clearly differences in 
spherulite morphology of polymer with increasing drug loading. Comparisons of morphology 
with the unloaded polymer can be made by reference to Figure 5.13(B). At an 8% loading 
of Methyl Red in PHB380K, there was some evidence to suggest exclusion of drug from 
spherulites grown at 80 and 90°C (Figures 5.24(B) and 5.25). This suggested that under 
such crystallization conditions a loading of 8% MR may have exceeded the capacity of 
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Figure 5.23. The influence of Methyl Red (MR) Inclusion on growth 
rate -  temperature profiles of PHB380K spherulites (Mean; n = at 
least 2). (S.D = less than 5% of Mean)
Figure 5.24. Optical micrographs showing morphology of drug 
loaded PHB380K spherulites isothermally crystallized at 90°C.
A = PHB380K +  2%W/W METHYL RED
Scale bar = 250um
B = PHB380K =  8%W/W METHYL RED
Scale bar = 500um
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Figure 5.25. Optical micrographs showing morphology of PHB380K 
spherulites containing 8%w/w Methyl Red isothermally crystallized 
at 80°C (A) and 90°C (B).
Scale bar = 250um

growth rates (close to Gmax) at these crystallization temperatures may have prevented 
adequate redistribution and entrappment of the drug within spherulites. The subsequent 
exclusion of drug to the surface resulted In open, fibrillar morphologies of polymer as 
shown in Figure 5.25. It Is expected that slower spherulitic growth rates would enhance 
drug exclusion from the polymer crystals. This is further discussed in terms of drug 
distribution in copolymers (which have slower crystallization rates) in chapter 7. No 
evidence of drug exclusion for 2% loadings of MR was obtained and at such low loadings
the drug was thought to be adequately trapped within the spherulites.
The effects of drug incorporation on the morphology and rate of polymer crystallization 
may be explained according to the theory of Keith and Padden [428 -  429]. This 
phenomenological theory proposed that molecular species which crystallize slowly or 
cannot crystallize will be rejected at the growth fronts. The rejected species (drug or 
impurities) then accumulate to give enhanced local concentrations above average values 
in the melt to magnitudes controlled by local diffusion fields. This segregation of 
material within spherulites has been confirmed by autoradiography [428,473]. The
addition of tracers and their subsequent location has shown segregation at
interspherulite boundaries and along radii. The reduced growth rate is observed because 
the accumulated drug or impurities at the growth interfaces depress the equilibrium 
(liquidus) temperature of the melt and, therefore, the under- or supercooling at the 
Isothermal interface. Keith and Padden [428] showed that when the rejected species are 
sufficiently mobile deviations from the linear growth rate were observed often giving 
rise to parabolic growth behaviour. This was not observed for the concentrations of 
Methyl Red used in this study and growth remained linear for all the undercoolings 
investigated.
The theory proposes that morphology of the spherulites is governed by the diffusion and 
distribution of accumulated Impurities. In particular, the openess of texture is related 
to the concentration of the impurity (or drug) present; and coarseness of texture, which 
is a measure of the "diameters" of crystalline fibres between which impurities become
concentrated during crystallization, is determined by 8=D /G , where D is the diffusion 
coefficient for impurities in the melt and G is the growth rate of the spherulites; 8 
has the dimensions of length.
Although excessively open structures were not generally observed in the Methyl Red-PHB  
380K system, slightly open structures were observed at the higher concentration of 
drug (8%w/w). Extrapolation of Keith and Padden’s theory suggests that the open 
structures would become more prevalent with increasing drug loadings. The type of 
polymer morphology obtained will be particularly important in determining drug release 
rates and mechanisms and is addressed in chapter 7.
The sensitivity of P(HB-HV) polyesters to electron beam damage has prevented direct 
observation of spherulitic morphologies by electron microscopy. However, very recent 
advances in etching techniques [224,437] and high resolution microscopy [474] specific 
to PHB have overcome some of these problems. The morphology of drug loaded polymer 
spherulites clearly invites much further study.
5.5.8 The incidence of cracking in aged spherulites.
In the course of this study it was noticed that the storage of spherulites at room 
temperature for several hours following complete crystallization resulted in cracking or 
fracture along radial and circumferential directions.
Figure 5.26 shows such cracking in PHB800K spherulites crystallized at 95°C and 110°C.
At a crystallization temperature (Tc) of 110°C, cracks were observed in both the radial 
and circumferential directions for PHB800K, whereas at a Tc of 95°C only radial cracks 
were observed. However in the case of PLA, predominantly circumferential cracks were 
observed in spherulites crystallized at 135°C (Figure 5.27(C)). At the same temperature, 
cracking is less obvious in PHB380K (Figure 2.27(B)). No other reports in the 
literature were found on the incidence of cracking in PLA Cracks were not observed for 
the high molecular weight P(HB-HV) copolymers. However, cracks were observed in PHV16
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Figure 5.26. Optical micrographs showing cracking in PHB800K 
spherulites crystallized at 95°C (A) and 110°C (B).
Scale bar = 1mm i----------------- —---------------- 1
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AFigure 5.27. Optical micrographs showing cracking in polymer 
spherulites.
A = PHV16 spherulites crystallized at 100°C.
B = PHB380K spherulites crystallized at 135°C.
C = PLA spherulites crystallized at 135°C.
Scale bar = 1mm I----------------------------- 1
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(Mw = 41K) spherulites. Figure 5.27(A) shows circumferential cracking in PHV16
spherulites crystallized at 100°C.
The explanation for the occurrence of cracking in PHB and PLA remains speculative. The 
radial and circumferential cracks in PHB may be due to the spherulites possessing 
different radial and circumferential thermal expansion coefficients which can result in 
the build up of sufficient internal stresses to initiate the cracks [475]. The variation 
in thermal expansion coefficients in the radial and circumferential directions of 
spherulites has previously been demonstrated for polyethylene but this did not result in 
cracking [476]. The fact that cracking is observed in spherulites crystallized at room 
temperature and the fact that crystallization temperature influences the type of
cracking observed has led to a suggestion that there may be a link between crystal
growth regimes and cracking [475]. However this has yet to be validated.
The absence of cracking in high molecular weight P(HB-HV) copolymers may be explained by 
the fact that the build up of thermally induced stresses, which causes cracks in PHB, is 
prevented either because of some internal rearrangement (as in polyethylene [476]) or 
because the differential expansion coefficients, simply, do not exist This clearly 
invites further investigation.
The presence of cracks for the low molecular weight PHV16 suggests that cracking may be 
related to molecular weight The fact that a minimum molecular weight of around 200K was 
required to produce a mechanically intact specimen of PHB from solution (chapter 2) may 
have some significance to this study. The incidence of cracking in PHV16 spherulites 
may correspond to the breaking up (into small pieces) of low molecular weight polymer 
films cast from solution upon drying. The number of tie-molecules present between 
radiating lamellae within the spherulite may therefore be critical in determining the 
occurrence and extent of cracking in polymers. However a recent report has suggested 
that cracking is not found in copolymers with HV contents in excess of 12 mole% [477]. 
These results were based on copolymers having molecular weights (Mw) in excess of 260 
Daltons and the effect of varying molecular weight was not considered [477].
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Cracking is known to occur in the spherulites of thin films fabricated by melt 
processing [475] and may explain the brittle nature of melt-pressed PHB (chapter 2). 
Whether the same explanation applies for the brittle behaviour in solvent cast films of 
PHB remains unclear. Cold rolling has been reported to heal the observed cracks and 
thereby improve the mechanical properties of melt-processed PHB films [475]. An 
alternative method of avoiding cracking in P(HB-HV) polymers is to limit the size of 
spherulites formed (e.g by increasing nucleation density) [475,477].
5.6 CONCLUSIONS
Polymer spherulites exhibited linear growth at any given crystallization temperature for 
all the systems studied. Growth rates were dependent on temperature. The growth rate- 
temperature profile was essentially independent of PHB molecular weight but dependent 
on P(HB-HV) copolymer composition. At any given crystallization temperature, the growth 
rate of copolymer spherulites was progressively reduced on increasing HV content
Spherulite morphology was Influenced by both crystallization temperature and copolymer 
composition. The variations in crystallite size and internal fine structure between 
copolymers may explain the dependence of physicomechanical properties on copolymer 
composition which cannot easily be explained by differences in the overall degree of 
crystallinity in P(HB-HV) systems.
The incorporation of increasing amounts of a model drug (Methyl Red) into PHB380K 
progressively reduced the rate of spherulitic crystallization. At a low loading (2%), 
the drug failed to crystallize and was thought to be distributed both inter- and intra- 
spherulitically in an amorphous state. At a higher loading (8%), some drug was excluded 
to the crystallite surface and dramatically influenced spherulite morphology. The extent 
to which drug-polymer morphology influences drug release is addressed in chapter 7.
Storage of polymer spherulites for a period of time at ambient conditions resulted in 
circumferential and radial cracking. The occurrence of cracking was thought to be 
dependent on both polymer molecular weight and copolymer composition.
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CHAPTER 6
SPRAY DRIED MICROPARTICLES FOR PARENTERAL ADMINISTRATION
6.1 INTRODUCTION
The use of polymer microspheres for drug delivery and other commercial applications has 
been extensively studied. Microparticulate systems have been investigated for use in 
drug targetting [11] and for the controlled/sustained delivery of many therapeutic 
actives including local anaesthetics [98 -  99], steroids [101], and peptides [109-111].
This study is concerned with the Use of biodegradable P(HB-HV) microparticulates as 
carriers or matrices for parenteral (intra-muscular and/or sub -  cutaneous) drug delivery.
The preparation of drug loaded microspheres or microcapsules can be achieved by many 
different methods [479 -  480] and a list of typical processes is given in Table 6.1. The 
most widely used of these methods is solvent evaporation [481] and the subject of this 
investigation. Primarily, there are two classes of solvent evaporation processes which 
may be used to form microspheres:
a) solidification of emulsions (emulsion deposition)
b) spray drying of drug in solvent
The emulsion deposition method of preparing microspheres is the most common method of 
solvent evaporation [481]. Indeed, previous work on PHB particulate carrier systems has 
involved the use of such single batch solvent evaporation techniques for producing 
microspheres [307 -  311]. Emulsion deposition generally produces discrete microspheres 
which are often of a narrow size distribution. Size ranges from submicron to 2000um can 
be produced by this method. Particle size can be controlled by a number of processing 
parameters such as rate of agitation and emulsifier concentration [481-482].
in contrast, spray drying, as a method of producing microspheres for controlled drug 
delivery, has received little attention in the pharmaceutical literature. This may, in 
part, be due to the volatile and often flammable nature of the solvents commonly used in 
dissolving hydrophobic polymers for drug delivery. The non-aqueous solvents can present 
problems in large scale drying because after solvent evaporation, exhaust gases have to 
be carefully vented out in a safe and appropriate manner or recovered for re-cycling. In
the mounting concern over environmental issues and strict governmental control, this may 
prove expensive in certain cases where solvent recovery is difficult.
However, spray drying has the advantage over emulsion deposition in being a rapid ,
single-stage operation suitable for batch or continuous production of large quantities
of product. Heat sensitive materials, such as proteins and peptides, can be spray dried
because exposure to elevated temperatures is short, normally ranging from 5 - 3 0  seconds
[483]. With these advantages in mind spray drying was investigated as a method of 
producing P(HB -  HV) microparticles for parenteral controlled release preparations.
Table 6.1. A summary of the processes used in preparing microparticles (After ref. 481).
Process Description Drugs Amenable to Process
A. Phase separation type
1 .Organic phase separation Drug suspended or dissolved 
and polymer dissolved in 
solvent (CH2 CI2 ) with a Phase 
inducer. Non-solvent added to 
harden microparticles.
W ater-soluble drugs such as 
peptides, salts and drugs 
insoluble in the solvent.
2. Emulsion phase separation Drug dissolved in aqueous 
phase of emulsion. Polymer in 
the organic phase. Non-solvent 
used to harden microparticles.
W ater-soluble drugs.
3. Low-tem perature phase separation Drug suspended in solvent 
containing dissolved polymer. 
Alcohols used to precipitate 
microparticles.
Drugs insoluble in the 
solvent (e.g. toluene)
B. Solvent evaporation type
1. Emulsion deposition Drug and polymer dissolved in 
organic phase of an emulsion 
with the aid of a surfactant. 
Organic solvent evaporated to 
leave solid microparticles.
Drugs soluble or suspended 
in the organic phase 
(e.g. steroids).
2. Spray drying Drug and polymer spray-dried  
in the usual manner.
Both water-soluble and organic 
soluble drugs.
C. Melt processing type
1. Prilling Drug and polymer co-m elted  and 
dropped from a small orifice 
through a tower.
Heat stable drugs 
(e.g. phenothiazines)
6.1.1 AIMS AND OBJECTIVES
1. To investigate the possible use of spray drying as a method of producing P(HB-HV) 
polymer microspheres for parenteral drug delivery.
2. To study the effect of operational variables in spray drying on the product
morphology and release characteristics.
3. To study the effect of molecular weight and copolymer composition on release
characteristics of the spray-dried product.
6.1.2 PRINCIPLES OF SPRAY DRYING
Masters [484] has defined spray drying as the transformation of feed (a solution, 
suspension or paste) from a fluid state Into a dried particulate form by spraying the 
feed into a hot drying medium (usually hot air). For pharmaceutical microencapsulation 
and microsphere production the feed consists of a drug either dispersed or dissolved in 
a polymer solution (aqueous or organic). The final form of the resulting dried product 
depends upon the physical and chemical properties of the feed and on both dryer and 
operational variables.
There are many different types of spray dryers available, varying in design to suit the 
requirements of the feed material and product [485]. The most common type used in 
industry is the open cycle, co-current spray dryer and is represented in a schematic 
diagram in Figure 6.1. Co-current, as opposed to counter-current, refers to the
direction of flow of the drying medium (hot air) being the same as that of the feed.
Open cycle refers to the layout in which exhaust gases are vented out into the 
atmosphere. This is the standard layout of industrial dryers and the most widely used 
[486]. Closed cycle layouts in spray dryers involve re-cycling of exhaust gases and 
solvents.
Spray drying involves atomization of feed (polymer or polymer-drug solutions) into a
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spray and contact between spray and drying medium resulting in solvent evaporation. The 
drying of the spray continues until solvent evaporation is complete and the dried 
product is then recovered from the drying medium [487].
Spray drying therefore consists of four different stages:
Stage 1 -  Atomization of feed: Atomization involves the break up of liquid into millions 
of individual droplets forming a spray. The energy needed for this process is supplied 
by pressure, centrifugal, sonic or kinetc effects depending on the type of atomizer 
used [488].
The two most commonly used atomizers are the rotary and pressure nozzle atomizers. The 
former involves centrifugal energy to form a spray. This is commonly achieved by
introducing the feed centrally onto a wheel or disc rotating at speed. The feed flows 
outwards over the surface, accelerating to the periphery and on leaving the wheel or 
disc the feed readily disintegrates into a spray of uniform sized droplets [488].
In the pressure nozzle atomizer the feed is fed into the nozzle under pressure. Pressure 
energy is converted to kinetic energy and the feed issues from the nozzle orifice as a 
high speed film that readily disintegrates into a spray due to the instability of the 
film [488].
The type of atomizer used can influence the dried product particle size and it has been 
reported by Masters [488] that rotary atomizers generally produce finer particles. 
However the final particle size will depend on a combination of other operational
variables.
Stage 2 -  Spray-air contact During spray-air contact, droplets meet the hot air and 
solvent evaporation takes place from the droplet surfaces. Evaporation is rapid due to 
the vast surface of droplets in a spray. However, high evaporation rates may expand or 
fracture droplets to give non -  spherical porous particles of low bulk density [488].
The manner in which the spray contacts the drying medium (hot air) is an important
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factor in spray dryer design because it has great bearing on the properties of the dried 
product. The droplet residence time within the drying air will be determined by the 
position of the atomizer in relation to the drying air inlet Co-current flow yields 
lower droplet residence times than counter-current flow and is widely used for heat 
sensitive materials [488].
The temperature distribution within the drying chamber will also influence dried product 
characteristics. The temperature distribution depends on whether the air disperser 
creates plug flow or swirling air conditions in the drying chamber. The greater the 
swirling motion the more uniform the temperature distribution throughout the chamber 
[488].
Stage 3 -  Drying of spray (solvent evaporation): As soon as droplets come into contact 
with the drying air, solvent evaporation takes place from the saturated vapour film 
which is quickly established at the droplet surface. The temperature at the droplet 
surface approximates to w et-bulb temperature of the drying air [488].
Solvent evaporation at first occurs at a constant rate because there is sufficient 
solvent within the droplet to replace that lost at the surface. This is termed the 
constant rate period [488] which continues as long as saturated surface conditions are 
maintained. When the solvent content within the droplet becomes too low to maintain 
saturated surface conditions, the so-called critical point is reached and a dried shell 
forms at the droplet surface. In this second or falling rate period of drying, 
evaporation is dependent upon the rate of solvent diffusion through the dried surface 
shell. The thickness of the dried shell increases with time, causing a decrease in the 
rate of evaporation [488].
The droplet residence time governs the rate of evaporation from the droplet surface and 
this in turn, governs the morphology and particle size of the dried product [488]. 
Different materials exhibit different evaporation characteristics. Some tend to expand, 
others collapse, fracture or disintegrate leading to porous, irregularly shaped
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particles. Others maintain a constant spherical shape or even contract so that particles 
become more dense {488].
Stage 4 -  Separation or recovery of dried product Product separation from the drying 
air follows completion of the drying stages, when the dried product remains suspended in 
the air [488]. Separation of dried product from the air influences particle properties 
by virtue of mechanical handling involved during the separation stage. Excessive 
mechanical handling can produce products having a high percentage of fines [488].
6.2 MATERIALS
P(HB-HV) copolymer containing 16mole% HV (Mw 14K) was purchased from Marlborough 
biopolymers Ltd, UK.
All other materials were identical to those used in chapters 2 and 3.
6.3 METHODS
6.3.1 Spray drying
6.3.1.1 Preparation of polymer-drug solutions
Polymers were dissolved by refluxing in chloroform (1%w/w). Accurately weighed amounts 
of a model drug (Methyl Red) were added to cooled polymer solutions. Suitable mixing of 
polymer-drug blends was achieved by either placing solutions in a sonic bath (Deakon 
FS100 Frequency Sweep; Deakon Ultrasonics Ltd, UK) for 5 minutes or by mechanical 
agitation with a glass rod for 5 -1 0  minutes.
6.3.1.2 Spray drying of polymer-drug solutions
A co-current, open cycle Buchl B190 Minispray Dryer was used to spray dry polymer-drug 
solutions. Before solutions were dried, the spray dryer was heated and stabilised at the 
desired inlet (Tin ) and outlet (Tout) temperatures. The inlet temperature was controlled 
by adjusting power supplied to the oven heater situated at the top of the drying 
chamber. Inlet temperatures up to a maximum limit of 220°C could be attained in the
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Buchi B190. The outlet temperature could not be independently controlled but was largely 
dependent on T in and the feed rate. In the Buchi B190 minispray dryer the inlet/outlet 
temperatures were monitored by PT-100 temperature sensors.
The polymer-drug solutions in chloroform were pumped into the pressure nozzle atomiser 
(0.7mm diameter) at a chosen feed rate. The feed rate could be controlled by a 
combination of the speed setting on the peristaltic pump and the diameter of the 
silicone feed hose. Pressure for the nozzle atomizer was provided by compressed air (5 -  
8 bar). Cooling water was used to minimise temperature rises in the nozzle. Air was 
drawn through a heated oven to provide a co-current flow of drying air through the glass 
drying chamber (10cm diameter) and the rate of hot air flow was controlled by the 
aspirator setting. Recovery of product into a sample collector was achieved following 
product separation in the cyclone. The chloroform -  air exhaust was vented out through a 
fume cupboard. A schematic diagram and photograph of this bench model spray dryer is 
given in Figures 6.1 -  6.2. Standard settings for operating variables are given in Table 
6.2.
Table 6.2. Standard spray drying parameter settings.
PARAMETER SETTING
Dryer Buchi B190 minispray
Type Open cycle, co-current
Atomiser Pressure nozzle (0.7mm diameter)
Drying chamber Glass, 10cm diameter, 50cm length.
Solvent Chloroform








5. Compressed air inlet
6. Cooling water inlet
7. Pressure nozzle
8. Hot air heater
9. Inlet temperature sensor
10. Drying chamber
11. Trap
12. Outlet temperature sensor
13. Cyclone
14. Product collecting vessel
15. Exhaust gases
16. Control panel
Figure 6.1. A schematic diagram of an open cycle, co -current Buchi 
spray dryer.




6.3.1.3 Preparation of replicate batches
A minimum of two batches were produced for each operating condition. Replicate batches 
were usually prepared on a separate day following thorough cleaning of the spray dryer.
The air orifice and nozzle tip were cleaned with a sponge between batches and clean 
glass parts were used for new batch preparation.The spray dryer was re-heated from 
ambient to the desired operating temperatures for each batch as described above.
6.3.2 Characterization of spray-dried product
6.3.2.1 Particle size
Particle size of spray dried material was determined using a Malvern 2600/3600 Laser
Particle Size Analyser VF.6 fitted with a 100mm focal length lens and a stirred sample
cell.
The samples were suspended in a light grade paraffin, Puremor (Castrol Oil Co.UK), which 
was found to be a suitable non-solvent for the drug loaded particles. The light grade
paraffin had been previously filtered through a 0.45um filter to remove any extraneous
matter. The suspensions were sonicated for 1 minute in the Malvern sonic bath to ensure 
breakdown of weakly held aggregates prior to size analysis.
The size distribution results were expressed according to the following parameters:
Volume Mean Diameter (VMD)= N(x).x4 = V(x).x
N(x).x3 V(x)
where N(x) is the number frequency
V(x) is the volume frequency
x is the particle diameter
Sauter Mean Diameter (SMD) = N(x).x3
N(x).x2
Dio%» D50X and D90% represent the sizes at which 10%, 50% and 90% of the volume (weight) 
of material is of smaller diameter. These values were obtained by linear interpolation 
of the cumulative volume (weight) undersize data.
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6.3.22 . Morphology by scanning electron microscopy
Small amounts of spray-dried product were mounted onto aluminium stubs (2.6cm diameter) 
coated with colloidal graphite (Conductive Carbon Cement; Leit C, FRG) as adhesive. The 
samples were sputter coated with gold using an Edwards sputter coater (Edwards S150B; 
Edwards High Vacuum, Crawley,UK). Typically samples were coated for 6 minutes In a 
vacuum (100m of mercury) with a current of 20mA and a voltage of 1.4KV.
The particle size and surface morphology of sputter coated samples were examined using a 
Jeol JSM 35C Scanning Electron Microscope (Japanese Electron Optics Ltd, Tokyo, Japan) 
with an electron beam energy of 5kV or 10kV. The gold and colloidal graphite layers 
ensured that specimens were fully earthed and prevented overheating and accumulation of 
charge.
6.3.2.3 Differential scanning calorimetry
Samples were heated from ambient to melt at a programmed heating rate of 20K/min in a 
Dupont DSC 910/ 9900 Thermal Analyser as described in chapter 3.
6.3.3 Assay of drug content
Accurately weighed samples of Methyl Red loaded PHB microparticles (10mg) were dissolved 
In 50ml of chloroform and diluted for assay at an absorption maximum of 490nm (Molar 
Absorption Coefficient = 36098). Drug loadings were calculated as %w/w.
6.3.4 in vitro drug release
Accurately weighed samples of drug loaded microparticles (approximately 50mg) were 
sealed in Clinbritic vials (30ml capacity) containing 25ml phosphate buffer (pH 7.4; 
formula given in appendix C) at 37°C. Vials were agitated in a direction normal to 
their length at 180 oscillations/min in a constant temperature shaking water bath. 
Variable amounts of release medium were sampled periodically and replaced with fresh 
buffer to maintain conditions close to sink. To prevent loss of spray-dried particles on
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sampling, vials were removed 5 -1 0  minutes before sampling to allow settling down of 
particles and a plastic hypodermic syringe (10ml) fitted with a 22 gauge needle was used 
for sampling of medium. Release of Methyl Red in buffer was determined by
spectrophotometric assay at 430nm using a Perkin Elmer uv-vis spectrophotometer (Molar 
Absorption Coefficient = 20263).
6.3.5 The Rotating basket method of agitation in release studies
This device consisted of a wire basket (40 x 40 x 20 cm) rotated about its central axis 
using a modified Kymograph motor. The Clinbritic release vials were positioned such that 
an en d -o n -en d  roll could be achieved to provide suitable agitation. The speed of basket 
rotation was set to provide a roll frequency of 2 cycles/min. Agitation was stopped 
periodically to remove samples. The device was kept in a 37°C incubation room in order 
to maintain constant temperature conditions.
6.4 RESULTS AND DISCUSSION
6.4.1 Preliminary studies on spray drying of P(HB-HV) polymers
The purpose of the preliminary investigation was to study the spray drying ability of 
PHB and the effect of polymer molecular weight (MW) on product characteristics. A series 
of molecular weights of PHB ranging from 23K to 800K were employed in this preliminary 
study. No drug was incorporated at this stage.
The results of this study (see Table 6.3) showed that low molecular weight PHB samples 
(140K and below) of concentration up to 2%w/v, could be spray dried to a product which 
appeared, at a macroscopic level, to be a fine, free flowing powder. The higher 
molecular weight PHB samples (275K and above) were more difficult to spray dry using the 
Buchi B190 minispray dryer. These higher molecular weight samples could only be spray 
dried from very dilute solutions (<0.5% w/v) and then only to form a fibrous end product 
At higher concentrations the polymer tended to line the glass drying chamber and cyclone 
as thin fibrous strands and no product was recovered. Scanning electron micrographs (at 
low magnifications) comparing the spray-dried products obtained for low and high
molecular weights of PHB are given in Figures 6.3 and 6.4.
Table 6.3. The effect of molecular weight on the spray drying characteristics of PHB.
Mw Feed Concentration Product appearance
23K Up to 2% w'/v Fine Powder
43K Up to 2% w /v Fine Powder
140K Up to 2% w /v Fine Powder
275K Less than 0.5% w /v Fibrous
380K Less than 0.5% w /v Fibrous
800K Less than 0.5% w /v Fibrous
A more detailed analysis of the low MW spray-dried product showed that it did not 
consist of discrete microspheres but aggregates (20 -  40um) consisting of smaller 
irreversibly fused microspheres (see Figure 6.5). Higher magnification of high MW PHB 
spray-dried product showed that this product consisted of even smaller particles 
irreversibly fused together to give a fibrous end product. In both cases, no pores were 
visible at the surface of particles at magnifications up to x3500. In contrast, PHB380K 
microspheres prepared by an emulsion deposition method using polyvinyl alcohol (2% w/v) 
as emulsifier resulted in discrete spherical particles with rough surfaces indicating a 
porous structure (Figure 6.6). Similar surface roughness was observed for PHB 
microspheres (170um) prepared by Juni et al [300] when using gelatin as emulsifier. 
However, Bissery et al [307], who prepared smaller PHB microspheres (1-12um ) by a 
similar emulsion deposition method reported an absence of surface pores when examined 
under the scanning electron microscope at magnifications of up to x10,000.
The difficulty in preparing high molecular weight PHB microparticles by spray drying was 
thought to be a consequence of the highly crystalline nature of PHB. Values of up to 
90% crystallinity have been reported for PHB [149,214]. It was noted that only the non- 
film forming molecular weights of PHB could be spray dried easily. This suggested that 
lower cohesive energies and fewer chain entanglements were necessary to form spray-dried 
microparticles compared to solvent cast films. A minimum molecular weight of
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Figure 6.3 (A -B ). Scanning electron micrographs of the low 
molecular weight (PHB43K) spray-dried product under low 
magnifications.

Figure 6.4. Scanning electron micrograph of the high molecular
weight (PHB800K) spray-dried product.
Scale bar = 500um.

Figure 6.5 (A-B). Scanning electron micrographs of the low
molecular weight spray-dried product under high magnifications.
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Figure 6.6. Scanning electron micrograph of PHB380K microspheres 
prepared by an emulsion deposition method.

approximately 190 -  200K was necessary to form a film [264] as reported in chapter 2. 
Molecular weights above this threshold value appeared to be more difficult to atomize 
using the pressure nozzle and consequently formed a poor quality product. The higher 
viscosities for high MW’s of PHB may have hindered formation of a good product but even 
at very low (<0.5% w/v) concentrations of PHB a poor product was recovered.
Rotary atomizers generally produce finer particles [488] but because of design 
constraints, a rotary atomizer could not be used in the Buchi B190 Minispray dryer. 
However, a study carried out using a pilot scale spray dryer (Mobile Minor Spray Dryer, 
chamber diameter 1 metre; Niro Atomizer, Denmark) equipped with a rotary atomizer showed 
similar results to those obtained with the Buchi model. Again, low molecular weights of 
PHB could be easily spray dried whereas no useful product could be recovered from 
higher molecular weights. Although the low molecular weight product again consisted of 
aggregates of smaller fused microspheres (similar to those shown in Figure 6.5), the 
aggregates were of smaller size (10-15um ).
These preliminary results suggested that only low molecular weights of PHB could be 
spray dried to form a suitable product for possible use in parenteral drug delivery 
systems. Consequently further studies were limited to polymers with molecular weight of 
140K and below.
6.4.2 Drug loaded microparticles from spray drying
6.4.2.1 Studies on batch-to -batch  variation of product
Batch -  to -  batch variation of the spray-dried product was investigated using 3 batches of 
PHB 43K microparticles containing 4%w/w Methyl Red. The batches were prepared on 
different days using the standard spray dryer settings as shown in Table 6.2.
In order to assess product variation between batches, the spray-dried material was 
analysed in terms of particle size, product morphology and drug release characteristics.
The product morphology was investigated using scanning electron microscopy. The same
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product morphology was seen for all 3 batches and was identical to that found in the 
preliminary studies using low molecular weights of PHB (see Figure 6.5). The size of the 
aggregates were determined using the Malvern (2600/3600) Particle Sizer and are given 
in Table 6.4.
Table 6.4. Product characteristics of 3  spray dried batches of PHB microparticles containing Methyl Red.
Batch Drug:Polymer Actual Drug Particle Sizes of Aggregates (urn);( M e a n  +  Range; n = 2)
Number Ratio Loading (%w/w) SMD 0 5 0 % ^90%  ^MD
1 4:100 4.27 20.85 ±0 .08  32.81 ±0 .19  10.72 ±0.11 69.27 ±2.11 38.30 ±0 .63
2 4:100 4.27 20.73 ± 0 .05  36.78 ± 0 .26  9.90 ± 0 .10  76.52 ±1 .32  41.48 ±0 .57
3 4:100 4.18 22.89 ± 0 .89  38.40 ± 1 .70  11.24 ± 0 .54  84.28 ±2 .80  47.14 ±1 .89
The results showed that although there were some differences in the particle sizes of 
the 3 batches, these were considered to be sufficiently close for the purposes of 
regarding these batches as reproducible in terms of particle size. Batches were also 
considered reproducible in terms of drug content. However, drug release profiles 
obtained using the rotating basket method suggested some variance between batches 
(Figure 6.7). Each datum point, in Figure 6.7, represents the mean of 2 replicate 
experiments from the same batch. Intra-batch variation in terms of particle size and 
morphology was minimal and drug release was reproducible. Typically, standard deviations 
of intra-batch release data were within 5% of the mean.
The release of Methyl Red from PHB microparticles appeared to be biphasic. The drug was 
released rapidly at first (burst effect) and then release continued at a slower rate.
The variation between batches was greatest over the first phase of release. Table 6.5 
shows that the standard deviation (S.D) expressed as a percentage of the mean release 
data for the three batches progressively decreased from a maximum value of 21% after
2.5 hours of release decreased to only 4% after 273.5 hours. This may be explained by 















Figure 6.7. Release profiles of 3 spray -  dried batches of PHB43K 
microparticles containing 4%w/w Methyl Red (Mean; n = 2).
(S.D = less than 5% of Mean)
leading to variable drug release over the initial phase.
Table 6.5. The mean release data for the 3 batches of spray dried PHB microparticles 
containing 4% w /w  Methyl Red.
Time
(hours)





S.D as a 
% of mean
2.5 23.2 4.9 21
5.0 26.5 5.1 19
7.5 29.0 5.0 17
12.0 34.9 4.3 12
24.5 41.6 4.2 10
36.0 45.9 6.3 14
48.0 49.0 5.3 11
60.0 50.7 5.1 10
72.0 52.9 4.8 9
84.0 53.4 3.9 7
132.0 56.9 3.5 6
273.5 61.6 2.7 4
In order to explain the mechanism of drug release from PHB microparticles attempts were 
made to fit the release data to the established models proposed by Hlguchl [489] and a
modification of this model as proposed by Brophy and Deasy [490]. Cardinal [491] has
stated that the general equation required to describe drug release from a matrix device 
(slab or particles) will depend on a number of factors, Including the design of the 
device, the geometry, the initial drug loading and the method of manufacture. 
Nevertheless, the basic elements of the release rate equation can ail be found in the 
Higuchl model. The equation was originally utilized to define drug release from a 
porous ointment base and can be stated as:
Q = A [D Cs (2Cc -  Cs) t]1' 2   (6.1)
where Q = fraction of drug released, D = diffusion coefficient, Cs = solubility of
drug in matrix, CQ= Initial drug loading, A = Area of device, and t =  time.
Although this equation describes release from a slab-type matrix, modifications of this
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equation have been used to model release from other geometries [491 -  492]. The principle 
of all is that drug release is proportional to the sq u are-ro o t-o f-tim e. The derivation 
of the Higuchi model is given in standard textbooks and will not be included here. In 
the development of this equation a number of assumptions were made which can be 
summarised as follows: a) infinite dimensions in two coordinates; b) a pseudo-steady 
state exists; c) A > > Cs; d) the diffusion coefficient is constant; e) diffusion through 
the polymer is the rate controlling step rather than dissolution of the crystal; and f) 
the diffusional process occurs through the polymer matrix rather than through solvent 
filled pores or channels within the matrix [491].
The Brophy and Deasy model is an extension of the sq uare-roo t-o f-tim e kinetics model 
proposed by Higuchi. In their original paper [490], the authors have given a summary of 
the complex mathematical derivation involved in their model but a more detailed 
derivation has been given by Majid [286]. The model was originally used to describe the 
in vitro release of sulphamethizole from PHB microparticles of general shape and can be 
summarised as:
F(t) = Bx t1/2 -  B2 t .............................. (6.2)
where f(t) is the fraction of drug released at time, t, and Bx and B2 are constants, the 
values of which can be determined from the intercept and slope respectively of a linear 
plot of equation 6.2 in the form p r(t)^j1/2 versus t1 /2 .
This extended model was developed to account for release over a greater time period and 
for release from a 3 -  dimensional matrix.
Figures 6.8 and 6.9 represent the data of the three spray dried batches of PHB43k 
containing 4%w/w Methyl Red plotted according to the Higuchi and Brophy and Deasy models 
respectively. The data did not fit either of the proposed models. This suggested that 
release of Methyl Red was not entirely controlled by passive diffusion but may have also 
involved drug release through aqueous pores or channels created by dissolution of 










Figure 6.8. Release profiles of 3 spray-dried batches of PHB43K 
microparticles containing 4%w/w Methyl Red plotted according to 
the Higuchi model (Mean; n = 2). (S D = |ess than 5% of Mean)
16
12
0 10 122 4 8
JTIME (hours1/2 )
Figure 6.9. Release profiles of 3 spray-dried batches of PHB43K 
microparticles containing 4%w/w Methyl Red plotted according to 
the Brophy and Deasy model (Mean; n = 2).
(S.D = less than 5% of Mean)
operating at any stage of the release process. The initial burst effect was thought to 
be due to dissolution of the drug at the surface of particles followed by slower release 
via aqueous pore diffusion. Polymer degradation was not thought to control the release 
over the initial stages but may be a contributing factor in the latter stages of drug 
release where drug particles may become effectively trapped within the poiymer matrix. 
The poor fit to the established models may also, In part, be due to difficulty in 
meeting all the assumptions of the respective models, such as achieving perfectly sink 
conditions.
Donbrow et al [493] have suggested that in polydisperse particulate systems the overall 
release profile recorded is a complex summation of release kinetics from individual 
particles. Using curve fitting mathematics, the authors found that drug release from 
ensembles of microparticles consisting of individual entities which release drug at 
constant rates may actually follow zero order, first order or biphasic equations. The 
release equation observed depends upon the statistical distribution of release 
determining parameters (such as drug loading) among the population. Donbrow et al [493] 
concluded that it is impossible to determine the true mechanisms or the nature of the 
heterogeneous distribution without extensive studies on individuals in populations.
It was beyond the scope of this study to assess whether the spray dried aggregates were 
homogeneous in release determining factors such as drug loading. In terms of particle 
size, spray dried aggregates of PHB exhibited normal size distributions as deduced from 
the Malvern particle sizer analysis. However in the case of the smaller Irreversibly 
fused spheres making up these aggregates, it would be a near impossible task to assess 
heterogeneities in release determining factors. Such heterogeneities may have 
contributed to the deviation from the Higuchi square -ro o t-o f-tim e kinetics of Methyl Red 
loaded PHB microparticles.
6A 2.2 The effect of drug loading
In- the study of drug loading on release characteristics, batches of Methyl Red-loaded
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microparticles of PHB43K were prepared in replicate using the standard spray drying 
parameters listed in Table 6.2. A selection of drug-polymer ratios were spray dried to 
obtain a range of Methyl Red concentrations from 2 to 8%w/w in PHB 43K microparticles. 
Table 6.6 shows the particle sizes and actual drug loadings achieved after spray drying.





Particle size (um) 
SMD
2.0 1.97 ±0.15 22.07 ±0.59
4.0 4.24 ±0.06 21.49 ±0.76
8.0 7.85 ±0.32 20.07 ±0.67
In vitro release experiments for different drug loadings were carried out at 37°C in the 
shaking waterbath (180 oscillations/ min). Release profiles of microparticles agitated 
in this way showed that release was more rapid than found with the rotating basket 
method. This may have been due to a reduction in the hydrodyanamic boundary layers 
around the particles. Figure 6.10 shows that at least 90% of drug release was complete 
within 2 days. Thus drug release was not controlled by polymer erosion. Figure 6.11 
shows release of Methyl Red from the same experiment over the first 7 hours. Release was 
dependent on drug loading. As the amount of drug incorporated into the polymer 
microparticles was increased the percentage of drug released also increased. The time 
taken for 50% (t50%) of the Methyl Red to be released increased from 1.5 hr for an 8%
loading to 4 hr for a 2% loading.
The findings of this study on the effect of drug loading were in agreement with those 
reported for PHB by Brophy and Deasy [306], Juni et al [310], and Korsatko et al [304].
However, the data did not fit the models of Higuchi (Figure 6.12) or Brophy and Deasy
(Figure 6.13). It was thought that release of methyl Red from these spray-dried
Figure 6.10. The effect of drug loading on release of Methyl Red 
from PHB43K spray-dried microparticles (Mean; n = 2).
(S.D = less than 5% of Mean)
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Figure 6.11. The effect of drug loading on the early phase of 
release of Methyl Red from PHB43K spray-dried microparticles 
(Mean; n = at least 2). (s.D = less than 5% of Mean)
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Figure 6.12. The effect of drug loading on release of Methyl Red 
from PHB43K spray-dried microparticles plotted according to the 
Higuchi model (Mean; n = at least 2). (S.D = less than 5% of Mean)
Figure 6.13. The effect of drug loading on release of Methyl Red 
from PHB43K spray-dried microparticles plotted according to the 
Brophy and Deasy model (Mean; n = at least 2).
(S.D = less than 5% of Mean)
microparticles occurred according to a combination of passive diffusion and aqueous 
channel formation as proposed by Langer and coworkers [494]. This model is further 
discussed for thin film matrices in chapter 8.
In order to assess if the drug was dispersed physically as a separate phase or at a 
molecular level within the PHB matrix of the microparticles, differential scanning 
calorimetric studies were carried out. No separate peaks for the melting of the drug 
were seen in the DSC traces at drug loadings up to 8%. However, no firm conclusions 
could be drawn because of similar melting temperatures for both the drug and the 
homopolymer. In the case of copolymer films, which had lower melting temperatures 
compared to the drug, DSC traces were generally devoid of a melting transition for the 
drug and thus suggested a molecular mix of drug and copolymers (see chapter 7). It Is 
therefore thought that a similar molecular mix of drug existed within the homopolymer.
6.4.3 The effect of polymer molecular weight on drug release
Figure 6.14 shows the release of 4%w/w loadings of Methyl Red from different molecular 
weights of PHB. The percentage of drug released increased when the molecular weight of 
PHB was Increased from 23K up to 140K. The results were consistent with the findings of 
Brophy and Deasy [306]. The authors found that high molecular weight of PHB (500 -
1000k) released sulphamethizole at a more rapid rate than PHB of 140K MW.
6.4.4 The effect of copolymer content on drug release
High molecular weight P (H B -H V) copolymers could not be spray dried to form an acceptable 
product A similar product to that obtained with high molecular weight PHB was 
observed. Problems were also encountered in spray drying PHV16 of molecular weight 41K. 
The only copolymer available in the study which formed a recoverable product was PHV17 
of Mw 14K. The release profile of this copolymer with a Methyl Red loading of 4% w /w  is 
compared with the equivalent product obtained with PHB 23K in Figure 6.15. Drug release 
from the copolymer appeared to be more rapid than from PHB 23K. No firm conclusions can 
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Figure 6.14. The effect of polymer molecular weight on release 
from PHB43K spray-dried microparticles containing 4%w/w Methyl 














Figure 6.15. Release profiles of PHB23K and PHV16 (14K) 
containing 4%w/w Methyl Red (Mean; n = 2).
(S.D =  less than 5% of Mean)
spray-dried particles since the molecular weights were not close enough to be considered 
equivalent A study of drug release from P(HB-HV) copolymer films containing up to 28 
mole% HV is presented in chapter 8.
6.4.5 The effect of spray drying processing parameters
The operational variables studied were polymer concentration, feed rate, inlet 
temperature and aspirator control. Each parameter was varied individually and the rest 
maintained as in the standard settings of Table 6.2. Release experiments were carried 
out using the rotating basket method.
6.4.5.1 The effect of polymer concentration.
The product morphology was similar for the different polymer concentrations used and was 
similar to that seen in Figure 6.5. The particle sizes, as shown in Table 6.7 increased 
with increasing polymer concentration and therefore, increasing the polymer 
concentration reduced the rate at which Methyl Red was released from PHB43K 
microparticles. The release profiles are given in Figure 6.16.
Table 6.7. Product characteristics of spray dried PHB43K microparticles containing 4% 






Particle size (urn) 
SMD
0.5 4.07 ±0.11 18.07 ±0.20
1.0 4.24 ±0.06 21.49 ±0.76
2.0 4.15 ±0.12 25.98 ±1.02
6.4.5.2 The effect of feed rate
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Figure 6.16. The effect of polymer feed concentration on drug
release from PHB43K spray-dried microparticles containing 4%w/w
Methyl Red (Mean ± S.D., n = 2)
±S.D = 4.09 ±1.2%; n=3), particle size (SMD ±S.D = 23.62 ±0.90um; n = 3) or product
morphology. The release data were similar for variations of feed rate from 14ml/min to 
37.5ml/min and are given in Figure 6.17. An Increase in the feed rate from 14ml/min to 
37.5ml/min resulted in a reduction in the outlet temperature of approximately 10-15°C  
but this did not seem to modify product characteristics.
6.4.5.3 The effect of inlet temperature
Variations in the inlet temperature did not significantly (p>0.05) affect the particle 
size (SMD ±S.D = 21.60 ±0.91 urn; n = 3), drug loadings (Mean ±S.D= 4.14 ±0.90%; n = 3), or 
the microscopic morphology of the product However macroscopic observations suggested 
that the product produced at an inlet temperature of 85°C appeared to be a 'wet mass’ 
and not as free flowing as the product produced at 205°C. This was attributed to 
incomplete drying at low outlet temperatures resulting from the low inlet temperatures.
The release profiles of products containing 4%w/w Methyl Red produced at varying inlet 
temperatures are shown in Figure 6.18. The rate of drug release decreased as the inlet 
temperature was increased. As particle sizes were similar, this was thought to be due to 
increasing matrix porosity with decreasing inlet temperature. Incomplete drying of 
product at low inlet and outlet temperatures suggested greater solvent retention within 
the polymer matrix. The associated porosity resulted in more rapid release of Methyl 
Red. However, there was no evidence of pores at the surface of microparticles in 
scanning electron micrographs taken at magnifications up to x3500.
6.4.5.4 The effect of aspirator setting
The aspirator control adjusts the flow-through of hot air drawn in to the drying 
chamber. At a maximum setting of 10 on the dial of the aspirator control, the Buchi is 
designed to have a hot air flow-through of about 45m3/h.This value was supplied by the 
manufacturers and not confirmed. The settings on the dial could be adjusted on an 
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Figure 6.17. The effect of feed rate on drug release from
PHB43K spray-dried microparticles containing 4%w/w Methyl Red











Figure 6.18. The effect of inlet temperature on drug release
from PHB43K spray-dried microparticles containing 4%w/w Methyl















Figure 6.19. The effect of aspirator setting on drug release
from PHB43K spray-dried microparticles containing 4%w/w Methyl
Red (Mean; n = at least 2) A = setting 1; B = setting 10.
(S.D = less than 10% of Mean)
Table 6.8 shows the variation in particle size with increasing aspirator setting. 
Although the particle size was significantly different (p<0.05) at the two settings the 
release profiles were similar as shown in Figure 6.19.
Table 6.8. The effect of aspirator setting on the spray-dried product characteristics. 
(Mean + Range; n = 2)
Aspirator Actual Drug Particle size (urn)
setting Loading (%w/w) SMD
1 4.11 ±0.15 16.49 ±0.16
10 4.24 ±0.06 21.49 ±0.76
6.5 CONCLUSIONS
PHB of molecular weights up to 140K could be spray-dried to form a fine free flowing 
product Film forming molecular weights of PHB could be spray dried from dilute 
solutions but the product was more fibrous.
Spray-dried microparticles were not spherical but fused aggregates (20 -  40um) of smaller 
spheres.
Release from microparticles was generally not controlled by polymer degradation. Drug 
release from PHB microparticles was dependent on drug loading and complete within 2 days 
under agitated conditions (180 oscillations/min in shaking water bath).
Release did not fit the Higuchi or Brophy and Deasy models and was thought to occur by 
aqueous channel formation between adjacent drug particles.
The Buchi spray dryer produced a similar product morphology irrespective of the 
operational settings chosen. Particle size could be controlled by varying the polymer 
concentration in the feed. The inlet temperatures chosen for spray drying in this study 
did influence release characteristics of the product Some batch -  to -  batch variation in 
release profiles was observed.
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CHAPTER 7
P(HB-HV) POLYMER FILMS AS IMPLANTABLE DRUG DELIVERY DEVICES
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7.1 INTRODUCTION
The use of biodegradable polymer devices as implants for sustained or controlled drug 
delivery has received much attention over the last two decades. The major advantage of 
these systems is that the polymeric device will degrade and thus will not require 
surgical removal after drug release is complete. In addition to colloidal carriers in 
the form of microspheres and nanoparticles (see chapter 6), macroscopic matrices such as 
films, slabs and cylinders [31,38,40,42,44] have also been investigated as possible sub­
cutaneous and/or intra-muscular implants. The major advantage of implanting large 
matrices is that they can be easily removed from the implant site should any 
complications arise during release.
In this chapter thin films fabricated by melt-processing and solution casting have been 
investigated as potential matrices for implantable drug delivery systems.
7.1.1 AIMS AND OBJECTIVES
1. To investigate and compare in vitro release of model drugs from solvent cast and melt 
processed P(HB-HV) films for implantation.
2. To study the mechanism of drug release from P(HB-HV) films containing low and high 
molecular weight drugs.
3. To study the effect of drug loading and P(HB-HV) copolymer composition on in vitro 
drug release
4. To fabricate drug-loaded thin films with known crystalline morphologies and to 
investigate the effect of film morphology on in vitro drug release rates and mechanisms.
7.2 MATERIALS
Azocasein was a gift from Dr. D.J. G. Davies, Head of School of Pharmacy and 
Pharmacology, University of Bath, Bath BA2 7AY.
All other materials were identical to those used in chapters 2 and 3.
7.3 METHODS
7.3.1 Preparation of P(HB-HV) polymer films
7.3.1.1 Solvent cast films
Polymer films (30 -  50um) were cast from chloroform solution (4%w/v polymer) as described 
in chapter 2. Methyl Red was incorporated into polymer films in variable amounts to 
achieve drug loadings of 2, 4 and 8%w/w. Films were stored for 2 weeks after casting 
and before use in release studies.
7.3.1.2 Incorporation of azocasein into solvent cast films
Azocasein was used as a model protein and macromolecule. Azocasein is the milk protein 
casein with an azo linkage added for easy assay by uv-vis  spectroscopy. A suitable 
dispersion of the model protein could not be achieved from simple solvent evaporation of 
a drug-polymer suspension. A better distribution of drug within solvent cast films was 
achieved by using ethanol as a cosolvent Incorporation of azocasein into polymers was 
achieved by firstly dissolving known amounts (approximately 6.4mg) of the drug in a 
mixture of 0.2ml distilled water and 0.4ml of ethanol. This was added to 7.4ml of a 
4%w/v polymer solution in chloroform. The mixture was sonicated in a bath (Deakon FS100 
Frequency sweep; Deakon Ultrasonics Ltd.UK) for Smins and then left to stand for about 
1 hour. Once the air bubbles had been removed the film was cast onto glass as described 
in chapter 2.
7.3.1.3 Melt pressed films
As-received polymer samples were size reduced in a pestle and mortar and blended with 
known amounts of drug (Methyl Red) to achieve a range of drug loadings up to 8%w/w. The 
powdered polymer-drug blends were melt pressed into films according to the method 
described in chapter 2. Films were stored for two weeks before use in release studies.
7.3.4 In vitro release studies
Solvent cast films (30 -  50um) containing Methyl Red or Azocasein were cut into 3 x 2  cm 
strips using a sharp scalpel and a glass template. Discs (1.5cm diameter) were cut out 
of the melt processed films using a cork borer. The thickness of melt pressed disks 
used in release studies was in the range 300 -  400um and mass of disks was in the range 
30-40m g. Each disc was weighed individually before use.
Release was carried out in vials containing 25ml phosphate buffer (see appendix C) pH
7.4 at 37°C. Vials were shaken in a waterbath at a frequency of 180 oscillations/min. In 
order to maintain conditions close to sink, variable amounts of medium were periodically 
removed. Release of Methyl Red and Azocasein was determined by uv-vis spectroscopy at 
430nm and 230nm respectively.
7.3.5 Assay of drug content
7.3.5.1 Methyl Red
In the case of both solvent cast and melt pressed films, a known weight of sample (20mg) 
was dissolved in 100ml of chloroform and assayed by uv-vis spectroscopy at 490nm.
7.3.5.2 Azocasein
Film samples (20 -  30mg) were dissolved in 50ml of chloroform. The azocasein was removed 
by repeated extraction with 2ml of phosphate buffer (at least 10 extractions) and the 
cumulative extractions were assayed by u v-v is  spectroscopy at 230nm. The drug loadings 
achieved with both Methyl Red (MR) and Azocasein (AZ) are summarized in Table 7.1.
Table 7.1. Summary of Drug loadings (Mean + Range; n = 2 )






PHB380K 2.0 1.98 ±0.21
4.0 4.12 ±0.32
8.0 7.89 ±0.21
PHV6 4.0 3.87 ±0.11
PHV20 4.0 3.92 ±0.27
PHV27 4.0 4.12 ±0.33
B. Solvent cast
films + AZ
PHB380K 2.0 1.91 ±0.24
PHV6 2.0 2.15 ±0.26
PHV12 2.0 2.04 ±0.19
PLA 2.0 1.89 ±0.23
C. Melt Pressed
discs + MR
PHB380K 2.0 1.82 ±0.20
4.0 3.89 ±0.31
8.0 7.75 ±0.26
PHV6 4.0 3.74 ±0.33
PHV20 4.0 3.97 ±0.17
PHV27 4.0 4.01 ±0.19
7.3.6 Scanning electron microscopy of films
Freeze-fractured samples were prepared by immersing films in liquid nitrogen until 
brittle and subsequent fracture with a single blow of a hammer. Both freeze-fractured 
and normal film samples were then sputter coated and examined by scanning electron 
microscopy as described in chapter 6.
7.3.7 Differential Scanning Calorimetry of films
Samples were heated from ambient to melt at a programmed heating rate of 20K/min in a 
Dupont DSC 910/ 9900 Thermal Analyser as described in chapter 3.
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7.4 RESULTS AND DISCUSSION
7.4.1 Characterization of solvent cast films.
P(HB-HV) polymer films prepared by solvent casting were characterized in terms of their 
surface properties. Surface properties of materials for implantation are known to be 
important in determining the wettability and surface biocompatibility [496]. 
Furthermore, initial solvation and wetting of the film surface will depend on the 
surface propensity of the pendent hydrophilic functional groups (i.e. carbonyl) at the 
surface and this in turn will affect the susceptibility of the polymer surface to 
hydrolytic attack [497]. It is thought that the initial stages of degradation may alter 
the distribution of functional groups and this may in turn result in altered biological 
response to the eroding polymer [497].
Static Secondary Ion Mass Spectroscopy (SSIMS) and X -ra y  Photoelectron Spectroscopy
(XPS) techniques have been used to investigate the surface composition of P(HB-HV) 
polymer films [497]. This work was carried out in collaboration with Nottingham and 
Surrey universities. The results of these studies are presented in appendix A. The XPS 
data confirmed the exceptional purity of P(HB-HV) polymers and gave good agreement
between the theoretical and experimental elemental ratios. Similarly the functional 
group analysis was consistent with the stoichiochemistry. The SSI MS data also showed no 
evidence of any extraneous or organic contamination in the polyester surfaces. The fact 
that SSI MS is useful in detecting impurities at the surface of devices was recently 
highlighted when SSIMS was successfully used to determine residual concentrations of 
surfactant (sodium dodecyl sulphate) on the surface of solvent evaporated PHB 
microparticles [498]. The surfactant was found to be present at the surface of particles 
even after extensive cleaning by dialysis and ultracentrifugation [498]. SSIMS was also 
useful in determining the HV content at the surface of P(HB-HV) copolymers. Studies
[499] on a range of P(HB-HV) copolymers showed that the HV content at the surface was
identical to the bulk HV content as determined by XH -N M R  (see chapter 2).
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P(HB-HV) polymer films cast onto glass had two contrasting surfaces. The film surface In 
contact with glass was smooth and shiny whereas the surface of the film exposed to the 
air was dull and rough. Contact angle measurements on both surfaces of solvent cast 
films using the aqueous sessile drop method are described in appendix B. The results are 
summarized in Table A2.2 of appendix B. Contact angles were essentially similar for the 
shiny and dull surfaces of P(HB-HV) films. However the contact angles for the dull 
surfaces of PHV12 and PHV20 were significantly higher (p<0.05) than the contact angle 
for their respective shiny surfaces.
The contact angles for all the P(HB -  HV) polymers were in the range 67 -  85°, suggesting 
that they are very hydrophobic. However for any given surface the contact angle appeared 
to be a complex function of HV content. The contact angles of PHB380K and PHV6 were 
similar to each other but significantly different (p<0.05) to contact angles for PHV12,
PHV20 and PHV27. The contact angles for the latter three copolymers were not 
significantly different (p>0.05) from each other. The significance of these results in 
terms of surface biocompatibility is yet to be determined.
On examination of the film surfaces with the electron microscope, it was found that both 
surfaces (polymer-glass and polymer-air) were porous (Figures 7.1 and 7.2). The flatter, 
more compressed appearance of the shiny surface is clearly visible. Pores were visible 
on both surfaces of films. The pores appeared to be more open on the dull surface as
this was the surface from which most of the trapped solvent had evaporated on drying of
films. However, the number of pores appeared to be independent of copolymer composition 
in P(HB-HV) copolymers. This suggested that porosity of copolymer films was similar to 
that of the homopolymer. Electron micrographs of freeze-fractured film samples confirmed 
that the films were porous throughout their thickness (Figure 7.3(A)).
7.4.2 Solvent cast P(HB-HV) films containing Methyl Red
Preliminary studies showed that storage of films after casting resulted in morphological 
and mechanical property changes (Chapter 4). Films were therefore stored at 25°C for 14
Figure 7.1. Scanning electron micrographs showing surface pores 
in a solvent cast film of PHB380K on
(A) the shiny surface; glass -  polymer interface and
(B) the dull surface; polymer-air interface.

Figure 7.2. Scanning electron micrographs showing surface pores 
in a solvent cast film of PHV27 on
(A) the shiny surface; glass -  polymer interface and
(B) the dull surface; polymer-air interface.
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Fiqure 7.3. Scanning electron micrographs showing 
fractured section (A) and Methyl Red on the surfac 




days prior to use in drug release studies. Ageing of Methyl Red loaded P(HB-HV) polymer 
films resulted in the accumulation of drug crystals at the surface. This was 
particularly noticeable at loadings in excess of 8% in PHB380K and loadings in excess of 
4% in copolymers. This was thought to be related to secondary crystallization resulting 
from further rearrangement of polymer chains on storage which caused the exclusion of 
Methyl Red from the polymer crystals. Figure 7.3(B) shows an electron micrograph of 
Methyl Red crystals (filaments) on the surface of PHB380K film. This drug at the surface 
of films was removed by washing in distilled water prior to release experiments. Removal 
of excess Methyl Red was confirmed by observation of washed films under a light 
microscope.
7.4.2.1 The effect of drug loading in solvent cast PHB films
The effect of drug loading on release profiles was investigated using Methyl Red as the 
model drug in PHB380K films. Figure 7.4 shows that release was a function of drug 
loading. The percentage of drug released from PHB films increased with increasing drug 
loading. The amount of drug released after 177 hours from a 2% loading was about 14% 
compared to 21% for a 4% loading of drug and about 52% release from films loaded with 
8%w/w Methyl Red. Although the release from solvent cast films was retarded to a greater 
extent than release from spray-dried particles (chapter 6), the bulk of the drug release 
for at least the high loading (8%) was not controlled by polymer erosion. The 
degradation half-life  for the surface erosion of thin films (85um) at 37°C and pH 7.4 
has been reported to be 152 weeks [286 -  287].
The release of Methyl Red from PHB380K films was biphasic. An initial rapid release of 
drug was followed by a much slower release of the remaining drug from the matrix. 
Release from PHB380K films did not fit the Higuchi square root of time kinetics [489] 
(Figure 7.5) or the model proposed by Brophy and Deasy [490] (Figure 7.6). The release 
of Methyl Red appeared to follow the mechanism proposed by Langer and coworkers [494] 
which was originally used to describe drug release from ethylene-vinyl acetate matrices.
At low loadings of Methyl Red (4% and below), the drug was believed to be trapped in the
Figure 7.4. The effect of drug loading on the release of Methyl 
red from solvent cast films of PHB380K (Mean; n = 2)












Figure 7.5. Release profiles of Methyl Red-loaded solvent cast 
films of PHB380K plotted according to the Higuchi model 
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Figure 7.6. Release profiles of Methyl Red-loaded solvent cast 
films of PHB380K plotted according to the Brophy and Deasy moaei 
(Mean; n = 2). (S.D = less than 5% of Mean)
matrix and release was essentially complete when all the drug particles at the surface 
had been released. A substantial proportion of drug can remain effectively trapped or 
surrounded entirely by a ’sea’ of polymer (see Figure 7.7). At higher loadings, the 
particles were not thought to be distributed as well and may often be touching. In this 
case greater amounts of drug can be released and at much faster rates when water 
penetrates into pores created by dissolving drug particles. This eventually leads to the 
formation of an aqueous channel or a network of pores within the matrix. A small amount 
of drug can still remain trapped within the matrix and will only be released by either 
polymer erosion or by possible diffusion of drug through polymer.
In the case of both high and low drug loadings the fast phase of the release profiles 
was thought to be due to a combination of drug dissolution at the surface of the matrix 
and aqueous pore formation. The slow phase of the release profile corresponded to the 
release of trapped drug particles. This may be due to slow diffusion of drug or even 
polymer erosion. In non-biodegradable systems the way in which macromolecular drugs are 
released In the slow phase remains unclear [494]. At present, It is not known whether 
the slow phase is due to defects (microcracks) in the polymer or due to ’reptation’ of 
the drug molecules through the polymer [494].
7A2.J2. The effect of P(HB-HV) copolymer composition in solvent cast films
Figure 7.8 shows the effect of copolymer composition on the release profiles of solvent 
cast films containing 4%w/w Methyl Red. The release of Methyl Red was substantially more 
rapid than from PHB 380K. The percentage of drug released increased with increasing HV 
content After 177 hours PHB380K films released only 21% of Methyl Red whereas 76, 92 
and 94% of the drug was released from PHV6, PHV20 and PHV27 respectively.
The release of Methyl Red from P(HB-HV) copolymers did not fit the Higuchi model (Figure 
7.9) and the mechanism of drug release was thought to be similar to that observed In 
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Figure 7.7. A schematic diagram showing matrix release patterns 
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Figure 7.8.The effect of copolymer composition on drug release 
from solvent cast films of P(HB-HV) copolymers containing 4%w/w 
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Figure 7.9. Drug release profiles of P(HB-HV) polyester films 
containing 4%w/w Methyl Red plotted according to the Higuchi 
model (Mean; n = 2). (s .d = less than 5% of Mean)
The reason for the more rapid release of drug from copolymers could not be explained in 
terms of their overall degree of crystallinity. The copolymers have been reported to 
have similar degrees of crystallinity to the homopolymer (60 -  70%) [210-211]. Since the 
physical dimensions, drug loading and method of manufacture were all similar, it was 
thought that the explanation may lie in the nature of drug distribution within 
copolymers and/or in the crystalline morphology of copolymers.
Visual inspection and examination by light microscopy showed that although drug was less 
well distributed in PHV27, drug distribution in PHV6 and PHV20 films could not be 
distinguished from that in PHB380K films (see Figure 7.10). The drug in PHV27 appeared 
to be present as clusters or aggregates but the remaining copolymers had uniform 
distribution of the drug. This may have been due to poor solubility of Methyl Red in 
PHV27 or due to exclusion of drug during the much slower crystallization process in
PHV27.
Analysis of drug distribution by DSC was carried out and DSC traces for the drug loaded 
copolymers are given in Figure 7.11. The DSC trace of PHV27 containing 4% Methyl Red was 
devoid of a separate peak corresponding to the melting of the drug at about 175°C. This 
suggested that although visual inspection showed that Methyl Red in PHV27 films appeared 
to be poorly distributed, DSC evidence indicated that the drug was generally well 
dissolved and well distributed in the films. Since melt endotherms for drug, PHV6 and 
PHV20 overlapped, no conclusions on drug distribution in these copolymers could be drawn 
form the available data. However, the shape and breadth of melt endotherms of 
copolymers were modified on the incorporation of drug (compare with DSC traces of pure 
polymers in Figure 3.5 of chapter 3). The drug generally acted as an impurity to lower 
the peak melt temperature and also to broaden the melt endotherm.
Crystallization studies have shown that the copolymers crystallize from the melt with 
different morphologies (chapter 5). It was thought that such morphological differences 
also existed in solution cast films and this accounted for the different release 
behaviour observed in P(HB-HV) copolymers. The morphology of solvent cast films cannot
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Figure 7.10. A photograph showing drug distribution in Methyl Red 
loaded solvent cast films of P(HB-HV) polymers.
A = PHB380K + 2%w/w Methyl Red
B = PHB380K + 4%w/w Methyl Red
C = PHV6 + 4%w/w Methyl Red
D = PHV20 + 4%w/w Methyl Red
E = PHV27 + 4%w/w Methyl Red
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5SlJr? 7' 11' DSC traces of solvent cast films of P(HB-HV) copolymers containing 4%w/w Methyl Red.
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easily be studied and certainly not with the same precision as meit-crystallized films.
Therefore to examine this hypothesis further, release from Methyl Red-loaded copolymer 
films crystallized from the melt was examined. P(HB-HV) polymer films with known, yet 
different, morphologies were prepared and the release determined as before.
7.4.3. Release from Methyl Red-loaded films with different crystalline morphologies.
Solvent cast films (1.5cm x 1.5cm; 30-50um ) of PHB380K containing 8%w/w Methyl Red
(identical to those used above) were heated to melt at 195°C for 3 0 -6 0  seconds and 
isothermally crystallized at 60, 90 and 110°C. Solvent cast films of PHB380K, PHV6 and 
PHV12 containing 4%w/w Methyl Red were also heated to melt and isothermally 
crystallized at 90°C for comparison. The spherulitic morphologies of the drug-loaded 
PHB380K films are shown in Figure 7.12. Note the differences in the internal fine 
structure of the respective spherulites.
Figure 7.13 shows drug release from PHB380K films with two different crystalline 
morphologies prepared at 60°C and 110°C. There is clearly a difference in the release 
profiles from the two morphologies. There appears to be a greater percentage of Methyl 
Red present at the surface of the films prepared at 110°C (approximately 13%) when 
compared with those prepared at 60°C (approximately 7%). This was evident in the 
photomicrographs of Figure 7.12 but the reason for this remains unclear. The release 
from the different film morphologies appeared to converge to similar values in the 
latter stages of the measured release.
Figure 7.14 shows drug release from these two morphologies and that prepared at 90°C
over a period of 600 hours. The release from films crystallized at 60 and 110°C
converged to similar values after 600 hours but the release from films crystallized at
90°C was significantly different (p<0.05) to the release from the other two
morphologies.
The release from P(HB -  HV) copolymer films crystallized at 90°C with a 4%w/w loading of
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Figure 7.12 Optical micrographs showing variation in spherulite 
morphology of isothermally crystallized films of PHB380K 
containing 8%w/w Methyl Red as s function of crystallization 
temperature.
A = 60°C, B = 90°C and C = 110°C.
Scale bar (A -C ) = 500um |___________ ■
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Figure 7.13. Drug release profiles of PHB380K films containino 
4%w/w Methyl Red isothermally crystallized at 60°C and 110°C 
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Figure 7.14. Drug release profiles of PHB380K films containing 
4%w/w Methyl Red isothermally crystallized at 60°C, 90°C and 
110°C. Standard deviations have been omitted for clarity 
(Mean; n = 2).
Methyl Red Is shown In Figure 7.15. The P(HB-HV) copolymer films having
characteristically different crystalline morphologies (Figure 7.16) clearly released 
drug at a more rapid rate than the homopolymer. Release of Methyl red from PHV12 films 
was essentially complete within 2 days. The drug leached out of the copolymer films to 
leave behind a "ghost" or film "carcass" similar to that observed in simple solvent cast 
copolymer films. The reason why the morphological differences in copolymers cause 
dramatic changes in release rates, whereas morphological changes within the homopolymer 
induce only modest changes in release rates, remains unclear. The explanation clearly 
lies in the way in which Methyl Red becomes entrapped within the crystals of the
different polymer morphologies during primary crystallization. It can be seen from
Figure 7.16 that owing to the slower rates of crystallization observed in the copolymers 
greater amounts of drug appeared to be excluded from the growing crystallites and 
deposited at the crystallite boundaries (Figure 7.16(E)) and/or close to the surface of 
the polymer film (Figure 7.16(A -D )). It is thought that during the more rapid
crystallization in the homopolymer, PHB380K, the drug becomes largely trapped within the 
interlamellar regions of the crystallites (absence of drug deposits on the film surface 
is shown in Figure 7.16(F)) and the release of this drug is much slower than that of 
drug deposited close to the film surface. The release profiles in Figure 7.15 and the
photomicrographs in Figure 7.16 support the hypothesis that progressively better drug
entrappment (less exclusion) is achieved with increasing rates of crystallization in
polymers.
The above results clearly suggest that the copolymers do not trap Methyl Red as
efficiently as the homopolymer and that this results from differences in their 
crystalline morphology and kinetics. Precisely where the drug is trapped within the 
crystallites and to what extent requires further study.
7.4.4 Melt processed films
Methyl Red was also chosen as the model drug to investigate release behaviour from m elt- 















Figure 7.15. Drug release profiles of P(HB-HV) films containing
4%w/w Methyl Red isothermally crystallized at 90°C
(Mean ± S.D., n = 2)
Figure 7.16. A series of optical micrographs showing morphology 
of isothermally crystallized (90°C) spherulites of P(HB-HV) 
polyester films containing 4%w/w Methyl Red.
A -B  = PHV6; C -E  =  PHV12 and F =  PHB380K.
Scale bar (A -  D,F) = 500um I------------- 1
Scale bar (E) = 500um |___________ I

former will be referred to as discs. This refers to the shape of the specimens used for 
release studies.
7.4.4.1 Stability of drug following melt pressing.
The main concern following melt pressing was to ascertain whether any degradation of 
Methyl Red had taken place such as to modify its assay. The fact that Methyl Red could 
still be assayed in the same way was confirmed by comparing the U V - absorption spectra of 
Methyl Red-loaded melt pressed disks with those obtained from Methyl Red-loaded solvent 
cast films and pure Methyl Red. The uv-vis absorption spectra were qualitatively 
identical and are shown in Figure 7.17.
7.4.4.2 Release of Methyl Red from melt pressed discs of P(HB-HV) polymers.
Figure 7.18 shows release of Methyl Red from melt pressed discs. It can be seen that 
release of Methyl Red was retarded to a greater extent in melt pressed discs than in 
solvent cast films. Although the copolymers again released drug more rapidly than the 
homopolymer, this was not as rapid as that observed in solvent cast films (Figure 7.19).
The reason for the greater sustained release seen in melt-pressed films was partly 
related to the greater thickness of films (300-400um ) compared to solvent cast films 
(30-50um ) and partly due to the absence of pores on the surface of the disks before 
release (Figure 7.20(A)). There was no evidence of pores in the melt pressed discs even 
in freeze-fractured cross-sections (Figure 7.20(B)). This reduced porosity of the matrix 
(due to fabrication under pressure and no evaporation of solvent) was thought to be 
responsible for delaying aqueous channel formation during release. The melt pressed 
discs were, by definition, more compact than solvent cast films and therefore the other 
factor that may have contributed in the greater sustained release is the expected slower 
erosion of compacts. This was not confirmed, however, and requires further study.
The dependence of release rates on the method of fabrication is not peculiar to the 
systems employed in this study. For example similar results have been reported for drug
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Figure 7.17. Absorption spectra in the uv-v is  region for 
chloroform solutions of (A) pure Methyl Red, (B) solvent cast 
film of PHB380K containing Methyl Red and (C) melt pressed discs 
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Figure 7.18. The influence of drug loading on release profiles of 
melt pressed discs of PHB380K containing Methyl Red; A = 8%w/w, 
B = 4% w/w and C = 2%w/w. (Mean; n = 2).
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Figure 7.19. The influence of copolymer composition on drug 
release profiles of Methyl Red loaded melt-pressed discs of P (H B -  
HV) copolyesters A) release over the first 11 days and B) release 
over the full study period of 132 days (Mean; n = 2).
(S.D =  less than 10% of Mean)
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Figure 7.20. Scanning electron micrographs showing absence of 
pores in melt pressed discs of PHB380K:
A) surface view and
B) view of a freeze -  fractured cross section.

release from polyanhydrides {130]. The results showed that using the same polyanhydride 
release of p-nitroaniline could be sustained for only a few weeks when fabricated by 
compression moulding but when fabricated by injection moulding release was sustained 
for up to several months [130].
It is clear that the method of manufacture and variation of processing conditions 
affects drug release. By controlling the fabrication procedure it was possible to 
produce different rates of Methyl Red release from P(HB-HV) polymers. This is in 
addition to the controls possible by varying drug loading, molecular weight (chapter 6) 
and copolymer composition.
7.4.5 Solvent cast films containing Azocasein
Azocasein was insoluble in P(HB-HV) polymers and unlike Methyl Red could not be simply 
dissolved in chloroform solutions of polymer to achieve adequate drug distribution.
However using ethanol as a cosolvent, aqueous solutions of azocasein could be mixed with 
polymer in chloroform as a single phase. The release of azocasein from polymer films 
cast from such solutions is shown in Figure 7.21.
If macromolecules such as azocasein can be effectively trapped within a biodegradable 
polymer matrix then because of the low diffusion coefficients of such molecules in 
polymers release may be controlled by erosion of polymer. However the results of Figure 
7.21 show that release of azocasein from solvent cast P(HB-HV) and PLA polymer films 
occurred relatively quickly and was not primarily controlled by polymer erosion.
Release of azocasein was most rapid from PHB380K (over 80% release after 8 days) and 
most retarded, at least over the early stages, from PLA films. Release of the 
macromolecule from the P(HB-HV) copolymers lay between the two extremes given above. 
These results can be explained in terms of azocasein distribution in the respective 
polymers. Although the use of a cosolvent enabled a good distribution of drug in polymer 
solutions, subsequent drying of the solvent cast films resulted in segregation of the 









Figure 7.21. Release profiles of biodegradable polyester films 
containing 2%w/w Azocasein; a=  PHB380K, b =  PHV6, c =  PLA and d = 
PHV12 (Mean, n = 2). (s.D = less than 10% of Mean)
deposited on the air exposed surface of the films when cast on glass. Consequently over 
70% of drug was released from such films over the first 4 days. The P(HB-HV) copolymers 
had a patchy distribution of drug and the best distribution of azocasein was found in 
PLA. The macromolecule appeared to be homogeneously distributed but as discrete solid 
particles embedded within the polymer matrix. However the thinness of polymer films (3 0 - 
50um) coupled with the large size of the azocasein molecules suggests that aqueous 
channels formed easily to effect rapid release of drug from all the polymers studied.
The results of Figure 7.21 suggested that some drug was trapped within the polymers 
which appeared to be released slowly but in all cases 40% or more of the drug was 
released over the first 4 days.
Evidently the effective delivery of peptides and macromolecules will depend on suitable 
entrappment within polymer matrices. Deviations from homogeneous distribution clearly 
lead to rapid drug release even of large molecules. It is thought that more efficient 
drug distribution of azocasein within polymer films may be possible by controlling the 
rate of drying in films. Insulin has been suitably incorporated into polyorthoester 
devices prepared by slow controlled solvent evaporation [500]. Furthermore, the use of 
cryogenic techniques to slow down solvent evaporation In ethylene -  vinyl -  acetate devices 
resulted in homgeneous drug distribution of peptides [64 -  65,69 -  70]. Clearly the 
incorporation of macromolecules in polymeric devices requires further investigation. 
However attention need not be focused on achieving zero-order release profiles as 
optimal delivery of endogenous peptides may only be achieved if release is controlled to 
mirror their normal physiological secretion [501]. This may often be of a pulsatile 
nature and will require temporal considerations as influenced by the chronopharmacology 
of the relevant peptide.
7.5 CONCLUSIONS
The method of fabrication was an important determinant of drug release rate. Release of 
Methyl Red from P(HB-HV) polymer films was retarded to greater extent In melt-pressed
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discs than in solvent cast films.
Drug release was dependent on drug loading and copolymer composition. Release of Methyl
Red from the P(HB-HV) copolymers was more rapid than from the homopolymer, PHB, from
both solvent cast and melt-pressed films. The more rapid release of drug from copolymers
was thought to be due to differences in their crystalline morphology and kinetics




The aim of this research was to study the physicomechanical properties of bacterial 
P(HB-HV) polyesters and to evaluate their potential for controlled drug delivery.
Physicomechanical and drug release properties of P(HB-HV) polymers were generally 
dependent on both polymer molecular weight and copolymer composition.
A study of the mechanical properties showed that a minimum molecular weight of 
approximately 190K-200K was necessary to form a mechanically Intact film of PHB by 
solvent casting. The properties of the homopolymer changed rapidly beyond this minimum 
molecular weight to reach a plateau at a molecular weight of approximately 300K.
PHB was relatively hard and brittle exhibiting a relatively high elastic modulus and low 
%elongation. On Increasing HV content, P(HB-HV) copolymers were progressively tougher, 
less brittle and more pliable. The copolymers were easier to handle and their superior 
mechanical properties were thought to make them preferable for manufacturing purposes.
The Inclusion of drugs may adversely affect polymer properties. The magnitude of the 
effect was found to be influenced by the nature and concentration of the drug. Sodium 
Fluorescein, a particulate water-soluble, drug progressively lowered both the tensile 
strength and % elongation of PHV20 films. The effect was marked even at low (<2% w/w) 
drug concentrations. However at concentrations up to 10%w/w, the mechanical properties 
of PHV20 films were little affected on incorporation of the chloroform soluble drug,
Methyl Red.
On the basis of polymer melting points, steam sterilization was thought to be acceptable 
for the virgin homopolymer but sterilization by gamma-irradiation may be preferable for 
P(HB-HV) copolymers. The sterilization method chosen will also be influenced by the 
nature and stability of the incorporated drug.
Thermoplastic P(HB-HV) polymers were found to have a wide range of melting 
temperatures. The peak melting temperature was progressively lowered from a value of 
174°C for PHB380K to 83°C for PHV27. Thermal degradation of all P(HB-HV) polymers
301
occurred over a narrow range (approximately 50°C) from around 300°C. The data on the 
thermal properties suggested that the window for safe thermal processing increased with 
increasing HV content of the copolymers and that the copolymers may be thermally more 
stable. It is, therefore, suggested that incorporation of thermally labile drugs (such 
as peptides) by melt processing may be more readily achieved by using copolymers with 
high HV contents which have lower melting temperatures and larger processing windows.
The glass transition temperatures of P(HB-HV) copolymers containing up to 28mole% were 
in the range - 5  to 20°C and thus, below body temperature. At physiological temperatures 
the polymers will be in a rubbery state.
In a study of the ageing properties of P(HB-HV) polymers, it was found that mechanical 
and crystalline properties changed with time following fabrication. Surface properties 
of solvent cast films stabilized relatively rapidly (within 1 day) whereas bulk 
properties (mechanical properties, bulk crystallinity and shape of DSC thermograms) 
continued to change for up to 31 days following manufacture and were a function of HV 
content
The obvious dependence of polymer properties on P(HB-HV) copolymer composition could not 
easily be explained by differences in their degrees of crystallinity. Although there had 
been conflicting reports on the relative crystallinity observed in the copolymers 
[149,246,247,210,211], the view held at the time of carrying out this research, was that 
the degree of crystallinity was independent of copolymer composition (at around 60 -  80%) 
[210-211]. It was originally proposed that this was due to isodimorphism in P(HB-HV) 
copolymers. However, the extent to which HV is incorporated into a common crystal 
lattice is now thought to be variable and requires further study.
In an attempt to further explain the dependence of physicomechanical properties of P(HB- 
HV) polymers on HV content, the crystallization morphology and kinetics of these 
polymers were investigated.
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Rate of polymer crystallization from the melt was dependent on crystallization 
temperature (and undercooling), presence and concentration of drug and on copolymer 
composition. At a given undercooling, increasing HV content progressively retarded the 
growth rate of polymer spherulites.
The crystalline morphology of copolymers, as evidenced by changes in the internal fine 
structure of polymer spherulites when observed through a polarized light microscope, was 
found to be different for each copolymer. Working on the assumption that the degree of 
crystallinity is independent of HV content, it is suggested that differences in the 
physicomechanical and other properties of P(HB-HV) polyesters may be better explained by 
differences in their crystalline morphology.
To examine this hypothesis further, the influence of crystalline morphology of polymers 
on drug release was investigated. Thin films of PHB380K containing similar loadings of 
Methyl Red were melt-crystallized at different temperatures to yield different 
crystalline morphologies and drug release from each polymer morphology was determined. 
Drug release profiles were found to be a function of polymer morphology and hence, 
crystallization rate.
Using thin films of P(HB-HV) polymers crystallized at the same temperature, It was found 
that drug release (at similar loadings) was progressively more rapid in the copolymers 
and increased with increasing HV content. This phenomenon could be explained by 
reference to altered drug distribution resulting from the combined effects of 
crystallization rate and polymer morphology.
The progressively slower rates of crystallization in copolymers on increasing HV content 
resulted in progressively greater exclusion of drug from intra-spherulitic regions and 
hence, poorer drug distribution. At the relatively faster crystallization rates observed 
in the homopolymer, better drug entrappment was achieved and drug release was slower. 
Drug molecules were thought to be present within inter-lamellar regions and also at 
inter-spherulite boundaries within the P(HB-HV) polymer films. However, this requires
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further study. It would also be Interesting to investigate the distribution of peptide 
drugs within crystalline polymer systems and their influence on crystalline morphology.
This may be best carried out using modern polymer etching techniques in combination with 
electron microscopy to reveal a more detailed picture of polymer morphology.
The influence of copolymer composition on drug release profiles was qualitatively 
similar for films prepared by solvent casting and melt-pressing suggesting that the same 
explanation holds true in both cases. However, exact rates of drug release were 
dependent on fabrication technique. Release of Methyl Red was sustained to a greater 
extent when P(HB-HV) devices were prepared by melt-pressing rather than by solvent 
casting. In most cases, drug release was not predominantly controlled by polymer 
erosion.
Drug release from spray-dried microparticles was more rapid than from both solvent cast 
and melt-pressed films. Release of Methyl Red was a function of drug loading and polymer 
molecular weight. Increasing molecular weight or drug loading in PHB resulted in more 
rapid release of drug.
The use of spray drying to produce injectable microparticles was limited to molecular 
weights of 140K and below for the homopolymer. The microparticles produced, even for low 
molecular weights, were not discrete individuals but aggregates. The morphology of the 
product produced was little affected by adjusting the processing parameters on the Buchi 
minispray dryer. Drug release from spray-dried microparticles was influenced by 
processing parameters such as polymer feed concentration and inlet temperature. However, 
these effects may have been complicated by the observed batch-to-batch variation in 
release profiles of microparticles produced with the bench model spray dryer. If such 
variation was to persist in particles prepared on a large industrial scale then batch-  
to-variation may preclude the use of spray drying as a method of producing injectable 
microparticulates. This requires further study.
In conclusion P(HB-HV) systems appear to be promising candidates for drug delivery and
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have obvious advantages over existing materials. The current literature suggests that 
these polymers are biocompatible [148,293,297 -  300], biodegradable [286 -  289] and can be 
extracted in a very pure form from bacteria [214,262]. There are also reports [286 -  287] 
suggesting that these polymers degrade by surface hydrolysis (heterogeneous degradation) 
offering the potential for reproducible drug release kinetics and that rate of erosion 
can be controlled by copolymer composition.
This study showed that although release of low molecular weight drugs was not 
predominantly erosion controlled, time scales over which release was possible with 
P(HB-HV) polymer systems could be varied from several hours to several months. Release 
could be controlled by controlling polymer molecular weight, copolymer composition, drug 
loading, fabrication technique and form of the drug delivery device employed.
The use of P(HB-HV) polymers for delivering peptide drugs will be influenced by drug 
distribution. If the peptide can be trapped effectively such that release is determined 
by polymer erosion then drug release could be further controlled. In addition, 
appropriate choice of the controls listed above will enable release to be tailored to 
specific requirements within the long time frames of polymer degradation. However, in 
order for P(HB -  HV) polymers to realize their full potential in drug delivery it is 
important to overcome the important technological challenge of how hydrophilic peptide 
drugs can be trapped homogeneously within these hydrophobic polymers such that release 
Is indeed controlled by polymer erosion.
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APPENDIX A
XPS AND SSIMS ANALYSIS OF P(HB-HV) POLYMERS.
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A1.1 INTRODUCTION
X -R ay Photoelectron Spectroscopy (XPS) and Static Secondary Ion Mass spectroscopy 
(SSIMS) are complimentary techniques for the surface chemical characterization of 
polymeric interfaces [503 -  504].
A1.1.1 X -R ay  Photoeletron Spectroscopy (XPS).
XPS, which is also known as ESCA (Electron Spectroscopy for Chemical Analysis) provides 
quantitative elemental (except for H and He) and functional group analysis of polymer 
surfaces to a sampling depth of approximately 1-10nm  [496,503]. The technique has been 
reviewed in many books [505 -  506] and articles [496,503,507.511] and only a brief outline 
of its principles is given here.
When a photon source (e.g. X -rays) is directed at a sample, the photons interact with 
the electrons present in the sample material. If the photon has sufficient energy, it 
causes an electron to be emitted from an orbital. The theoretical relationship that 
describes this process is given by [503]:
KE = hv -  BE -  a
where KE is the kinetic energy of the emitted photoelectron, hv is the energy of the 
photon, Be is the binding energy of the photon, and a is an instrument specific work 
function. KE is determined in the XPS experiment, hv and ’a’ are known, and BE can be 
calculated, yielding the energy with which the emitted electron was held in Its atomic 
or molecular environment
A schematic diagram of an XPS apparatus is shown in Figure A1.1. The sample for analysis 
is placed in an ultra high vacuum, typically less than 10"8 Torr and exposed to a low 
energy monochromatic X -ra y  source which causes the emission of photoelectrons from 
atomic shells of elements present in the surface. These electrons possess an energy 
characteristic of the element and molecular orbital from which they are emitted. The 
electrons are detected and counted according to the energy they possess and by counting
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Figure A1.1. A schematic diagram of a XPS apparatus (after ref. 
502).
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the number of electrons at each energy value, a spectrum of peaks corresponding to the 
elements on the surface is generated. The area under each peak is a measure of the 
relative amount of each element present, while the shape and position of the peak 
reflects the chemical state of each element.
XPS is restricted to the surface ( < 10nm) because electrons from much below the surface 
are not detected. They either suffer energy loss through collisions and are unable to 
make it out of the surface, or escape the surface with considerable energy loss. A 
summary of the information available from XPS is given in Table A1.1.
Table A1.1. Information derived from XPS Experiments on Polymers (After ref. 502)
-  All elements except H and He.
-  Surface concentrations of elements.
-  Molecular environments (bonding state) and/or 
oxidation levels of most elements.
-  Information on unsaturated or aromatic structures 
from shake up transitions.
-  Positive identification of functional groups using 
derivatisation reactions.
A1.1.2 Static Secondary Ion Mass Spectroscopy (SSIMS).
SSIMS provides information on the molecular species present at the polymer surface [504] 
and is thought to be more surface sensitive than XPS in that it provides molecular 
information from a sampling depth of only 1-1.5nm  [496-497,509,512].
In the SSIMS process a sample under ultra high vacuum (10-7 to 10"9 Torr) is bombarded 
with inert atoms or ions resulting in the sputtering of neutral species, electrons and 
ions from the surface region. The mass to charge ratio (m/e) of cationic or anionic 
species can be measured and a spectrum plotted of signal intensity as a function of m/e.
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This spectrum or fragmentation pattern can be analysed using conventional mass 
spectrometry rules.
A1.2 MATERIALS AND METHODS
All materials used were identical to those given in chapters 2 and 3.
Thin films were prepared by spin casting from 0.1% chloroform solutions onto 
acetone/chloroform washed aluminium foils which were mounted directly onto analysis 
stubs (1cm3). Samples were analysed within 24 hours of preparation.
XPS spectra were obtained using a VG Scientific ESCALAB Mk II electron spectrometer 
employing Mg K-alpha X -rays (hv = 1253.6 eV). A scan spectrum (1000 eV) and Narrow scans 
in the C1s and 01s regions were recorded for all the samples. The analyser was operated 
in Fixed Analyser Transmission mode and a pass energy of 50 eV (for survey scans) and 20 
eV (for C1s and 01s envelopes). Data acquisition and analysis was performed by a VGS 
5000 datasystem based on a DEC PDP 11/73 computer. Spectra were corrected for sample 
charging (referenced to C -H /C -C  at 285 eV in the 01s envelope).
SSIMS spectra were acquired using a modified VG Scientific SIMSLAB which has been 
described in detail elsewhere [510]. Samples were bombarded with 2 eV argon atoms of 
flux density 3x109 particles cm~2s_1 in UHV. Sample charging was neutralized using an 
electron flood gun in a manner described by Brown and Vikerman [511] for both positive 
and negative ion spectra. The total dose for setting up and acquisition of both positive 
and negative ion spectra was of the order of 2x1012 particles cm-2 per sample and lies 
within the limits established by Briggs and Hearn [508] for SSIMS spectra of "undamaged" 
surfaces.
A1.3 RESULTS AND DISCUSSION
The C1s and 01 s core level spectra for the thin films of PHB and PHV20 from XPS are 
shown in Figure A1.2. There was good agreement between the experimental area ratios 
within the C1s envelope and those derived from the stoichiochemistry of the polyesters
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Figure A1.2. The C1s and O is core level spectra for thin films of 
PHB380K and PHV20 from XPS analysis.
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in terms of the - C - H ,  - C - 0 ,  0 - C - 0 ,  and -C -C O O R  environments. Similarly the C:0 ratio of 
PHB and PHV20 determined from XPS correlated well with the stoichiochemistry (see Table 
A1.2).





The above results from XPS suggested the absence of C and O containing impurities at the 
surface of the polymers. No evidence was found for other elemental impurities. The 
absence of peak signals from the underlying aluminium substrate, i.e. the Ai 2p core 
level, suggested that the spin cast films were at least 8-10nm  thick.
Positive and negative ion SSIMS spectra for PHB are given in Figures A1.3 and A1.4 
respectively. Both spectra were dominated by diagnostic fragments of the PHB monomer 
repeat units. In the positive ion spectrum (Figure A1.3), nM ±H and nM ±H were prominent 
for n = 1 -4  where M is the molecular weight of the PHB monomer. The nM ±H ions were 
observed at 85/87, 171/173, 257/259 and 343/345 Daltons (D) for n = 1 -4  respectively. 
Similarly, the n M -0  ±H ions were present at 69, 155/157, 241/243 and 325/327 D for n = 1 -4  
respectively. General structures for these ions are given in scheme 1 of Figure A1.5.
In the negative ion spectrum of PHB (Figure A1.4), the dominant ions were again 
diagnostic of the PHB monomer unit i.e. nM ±H at 85/87 and 171/173 and nM + 0  ±H at 
101/103 and 187/189 D for n = 1 -2 . The general structures for these negative ions are 
shown in scheme 2 of Figure A1.5.
The positive ion SSIMS spectrum of PHV20 (Figure A1.6) contained many fragments seen for 































Figure A1.4. Negative ion SSIMS spectrum for PHB380K.
CHCH
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HO CH— CH2-C O"*ch2- ch2- c 0“
Scheme 2
Figure A1.5. Chemical structures for schemes 1 and 2 in the 
fragmentation of PHB380K during SSIMS.
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Figure A1.6. Positive ion SSIMS spectrum for PHV20.
257/259 D and n M -0  ±H at 69/71, 155/157, and 241/243 for n = 1 -3  respectively, were also 
prominent In the SSIMS spectrum of PHV20 In Figure A1.6. However, a number of 
significant ions were observed in the PHV20 spectrum which were not detected within the 
positive ion spectrum of PHB and can be attributed to the PHV monomer fragments. Namely, 
the 99/101 and the 199/201 D Ions can be assigned to those of the PHV monomer unit, nM 
±H, and 83/85 and 185/187 D cations are diagnostic of n M -0  ±H, for n = 1 -2  respectively. 
The structures of these ions are given in scheme 3 of Figure A1.8.
In the positive ion spectrum of PHV20, there is also evidence of P(HB-HV) fragments.
Namely cations corresponding to 187, 169/171 and 255 D are assigned to (MPHB + MPHV) + H, 
(Mphb + Mphv) ±H and (2MPHB + MPHV) ±H respectively. The structures of these Ions are 
shown in scheme 4 of Figure A1.8. Clearly the positive ion SSIMS spectrum not only 
allows differentiation of PHB and PHV monomer units but also enables detection of
fragments containing both monomer units.
The negative ion SSIMS spectrum of PHV20 (Figure A1.7) also provides a number of 
diagnostic ions for PHB at nM ±H and nM + O ±H i.e 85/87 and 171/173 D and 101/103 and
187/189 D respectively for n = 1 -2 . Again a number of dominant ions were, however,
detected for PHV20 which were absent in the negative ion SSIMS spectrum of the 
homopolymer, PHB. In this respect, 99/101 and 115/117 D ions may be assigned to M ±H and 
M + O ±H arising from the PHV portion of the copolymer. Similar to the findings in the 
positive ion spectrum of PHV20, the negative ion spectrum also provides evidence for 
the anions containing both monomers i.e the (MPHB + MPHv) ±H ion at 185/187 D.
It is evident that many of the fragmentation patterns obtained previously from the SSIMS 
analysis of other polymers, such as PLA and PGA [504], extends to the higher molecular 
weight monomers of PHB and P(HB-HV) copolymers. The formation of the M ±H ions in both 
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Figure A1.8. Chemical structures for schemes 3 and 4 in the 
fragmentation of PHV20 during SSIMS.
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A1.4 CONCLUSIONS
It has been shown that the quantitative elemental information from the XPS data coupled 
with the detailed molecular analysis provided by SSIMS spectra allow some insight into 
the surface chemical structure of P(HB-HV) polymers. The XPS data provides confirmatory 
evidence for the purity of these biopolymers extracted from a bacterial source. There 
was good correlation between the experimental and elemental ratios. Similarly the 
functional analysis is consistent with the expected stoichiochemistry of the polymers.
The SSIMS data also showed no evidence of any extraneous inorganic or organic 
contamination of bacterial polyesters.
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APPENDIX B
THE SESSILE DROP METHOD FOR DETERMINING CONTACT ANGLES
321
A2.1 METHOD
Solvent cast films were prepared as In chapter 2. Equilibrium aged films (for at least 3
months at 25°C)) were used In contact angle determinations. Water contact angles were
measured for both the rough and smooth surface of P(HB-HV) films.
Triple distilled water used for contact angle measurements was prepared in an all glass 
still. All vessels used for transporting water were of glass which had previously been 
cleaned using chromic acid.
A 3 ul sessile drop of triple distilled water was placed onto the surface of the polymer 
film using a micropipette. The film had previously been placed onto the flat stage of a 
contact angle gonio-telemicroscope (Figure A2.1) specially constructed from commercially 
available parts (Table A2.1). The formed drop was illuminated via a cold light source 
and the required angle measured with a protractor eye piece following alignment of the 
eye piece cross-hair at both sides of the liquid drop. Contact angle measurements were
performed on both sides of at least 5 drops for each sample surface.
Table A2.1. Parts used to construct the contact angle gonio -  telescope (after ref. 502).
Part description Catalogue No.
Viewing microscope 22-9153
Rack and pinion draw tube 11-8166
50mm objective lens 11-8232
mounting pin 22 -  7868
x10 eyepiece with cross line 24-4780
Protractor eyepiece 11-5188
Triangular optical bench 44 -  4315
Leveling cross feet 22-7108
Circular table 22-7900
Tranverse and vertical 22-5110











Figure A2.1. A schematic diagram of a contact angle gonio-  
telemicroscope (after ref. 502).
A2.2 RESULTS
Table A2.2 Summary of water contact angles for P(HB -  HV) polyester films cast from 
chloroform (Mean ± S.D; n = 10).
Polymer Smooth surface of film Rough surface of film
Contact angle Work of adhesion Contact angle Work of adhesion
(degrees)
CM1E-DE, (degrees) (mJm-2 )
PHB380K 84.9 ±2.5 79.3 ±2.6 82.7 ±2.7 82.1 ±3.5
PHV6 80.2 ±3.4 85.2 ±4.3 82.6 ±1.2 82.2 ±1.5
PHV12 67.1 ±2.1 101.1 ±2.5 74.2 ±2.0 92.6 ±2.4
PHV20 69.6 ±0.7 98.2 ±0.9 74.2 ±2.9 92.6 ±3.5
PHV27 67.3 ±2.6 100.9 ±3.1 69.8 ±2.3 97.9 ±2.7
where Work of adhesion = Wslv = p1v (1 +  cos 0)
plv  = surface tension of water = 72.8 m Jrrr2 (from ref. 502). 
0 = contact angle
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APPENDIX C 
FORMULA FOR PHOSPHATE BUFFER.
Phosphate buffer pH 7.4 at 37°C.
Potassium dihydrogen orthophosphate  13.625g
Disodium hydrogen orthophosphate  24.200g
Sodium chloride.................................  9.350g
Distilled Water to..................................  5000cm3
All salts were purchased from BDH Chemicals, Poole, Dorset.
APPENDIX D 
STATISTICAL METHODS
All student 't' tests presented in this thesis were evaluated using the 
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